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Abstract 
The molecular and cellular basis of stress neurobiology remain an important research 
question in clinical science. Indeed, stress-related mental disorders, including 
depression and anxiety, are currently a major public health concern. Thus, improving 
our knowledge about the pathophysiology of these neuropsychiatric disorders may 
enable the development of novel strategies for their treatment and prevention. On the 
other hand, the inefficacy of currently available therapies for various stress-related 
disorders, and the numerous side effects that accompany these treatments, have 
strengthened the search for less invasive strategies with fewer negative side effects. In 
this regard, the emerging and compelling evidence for nutrition as a potential 
therapeutic avenue for the treatment of mental disorders suggests that changes in diet 
are a viable strategy for improving mental health and treating stress-related psychiatric 
disorders. Moreover, there is considerable evidence suggesting that certain natural 
compounds available in diet have a therapeutic potential to improve mental health and 
disease.  
For instance, naturally occurring phytochemicals, namely polyphenols, are molecular 
compounds found in different plant sources, such as vegetables and fruits. Also, 
phospholipids are a class of lipid that comprise a major component of all cell 
membranes, specially concentrated in lean meat and dairy products. Both polyphenols 
and phospholipids have demonstrated interesting beneficial effects for human health. 
However, their therapeutic potential to act prophylactically against the detrimental 
effects of neuropsychiatric disorders have just begun to be taken seriously. Therefore, 
in this thesis we have tested the hypothesis that polyphenols and/or phospholipids 
could improve behavioural and neurobiological outcomes in cellular and animal 
models of stress.  
Further, we provide evidence that polyphenols and phospholipids exert 
neuroprotective effects against the cytotoxicity produced by corticosterone, the main 
rodent stress hormone, in cortical neurons. Specifically, we have elucidated the 
potential mechanisms underlying polyphenol-mediated neuroprotection in vitro, and 
demonstrated that phospholipid exposure positively impacts on neurodevelopmental 
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processes, such as proliferation and differentiation of cultured neural progenitor cells. 
In addition, we confirmed the therapeutic potential of a dietary intervention with 
polyphenols by detecting its capacity to reverse depressive- and anxiety-like 
behaviours induced in a rat model of early-life stress. Moreover, we demonstrated 
potential implications to modulate BDNF-dependent recovery, regulation of the HPA 
axis and the microbiota-gut-brain axis in polyphenol-mediated behavioural 
improvement.  
Taken together, our findings support the therapeutic potential of polyphenols for 
stress-related mental disorders, and we further provide evidence for the possible 
mechanisms by which they may exert these effects. On the other hand, our data reveal 
that the novel neuromodulatory potential of phospholipids in vitro does not correlate 
with their inefficacy in attenuating chronic stress-induced behavioural impairment in 
mice. Nevertheless, these findings contribute to an exciting and growing body of 
research suggesting that nutritional interventions may have an important role to play 
in the treatment of stress-related psychiatric conditions. 
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Chapter 1 
General 
Introduction 
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1.1 The stress response 
The fight-or-flight, or stress responses is a physiological reaction that occurs in 
response to intrinsic or extrinsic forces capable of threat to the physical and 
psychological equilibrium, or homeostasis (Jansen et al. 1995). All these forces or 
stressors, including harmful events, extreme pain or anguish, or threat to survival, can 
trigger a repertoire of complex biochemical and behavioural reactions, also known as 
allostasis, a physiological process aimed to counteract the effects of stressors and re-
establish homeostasis (Sterling 2012). Within these adaptational responses to stress 
are included central and peripheral reactions that lead to the facilitation of neural 
pathways associated with arousal, alertness, vigilance, cognition, and focused 
attention with concurrent inhibition of pathways that mediate passive functions such 
as feeding and reproduction (Chrousos et al. 1992). When these adaptive systems are 
turned on and turned off again efficiently and not too frequently, the body is able to 
cope effectively with challenges that it might not otherwise survive. However, there 
are a number of circumstances in which allostatic systems may either be 
overstimulated or not perform normally, and this condition has been termed allostatic 
load, which can lead to disease over long periods (McEwen et al. 1993). 
1.2 Neurobiology of stress 
The impact of the stress response on brain cellular and behavioural function is 
dependent of the activation of specific neurocircuitry and physiological cascades. For 
instance, the stress response leads to the activation of neuronal circuits involved in the 
efferent sympathetic/adrenomedullary system together with the hypothalamic-
pituitary-adrenal (HPA) axis (Dunn et al. 2008). Acting in concert, both components 
coordinate emotional, cognitive, neuroendocrine and immune inputs to determine the 
magnitude and specificity of behavioural and hormonal responses to stress. 
Specifically, parvocellular corticotropin releasing factor (CRF) is the principal 
hypothalamic stimulus to the HPA axis activation, that induces the increase of 
adrenocorticotropic hormone (ACTH) from the pituitary, resulting in glucocorticoid 
secretion in the adrenal cortex, which is also critical for the regulation of the HPA axis 
by negative feedback (Fig. 1.2.1) (Tsigos et al. 2002).  
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Figure 1.2.1 A simplified schematic representation of the activation of the HPA axis. During stress 
the hypothalamus secretes corticotropin releasing factor (CRF), that induces the increase of 
adrenocorticotropic hormone (ACTH) from the pituitary, resulting in the release of glucocorticoids, 
such as cortisol (humans) and corticosterone (rodents), which mediate the negative feedback of the 
HPA axis. 
Glucocorticoids reach every organ by way of the circulation, where their effects are 
differentiated into two classes of action: modulating actions, which alter the 
organism’s response to the stressor, and preparative actions, which alter the 
organism’s response to a subsequent stressor or aid in adapting to a chronic stressor 
(Sapolsky et al. 2000). The underlying mechanism involves an integrated response, 
which starts with rapid hormone-induced changes in receptor conformation that lead 
to slower modulations of gene transcription (de Kloet et al. 2005). Specifically, the 
receptor system of glucocorticoids consists of two related receptor molecules, the low 
affinity glucocorticoid receptor (GR) and the high affinity mineralocorticoid receptor 
(MR), which bind the same hormone (primarily cortisol in humans and corticosterone 
in rodents); however, the GR becomes progressively activated during stress (Kitchener 
et al. 2004).  
Glucocorticoid binding provokes conformational changes in the GR that activate 
multiple functional domains, including nuclear-localization sequences. After 
translocation into the nucleus, GR associates with specific genomic glucocorticoid 
response elements (GREs) and nucleates the assembly of transcription regulatory 
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complexes containing GR, and co-regulatory factors, which together activate or 
repress the transcription of glucocorticoid-responsive genes (Fig. 1.2.2) (Weikum et 
al. 2017). 
 
Figure 1.2.2 Glucocorticoid receptor signalling and DNA binding. Cortisol interacts with the 
glucocorticoid receptor (GR) in the cytoplasm. Once the GR is activated, it translocates into the nucleus 
and bind to specific DNA sites named glucocorticoid receptor elements (GREs). GRE1 and GRE2 
represent distinct GREs within the genome, Gene X and Gene Y represent the genes under the control 
of GRE1 and GRE2, respectively. 
Some of the effects produced by activation of the glucocorticoid cascade and 
catecholamine elevation during stress, include the mobilisation and replenishment of 
energy stores needed for brain and body function under challenge, and in other 
contexts have been detected through changes in food intake, dramatic shifts in 
metabolism, muscle morphology, and increases in blood pressure. These adaptations 
maintain essential metabolism and body temperature homeostasis (McEwen et al. 
2003). 
At molecular level, some of the genes induced after GR activation and translocation 
into the nucleus include those associated with the intracellular negative feedback of 
GR activity (Gjerstad et al. 2018). For example, the FK506 binding protein 5 (FKBP5) 
is a co-chaperone of hsp90 which regulates GR sensitivity. When it is bound to the 
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receptor complex, cortisol binds with lower affinity and nuclear translocation of the 
receptor is less efficient. FKBP5 mRNA and protein expression are induced by GR 
activation via intronic hormone response elements and this provides an ultra-short 
feedback loop for GR-sensitivity (Binder 2009, Fries et al. 2017). 
1.3 Stress-related mental disorders 
Although it is believed that mild, brief, and controllable states of challenged 
homeostasis could be perceived as positive stimuli to emotional and intellectual 
growth and development, if the stress response is inadequate or excessive and 
prolonged, the cost of reinstating homeostasis might become too high, producing a 
vulnerable phenotype increasing the risk of developing mental illness (de Kloet et al. 
2005). Indeed, it is well known that stressful events in early life, or acute and chronic 
stressors, can exert long-lasting changes later on in brain structure and function (Cryan 
et al. 2013). Accumulating evidence indicates that these adversities are associated with 
an increased risk for developing stress-related mental disorders such as anxiety and 
depression (Chapman et al. 2004, Heim et al. 2012). 
Major depressive disorder (MDD), is a serious stress-related mental disorder 
characterised by at least two weeks of low mood, accompanied by low energy, low 
self-esteem, loss of interest in usually enjoyable activities, and sometimes includes 
pain without apparent cause (Smith 2014). On the other hand, anxiety disorders 
including generalised anxiety disorder (GAD), phobias, panic disorder, obsessive-
compulsive disorder and post-traumatic stress disorder, are characterised by strong 
feelings of apprehension, uneasiness, and an unpleasant state of inner turmoil (Nagata 
et al. 2015). In general, stress and hyper activation of the HPA axis have been 
demonstrated to mediate, or even promote mental disorders, including anxiety and 
major depression (Esch et al. 2002). In 2015, depressive disorders were estimated to 
be the third leading cause of disability worldwide. Now, the WHO indicates that 
depression is a leading cause of disability worldwide and is a major contributor to the 
overall global burden of disease (Park et al. 2019). 
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1.4 Pathophysiology of stress-related disorders 
Stress-related neuropsychiatric disorders, especially depression, do not have a clear 
aetiology due to their multiple environmental and genetic factors (Saveanu et al. 
2012). However, there are some promising biomarkers that have been associated with 
the pathophysiological mechanisms involved in development and onset of these 
mental disorders (Fig. 1.4.1). For instance, depression, stress and the HPA axis have 
been associated through several lines of evidence; for example, the core symptoms of 
depression including low mood, inability to enjoy activities usually considered 
pleasurable and low energy, are a clear cross-cultural response to stressful events. In 
addition, the HPA axis is activated in response to stress, leading to a potent release of 
glucocorticoids into the bloodstream, whereas depression in severe cases is also 
characterised by over activation of the HPA axis (Pariante 2003). On the other hand, 
the correlation between early stress events, such as childhood abuse or neglect, and 
development of anxiety disorders in adulthood, as well as increased hypothalamic 
CRF neuronal activity strongly support the link between stress, the HPA axis and, 
anxiety disorders (Arborelius et al. 1999). 
Studies into the pathophysiology of MDD have confirmed that the neurochemical 
balance of depressed people is altered, specifically at the main monoamine 
neurotransmitter level (i.e. dopamine, noradrenaline and serotonin) (Nutt 2008). 
Accumulated lines of evidence indicate that abnormal concentrations of monoamine 
neurotransmitters and their metabolites in brain regions that contribute importantly to 
regulation of mood and motivation, could significantly impact on pathogenesis of 
depression (Liu et al. 2018).  
Chronic neuroinflammation has also been associated with the emergence of depressive 
symptoms (Brites et al. 2015). Activation of the peripheral immune system leads to 
pro-inflammatory cytokine production that eventually reach the CNS stimulating 
astrocytes and microglia with significant implications for psychiatric disorders (Muller 
et al. 1998). Indeed, human and animal studies revealed increased activation and 
numbers of microglia in depression and anxiety disorders (Frick et al. 2013), and 
elevated production of cytokines in different animal models of stress (Goshen et al. 
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2007, Liu et al. 2013). Taken together, the study of cellular and molecular mechanisms 
of inflammation in stress-related disorders, offers a new perspective for treatment 
targeting neuroinflammatory signalling pathways. 
1.4.1 The gut microbiota, stress and mental health 
Several lines of evidence identify the gut microbiome as a key player in maintaining 
homeostasis and that a disruption in its composition contributes to various diseases, 
including mental disorders (Cryan et al. 2012, Lucas 2018, Taylor 2019). The human 
microbiome represents a complex ecosystem that consists of a multitude of 
microorganisms including bacteria, archaea, yeasts and viruses (Eckburg et al. 2005), 
and there is a growing body of data focused on the impact of the gut microbiome on 
behaviour supported by the concept of the microbiota-gut-brain axis (Rhee et al. 2009, 
Cryan et al. 2019), a complex network formed by the enteric nervous system (ENS), 
sympathetic and parasympathetic divisions of the autonomic nervous system, 
neuroendocrine and neuroinmune components of the central nervous system (CNS), 
and the gut microbiota (Mayer et al. 2014).  
The brain can influence the gut microbiota indirectly via changes in gastrointestinal 
motility and secretion, intestinal permeability, or directly, via signalling molecules 
released into the gastrointestinal lumen from cells in the lamina propria such as 
enterochromaffin cells, neurons and immune cells. On the other hand, communication 
from gut microbiota can occur via multiple mechanisms, including receptor-mediated 
signalling or through direct stimulation of host cells in the lamina propria (Collins et 
al. 2009). For instance, vagal innervation has been identified as a major constitutive 
communication pathway in probiotic mediated improvements in emotional behaviour 
and central GABA receptor expression in the mouse (Bravo et al. 2011). A probiotic 
is a mono- or mixed culture of live microorganisms which, applied to animal or man, 
affect beneficially the host by improving the properties of the indigenous microflora 
(Jezewska-Frackowiak et al. 2018). 
Alterations in brain-gut interactions are associated with gut inflammation, chronic 
abdominal pain syndromes and eating disorders, and that modulation of gut-brain axis 
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is associated with alterations in the stress response and behaviour (Cryan et al. 2012). 
For instance, studies have demonstrated that chronic stress alters the structure of the 
intestinal microbiota in rodent models and humans (Bailey et al. 2011, Karl et al. 
2017). In addition, changes in the gut microbiota composition have been associated 
with depressive- and anxious-like behaviours, as well as with altered serotonin levels 
in a mouse model of depression (Park et al. 2013). In this regard, many studies have 
reported a restoration of gut microbiota after antidepressant treatments. Taken 
together, research focused on developing novel therapeutic strategies to treat 
neuropsychiatric disorders by targeting the gut microbiota is rapidly growing (Long-
Smith et al. 2019). Indeed, it has recently been proposed that depression is an ‘unholy 
trinity’ of stress, inflammation and microbiota (Cruz-Pereira et al. 2020). 
 
Figure 1.4.1 Physiological components involved in stress-related disorders pathology. HPA 
dysregulation, altered neurochemical balance, chronic neuroinflammation and disrupted microbiota-
gut-brain axis, are some components associated with the pathophysiological mechanisms of stress-
related mental disorders. 
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1.5 In vitro models of stress-related conditions 
In vitro, the Latin for in glass, is referred to those scientific studies performed with 
cells, microorganisms, and biomolecules outside of their usual biological context. 
Indeed, in vitro models for drug discovery and research have gained great interest 
because of the limitations of animal models in terms of feasibility and ethical concerns. 
Therefore, by reducing the animal usage for drug research, in vitro models can serve 
as platforms for more controlled screening of compounds with potential 
pharmacological effects (Elliott et al. 2011). In addition, other advantages of in vitro 
experimentation include an expedited study of biological mechanisms of action, such 
as activation/downregulation of specific signalling pathways as it is easier to measure 
the impact of a single experimental variable (e.g. a drug) on a simple and well 
controlled system, and allows testing of a large number of different combinations of 
experimental parameters (Bajpai et al. 2002). 
Different in vitro models have been developed to understand diverse physiological 
conditions and cellular processes including cell differentiation and proliferation, 
metabolism, epigenetics, apoptosis, etc., as well as the elucidation of molecular 
determinants of disease, including cancer, degenerative and cardiovascular diseases 
(CVD), viral infective mechanisms, and neurobiological disorders (Abid et al. 2005, 
Katt et al. 2016, Mathur et al. 2016). Here, in vitro models have been extremely 
important in studying brain development, and exploring therapeutic options for 
disorders associated with alterations of the central nervous system (CNS) structure and 
function (Shuler et al. 2014). Several classes of in vitro models of the brain have been 
described, including immortalised neuronal cell lines and primary cell cultures from 
CNS tissue (Fig. 1.5.1 A). However, “neurons” include many diverse cell types among 
which perhaps just one or a few may be ideal for a particular experiment (Hollenbeck 
et al. 2003).  
For instance, it has proven particularly challenging to develop in vitro approaches to 
study psychiatric treatment for mood disorders, as they are linked with the alteration 
of a number of brain regions and produce a complex array of clinical symptoms. 
However, basic phenotypes may exist at the level of single neurons (Brennand et al. 
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2012). Indeed, it is hypothesised that many psychiatric disorders are amenable for cell-
based in vitro studies because of their highly heritable component (Bearden et al. 
2006). For example, using induced pluripotent stem cell-derived (IPSCs) neural tissue, 
specific in vitro models can be generated from patients with a particular mental 
disorder, including depression and anxiety (Fig. 1.5.1 B) (Soliman et al. 2017). (Tatro 
et al. 2009). Similarly, the recent development of 3D brain organoids derived from 
human pluripotent stem cells (hPSCs) offers a promising approach for investigating 
the phenotypic underpinnings of these highly polygenic disorders and for 
understanding the contribution of individual risk variants and complex genetic 
background to human pathology (Fig. 1.5.1 B) (Quadrato et al. 2016). 
On the other hand, blocking or reducing the expression of genes potentially involved 
in depression can offer a useful tool to understand the role of specific proteins in the 
development of this mental disorder. Indeed, using knock-down or knock-out 
techniques in cellular models to manipulate genetic expression of potential biomarkers 
involved in stress-related neuropsychiatric disorders, allows to elucidate novel 
signalling pathways and molecular targets for therapeutic approaches (MacLaren et al. 
2011, Shah et al. 2016) (Fig. 1.5.1 C). 
An alternative approach to study the neurobiological changes produced during stress-
related disorders in vitro, use cell-based high glucocorticoid exposure models. These 
models are based on the high glucocorticoid release produced after abnormal HPA 
activity during chronic stress events (Pariante 2003). It has been demonstrated that 
exposure to elevated concentrations of corticosterone (main rodent glucocorticoid 
hormone) induces neurotoxic effects in different neuronal in vitro models, including 
hippocampal neurons (Latt et al. 2018), PC12 cell line (Li et al. 2014), hypothalamic 
neurons (Zhang et al. 2012), and neurons derived from brain cortex (Pusceddu et al. 
2016). For this reason, corticosterone-induced neurotoxicity approaches represent an 
interesting in vitro model to understand the detrimental effects of high glucocorticoid 
exposure at the molecular and morphological level in neurons, and provide an 
excellent platform to explore novel drugs with potential therapeutic effects against 
stress-related disorders (Fig. 1.5.1 C). 
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Finally, in vitro models of stress-related conditions are excellent platforms to test 
novel chemical-based drugs and naturally-derived compounds with 
neuropharmacological activity and for selecting which ones with potential therapeutic 
effect (Kelava et al. 2016) (Fig. 1.5.1 C). Indeed, pharmacological research is critical 
to elucidate signalling pathways associated with stress response and altered 
gene/protein expression profile of patients suffering of stress-related disorders, and 
eventually to discover agonist or antagonist drugs able to ameliorate this phenotype 
(Ghanemi 2014). New treatments for neuropsychiatric disorders associated with stress 
depend of pharmacological research, and cell-based models of disease-related 
phenotype represent a powerful tool to carry on these investigations.  
 
Figure 1.5.1 Strategies to study stress-related conditions in vitro. (A) Traditional methods to obtain in 
vitro models of the brain from CNS tissue, including primary cell cultures and immortalised cell lines. 
(B) Using human pluripotent stem cells from patients with stress-related disorders to generate induced 
pluripotent stem cell-derived (IPSCs) neuronal cultures and 3D brain organoids. (C) Molecular 
techniques available to study the neurobiology of stress, such as gene knock-down or knock-out, 
glucocorticoid exposure and pharmacological screening. 
1.6 Animal models of stress 
The necessity to understand the neural processes underpinning behaviour in humans 
has boosted the field of comparative psychology, which refers to the scientific study 
of behaviour and cognitive actions of non-human animals (Krupenye et al. 2019). 
Thus, comparative psychology has been crucial for the development of in vivo animal 
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models for evaluating novel treatment approaches in human disease. In addition, the 
large cost of clinical trials and psychiatric human studies represents a difficult barrier 
for the development of novel drugs aimed at the central nervous system (CNS) (Frantz 
2004). 
Indeed, many models and tests for assessing depressive- and anxious-like behaviours 
in rodents were designed to investigate potential psychiatric drugs such as 
antidepressants and anxiolytics (Cryan et al. 2005). An important number of these 
animal models of stress-related disorders involve exposure to stressful situations, 
because it has been demonstrated that trauma or chronic stress are important 
predisposing factors to depression and anxiety (Kessler 1997). For instance, some 
chronic stress-based models include chronic unpredictable stress (CUS) and chronic 
social defeat stress (CSDS) in adult rodents, and maternal separation (MS) and 
prenatal stress in young rodents (Fig. 1.6.1). CUS is a model that comprises rodent 
exposure to several different and unpredictable stressors over a number of weeks. It 
has been reported that CUS induces depressive-like behaviour in adult rodents, 
specifically anhedonia, a behaviour associated with reduced motivation and inability 
to experience pleasure  (Willner 1997). In contrast, the CSDS procedure exposes the 
animals to an aggressive and dominant conspecific rodent during a specific period. 
This psychosocial stress on these animals induces social avoidance behaviours when 
they are exposed again to an unfamiliar rodent, and exhibit depressive- and anxiety-
like behaviours (Finger et al. 2011). 
On the other hand, the necessity to understand the implications of early-life adversity 
on emotionality and behaviour, leaded to investigate the role of maternal and 
environmental influence on the neurobiology of stress in rat pups around 50 years ago 
(Levine 1967). This work and other later studies (Meaney 2001, Plotsky et al. 2005) 
demonstrated that changes in rodent early postnatal experiences can induce profound 
long-lasting effects on gene expression, hippocampal architecture and CRF system in 
adult offspring. Thus, the MS model is based on the negative effects of early life stress 
on brain function and structure, which are associated with development and onset of 
depression and anxiety in adulthood (Lupien et al. 2009). This procedure involves 
separation of pups from their mothers for a defined period (usually 3 hours per day 
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from post-natal day 2 to 12) (O'Mahony et al. 2009). Evidence indicates that MS in 
rodents can produce significant changes in neurochemical balance and depressive- and 
anxious-like behaviours in adult animals (O'Mahony et al. 2011). Finally, the prenatal 
stress model involves exposure of a pregnant mouse or rat to a stressor during a defined 
timeline, inducing depressive and anxiety-like behaviours in the litter later in 
adulthood (Abe et al. 2007). 
 
Figure 1.6.1 Some preclinical approaches to study stress-related conditions in rodent models. Modified 
from (Gururajan et al. 2019). 
In contrast, other animal models of stress do not involve repeated stress exposure. For 
instance, preclinical studies have favoured an approach that models HPA hyperactivity 
by supplementation of corticosterone through injections (Demuyser et al. 2016). 
Indeed, it has been found that HPA axis dysregulation and increased release of 
peripheral cortisol (corticosterone in rodents) is associated with the neuromolecular 
and behavioural phenotypes of stress-related disorders (Anacker et al. 2011). 
However, there are some limitations in using corticosterone supplementation, 
including sex specific effects and hepatic metabolism of exogenous corticosterone 
(endogenously secreted corticosterone goes directly to systemic circulation) 
(Gururajan et al. 2019). 
In order to assess and quantify behaviours associated with depression and anxiety 
produced by  the rodent stress model, several tests have been developed to detect 
specific symptoms and markers of stress-associated mental disorders (Cryan et al. 
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2007). For example, one of the most reproducible behaviours linked to depression in 
animals is learned helplessness.  This behaviour occurs when the subject, unable to 
escape, undergoes repeated painful or stressful stimuli that are unavoidable. 
Eventually, the subject accepts these aversive stimuli without trying to escape or avoid, 
and is said to have learned that it is helpless. The theory of learned helplessness is 
associated with the psychopathology of depression and other stress-related mental 
illnesses in humans (Seligman 1972, Pryce et al. 2011).  
For instance, the learned helplessness paradigm in rodents can be tested through the 
forced swim test (FST; see Fig. 1.6.2 A), which is based on the observation that when 
rats are exposed to water they demonstrate passive immobile behaviour after 
struggling (swimming/climbing), reflecting behavioural despair (Slattery et al. 2012). 
The tail suspension test (TST; see Fig. 1.6.2 B) is another assessment used to detect 
behavioural despair related to learned helplessness after stress. Usually, mice are 
suspended by their tails, in such a way that they cannot escape or hold on to nearby 
surfaces (Steru et al. 1985, Cryan et al. 2005). In both tests, immobility is associated 
with depressive-like behaviours.  
Anxiety-like behaviours in rodent models of stress can be assessed using the elevated 
plus maze test (EPM; see Fig. 1.6.2 C). The EPM consists of a maze composed by two 
crossed narrow corridors, where two opposite arms are open and the other two opposite 
arms are closed (open roof, but enclosed by walls). This test is based on rodent’s 
natural aversion to elevated and open spaces (File et al. 2004). Similarly, the open 
field test (OFT; see Fig. 1.6.1 2 D) consists of an arena (circular, square or 
rectangular), where the animal is placed in the centre. Anxious behaviours are 
associated with reduced time spent in the centre of the arena, as well as with decreased 
entries to the centre (Prut et al. 2003). Other tests designed to measure anxiety in 
rodents are based in avoidance of aversive situations, including the elevated zero maze 
(EZM) and the light/dark box (Fig. 1.6.2 E and F) (Cryan et al. 2005).  
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Figure 1.6.2 Behavioural tests designed to detect anxiety- and depressive-like behaviours in rodent 
models. Modified from (Cryan et al. 2005). 
Taken together, although several techniques have been developed for understanding 
underlying mechanisms of novel compound treatments, the final output of the CNS is 
the behaviour, and should be the basis for conclusions in preclinical studies for drug 
discovery research.  
1.7 Pharmacological treatments for stress-related 
disorders 
Depression and anxiety have significant economic and social consequences worldwide 
(Greenberg et al. 2003), for this reason the search for effective therapeutic strategies 
to treat these neuropsychiatric disorders has become a major public health priority. 
Since the monoamine hypothesis of depression was first articulated around 55 years 
ago (Bunney et al. 1965, Schildkraut 1965, Delgado 2000), the initial approaches 
employed to pharmacologically induce an antidepressant effect involved increasing 
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the levels of monoaminergic neurotransmitters in the synapse to modulate 
postsynaptic receptor activity (e.g. serotonin, dopamine, and noradrenaline). 
On the other hand, clinical observations have found both direct and indirect evidence 
of glutamatergic dysfunction in MDD. For example, different studies have reported 
increased levels of glutamate in plasma of patients diagnosed with MDD (Mauri et al. 
1998, Kucukibrahimoglu et al. 2009); other reports using proton magnetic resonance 
spectroscopy found reduced metabolic glutamate/glutamine exchange in hippocampus 
(Block et al. 2009) and anterior cingulate cortex (Mirza et al. 2004) of people suffering 
from MDD. In addition, post-mortem analysis of MDD patients revealed changes in 
expression of N-methyl-D-aspartate (NMDA) receptor subunits. For instance, MDD 
patients showed altered expression of NR2A, NR2B and NR2C in different brain 
regions (Beneyto et al. 2008, Karolewicz et al. 2009, Chandley et al. 2014). This 
evidence has motivated new research focused on antidepressant drugs based on the 
glutamatergic system and NMDA receptor activity. 
In contrast, early research in the field of tranquilizers lead to the discovery of chemical 
compounds with similar properties of another neurotransmitter, γ-aminobutyric acid 
(GABA). These drugs showed strong sedative, anticonvulsant, and muscle relaxant 
properties, with potential use for anxiolytic treatment (Froestl 2011). In this regard, 
the first successful pharmacological treatment for depression was iproniazid, an 
antitubercular compound under the trade name Marsilid® in 1958, after clinical 
observations that reported the side effects of this drug (Loomer et al. 1957). At the 
pharmacological level, Iproniazid was found to block monoamine oxidases (MAO), a 
family of enzymes that catalyse the oxidative disamination of biogenic amines 
decreasing monoamine levels in the synapse (Thase 2012). After iproniazid the 
antidepressant research was focused on the development of new MAO inhibitors 
(MAOI’s), including non-selective MAOI’s, and selective MAOI’s for  MAO-A and 
MAO-B (Yamada et al. 2004).  
Although, some MAOI’s have proven to be efficacious in the wide spectrum treatment 
of major depression (Amrein et al. 1993), and in some types of anxiety disorders 
(Yamada et al. 2004), there are serious side effects and adverse reactions associated 
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with MAOI’s consumption, including hepatotoxicity, hypertensive crisis 
(Fiedorowicz et al. 2004), and withdrawal syndrome (van Broekhoven et al. 2002). 
For this reason, MAOI’s are used in clinical situations in which patients respond 
poorly to first line antidepressants, and when other drugs have failed; thus, they are 
considered a last line of treatment. 
On the other hand, the study of the first antidepressant also is attributed to Roland 
Kuhn, a Swiss psychiatrist who examined the therapeutic effects of an unknown 
compound designated G22355. As a result of the search of antipsychotic drugs for the 
treatment of schizophrenia, Kuhn noted that G22355 seemed to alleviate depression in 
the few schizophrenia patients who had prominent depressive symptoms (Brown et al. 
2015). Eventually, he gave G22355, later named imipramine, to 100 patients suffering 
depression and his results were published in 1957 (Kuhn 1957). His findings supposed 
a major breakthrough in the history of psychiatry, that still have an impact on the 
treatment of depression and on the development of antidepressant drugs (Brown et al. 
2015). 
Since imipramine and other similar drugs (Gillman 2007) discovered later were 
characterised by a three benzene ring molecular core and their mechanism of action 
was unknown at the time of discovery, they were classified as tricyclic antidepressants 
(TCAs) (Hillhouse et al. 2015). Now, TCAs are described as having several 
pharmacological actions, including inhibiting presynaptic noradrenaline and serotonin 
reuptake transporters, blocking postsynaptic adrenergic α1 and α2 receptors, blocking 
postsynaptic muscarinic receptors, and blocking postsynaptic histamine H1 receptors 
(Cusack et al. 1994, Owens et al. 1997, Vaishnavi et al. 2004). Their antidepressant 
effects are mainly attributed to the inhibition of noradrenaline and serotonin reuptake. 
On the other hand, because of their non-selective pharmacological targets, TCAs also 
have negative side effects, including dizziness, memory impairment, and drowsiness 
(Bet et al. 2013). 
To date, antidepressant drug discovery research has become more focused on highly 
selective compounds with specific pharmacological targets. In addition, the evidence 
has begun to suggest a significant role for serotonin in MDD. During the 1960’s, after 
30 
 
a post-mortem study that revealed decreased levels of this neurotransmitter in 
depressive suicides (Shaw et al. 1967), pharmaceutical companies began developing 
ligands that would selectively inhibit serotonin reuptake, to increase serotonin levels 
within the synaptic cleft. Thus, the first compound reported as a selective serotonin 
reuptake inhibitor (SSRI) with potential antidepressant activity was fluoxetine 
(LY110140) (Wong et al. 1974). After FDA approval in 1987, fluoxetine was 
launched under the trade name Prozac®. 
Although, antidepressant drugs based on the monoaminergic hypothesis have had 
relevant utility in improving mood and normal daily functions in depressed patients, 
only 60% show considerable improvement after two months of treatment and all 
patients have to deal with numerous side effects (Al-Harbi 2012). For those patients, 
these drugs represent a valid alternative for MDD therapy. Indeed, excessive glutamate 
and subsequent over-stimulation of NMDA receptors leading to excessive Ca2+ influx 
has been implicated in the pathophysiology of many neurodegenerative diseases, 
including depression and anxiety (Sanacora et al. 2012). In addition, there are early 
findings suggesting that NMDA receptor antagonists possess antidepressant-like 
activity (Trullas et al. 1990), and that chronically administered antidepressants from 
different classes are able to modulate NMDA receptor function (Nowak et al. 1993, 
Paul et al. 1994). Thus, this evidence has raised a lot of interest in NMDA receptor 
antagonist research for MDD treatment. 
The drug that has attracted most attention in this regard is ketamine, a non-selective 
NMDA receptor antagonist mainly employed as a dissociative anaesthetic, and 
recently approved by the FDA for treatment of depression at sub-anaesthetic doses 
(Chang et al. 2019). Although it has been reported that ketamine can induce rapid 
(within 24 hours) and long lasting antidepressant effects (Murrough et al. 2013), the 
mechanism is still unclear. However, accumulated lines of evidence suggest that 
ketamine-mediated improvements in depressive behaviours might be associated with 
modulation of synaptogenesis, stimulation of the mammalian target of rapamycin 
(mTOR) pathway, and increased synaptic proteins (Duman et al. 2012, Moda-Sava et 
al. 2019). Unfortunately, similar to other NMDA receptor antagonists, ketamine has 
demonstrated a tendency to invoke psychotomimetic side effects, including 
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hallucinations, paranoid delusions, confusion, and learning and memory deficits 
(Iadarola et al. 2015). 
In contrast, anxiolytic drugs are chemical compounds designed to alleviate anxiety 
disorders. GABA is the most abundant inhibitory neurotransmitter in the mammalian 
brain, because of its capacity to bind to the GABA receptors and subsequently induce 
neuronal membrane polarisation (Mohler 2006). In this regard, during the 1960’s the 
first drugs discovered that induced anxiolytic effects were benzodiazepines (chemicals 
with a benzene ring linked to a diazepine ring), which were found to positively 
modulate GABAA receptors,  (Haefely et al. 1975, Masiulis et al. 2019). GABA 
receptors are widely distributed throughout the CNS, and the neurobiological 
consequences of their activation in different brain regions are not fully understood 
(Bowery et al. 1987, Uzun et al. 2010). Indeed, benzodiazepines are associated with 
adverse reactions, including drowsiness, hangover, and dizziness, as well as with 
memory impairment/amnesia (Vgontzas et al. 1995). On the other hand, 
pharmacological treatments with SSRIs have displayed positive effects for certain 
anxiety disorders (Thibaut et al. 2017). Moreover, due to their good risk/benefit 
balance, SSRIs were recommended as first line treatments for anxiety (Wehry et al. 
2015, Thibaut et al. 2017). 
Taken together, most of the pharmacological research focused on treatment for stress-
related disorders are mainly based on restoring and compensating the neurochemical 
imbalance observed in these conditions (Fig. 1.7.2). Nevertheless, numerous side 
effects accompany these treatments, and some medications are ineffective in a 
proportion of patients, around 20 to 30% for MDD (Olchanski et al. 2013, Aust et al. 
2019). For these reasons, more investigation is urgently required in the field of 
antidepressant and anxiolytic therapies, and the search for strategies less invasive with 
fewer negative side effects is needed. 
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Figure 1.7.2 Long-term effects of antidepressants on synaptic plasticity. Antidepressant drug actions 
focused on different cellular pathways associated with neuroplasticity, including mechanisms of 
neurotransmitter release, postsynaptic Ca+2 signalling, trafficking of glutamate AMPA receptor 
subunits. At molecular level, other pathways have been linked with antidepressant activity, such as 
BDNF, mTORC1, PSD95, VDCC, and GSK3. AMPA=α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor. BDNF=Brain-derived neurotrophic factor. GSK3=Glycogen 
synthase kinase-3. mTORC1=mammalian target of rapamycin complex 1. PSD95=Post synaptic 
density 95. VDCC=voltage dependent calcium channel. Modified from (Duman et al. 2016).  
1.8 The role of nutrition in mental health and disease 
It is widely accepted that nutrition and consumption of a balanced diet is an important 
factor of human health, including metabolism (Oresic 2009), cardiovascular health 
(Ignarro et al. 2007), as well as a protective role against mental illness (Rao et al. 
2008). Indeed, the relationship between health and nutrition has been recognised by 
clinicians since Hippocrates, who said “Let food be thy medicine and medicine be thy 
food.” 
Evidence in this regard suggests that nutritional deficiencies are associated with a high 
prevalence of mood symptoms and cognitive dysfunction, which correlate with 
development and onset of stress-related mental disorders. On the other hand, clinical 
studies found that depressive symptoms were associated with food insufficiency and 
nutritional deficiencies (low folate, vitamin, minerals and polyunsaturated fatty acids 
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intake) in women of childbearing age and elderly populations (Bodnar et al. 2005, 
German et al. 2011). In addition, the increased prevalence of mental disorders in 
developed countries is highly correlated with the consumption of westernised diets 
(Young 2002), which is characterised by increased intake of red meat, pre-packaged 
foods, fried foods, high-fat dairy products, refined and processed grains and fruits, and 
high-sugar drinks (Cordain et al. 2005, Yeomans 2017). For instance, a preclinical 
investigation demonstrated that feeding mice with an energy-dense food (considered 
as western diet) induced cognitive impairments and increased anxiety-like behaviour 
in these animals (Andre et al. 2014). Similarly, a longitudinal investigation of people 
aged 60-64 years found that western diet consumption was associated with reduced 
hippocampal volume (Jacka et al. 2015). 
The majority of mental disorders are treated with prescription drugs, but many of these 
drugs cause unwanted side effects and their cost is continuously rising (for more 
details see section 1.7). For these reasons, nutritional therapies for mental illness have 
become interesting candidates for alleviating and mitigating stress-related disorder 
symptoms. In this regard, accumulated work in the field of nutritional psychiatry has 
proposed different dietary interventions to supplement apparent deficiencies 
associated with stress-related disorders, including amino acids, polyunsaturated fatty 
acids (PUFAs), polyphenols, and phospholipids (Sureda et al. 2015, Martinez-
Cengotitabengoa et al. 2017, Smith et al. 2018, Adan et al. 2019, Boyle et al. 2019). 
Indeed, all of these components have been found enriched in Mediterranean diet, 
firstly defined because it reflects food patterns typical of countries around the 
Mediterranean Sea, including Crete, Greece and southern Italy (Willett et al. 1995, 
Gerber et al. 2015). In particular, the Mediterranean diet have attracted great attention 
since it has been associated with low rates of chronic diseases and high adult life 
expectancy (Martinez-Gonzalez et al. 2016, Galbete et al. 2018). 
Perhaps, one of the most studied nutritional interventions for the treatment of 
depression is tryptophan supplementation (Shaw et al. 2002). Tryptophan is an 
aromatic amino acid, which is enriched in high-protein sources, including eggs, fish, 
soybean, cheese, and sesame seed (Markus et al. 2008). Tryptophan diet interventions 
for stress-related disorders, and especially MDD, are based on the monoaminergic 
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hypothesis of depression (see section 1.7), since tryptophan is an important precursor 
of serotonin in its synthesis pathway, hence favouring the serotonin production and 
concentration in the brain (Markus et al. 2008).  
However, clinical trials in which patients have been administered tryptophan have 
given conflicting results and reached differing conclusions (Shaw et al. 2002). In 
addition, tryptophan supplementation is known to have side effects. Occasionally, 
tryptophan administration at higher doses is accompanied with gastrointestinal 
distress, nausea, dizziness, and tremor. In rare cases, when tryptophan treatment is 
combined with serotonin drugs (e.g. SSRIs), can result in abnormal serotonin 
stimulation, which is called “serotonin syndrome”. The symptoms of serotonin 
syndrome include agitation, delirium, coma, mydriasis, sweating, and hyperthermia 
(Fernstrom 2012). 
PUFAs represent another alternative for neuropsychiatric treatment obtained from 
natural-derived diets. PUFAs are fatty acids constituting a long hydrocarbon chain that 
possesses two or more carbon-carbon double bonds (Wiktorowska-Owczarek et al. 
2015).  Early studies first linked the beneficial effects of PUFAs with improvements 
in CVD (Hu et al. 2002, Watanabe et al. 2017). Later, several studies demonstrated 
that PUFAs, especially Omega-3 fatty acid derivatives play a significant role in 
modulation of neurotransmission and cell signal transduction in the CNS (Chalon et 
al. 2001, Alessandri et al. 2004). Indeed, abnormalities in fatty acid metabolism and 
Omega-3 fatty acid deficiencies may play a causal role in development and onset of 
stress-related conditions, especially in depressive disorders (Lin et al. 2017, 
Messamore et al. 2017). 
For these reasons, Omega-3 dietary interventions have attracted a lot of interest for the 
treatment of depression. Particularly, the Omega-3 fatty acids docosahexaenoic acid 
(DHA) and eicosapentaenoic acid (EPA) (Fig. 1.8.2), have shown promising results in 
preclinical studies (Pusceddu et al. 2015), as well as in clinical trials treating 
depressive disorders (Stoll et al. 1999, Nemets et al. 2006). Although several lines of 
evidence suggest that Omega-3 PUFAs might have an antidepressant effect, there is 
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still limited data from clinical studies and in some cases the validity of findings is 
questionable (Rogers et al. 2008). 
 
Figure 1.8.2 Chemical structure of DHA and EPA. DHA=Docosahexaenoic acid. EPA= 
Eicosapentaenoic acid. 
1.8.1 The impact of nutrition on the microbiota-gut-brain axis 
During the last decade, the gut microbiota composition has emerged as a relevant 
biometric for health status (Claesson et al. 2012). In this regard, microbial composition 
imbalance in the body has been associated with behavioural alteration, including 
attention deficit disorder and autism (Borre et al. 2014, Rosenfeld 2015, Cenit et al. 
2017), therefore it is considered that positively modulating the microbiota composition 
might have potential in ameliorating disease. There are numerous environmental and 
genetic factors able to influence the gastrointestinal microbiota (Spor et al. 2011, 
Blekhman et al. 2015), however diet represents the most critical element in terms of 
changes of microbiota composition during the lifespan (Lankelma et al. 2015, Xu et 
al. 2015). 
Thus, dietary interventions focused on manipulating gut microbiota composition may 
have the potential to modulate psychiatric symptoms associated with gut-brain-axis 
dysfunction. For instance, research using a diet containing meat reported changes to 
gut microbial diversity, which correlated with improvements in cognition and working 
memory, and decreased anxiety-like behaviours (Li et al. 2009). Specifically, dietary 
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interventions based on prebiotics (compounds that induce the growth or activity of 
beneficial bacteria) have attracted a lot of interest in research as modulators of mood 
in stress-related disorders (Hutkins et al. 2016). In this regard, recent preclinical work 
demonstrated that prebiotics consisting of fructooligosaccharide (FOS) and 
galactooligosaccharide (GOS) induced antidepressant and anxiolytic effects in 
chronically stressed mice (Burokas et al. 2017). 
Dietary interventions designed to treat neuropsychiatric disorders are clearly focused 
on providing novel and “natural” therapies, which represent valid alternatives for drug 
resistant patients and those that are afraid or suffering from negative side effects 
associated with prescription antidepressant and anxiolytic drugs. Therefore, research 
on dietary interventions for mental disorders is critical to understand the role of 
nutritional components in mental health and disease. Thus, the purpose of the work 
presented in this thesis is to further explore the role of naturally-derived compounds, 
especially polyphenols and phospholipids, which have been gaining increasing interest 
as potential biomolecules for the development of novel therapies for stress-related 
disorders. In the following sections the biochemical characteristics and biological 
implications for mental health of polyphenols and phospholipids will be reviewed in 
detail. 
1.9 Polyphenols 
Over the past 20 years, scientists and food manufacturers have become increasingly 
interested in polyphenols. The key reason for this interest is the recognition of their 
antioxidant properties, their great abundance in our diet, and their potential role in the 
prevention and treatment of various diseases associated with oxidative stress, 
including cancer, CVD, metabolic and neurodegenerative diseases (Manach et al. 
2004, Pandey et al. 2009). Although there are accumulating data from animal and 
human studies showing that polyphenols are capable of modulating the activity of a 
wide range of enzymes and cellular receptors (Vauzour et al. 2010), polyphenols also 
have several other specific biological actions that remain poorly understood.  
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1.9.1 Structure and natural sources of polyphenols 
Polyphenols vary both in chemical structure and functional activity, therefore their 
biological actions strongly depend of their molecular size, specific substituents and 
solubility. Indeed, their chemical structure is characterized by the presence of at least 
one aromatic ring with one or more hydroxyl group attached. Polyphenol size range 
from simple small single phenolic ring compounds to complex, weighty condensed 
structures; therefore, these compounds have been classified into different groups based 
on the function, number and distribution of phenolic rings, as well as structural 
elements present in these rings (Bravo 1998). Although there is no universal 
classification system of polyphenols, it is widely accepted that they fall into one of 
two categories: flavonoids and non-flavonoids (Fig. 1.9.1). Flavonoids contain a 
common structure consisting of two phenolic rings linked by a three carbon atom 
bridge that form an oxygenated heterocycle. Non-flavonoids include other 
polyphenolic compounds such as phenolic acids, phenyl alcohols, stilbenes, lignans 
and chalcones (Motilva et al. 2013). 
 
Figure 1.9.1 Classification of dietary polyphenols, some examples and their molecular structure.  
Polyphenolic compounds are molecules that are mainly found in fruits and vegetables 
where they act as secondary metabolites which are involved in host defence against 
pathogens and UV radiation (Haslam 1988). Indeed, major dietary sources of 
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polyphenols include fruits, vegetables, cereals, tea and wine. Certain polyphenols are 
found in all plant products (e.g. quercetin), whereas others are specific to particular 
foods (e.g. flavanones in citrus fruits) (Manach et al. 2004). On the other hand, there 
are many plant products where the polyphenol composition is not fully defined. 
Furthermore, numerous factors can affect the polyphenol content in certain foods, 
including ripeness, environmental factors, processing and storage (Manach et al. 
2004). 
1.9.2 Polyphenols as modulators of brain health 
It has been recognized for many years that a diet rich in polyphenols can protect 
against an array of chronic diseases (Vauzour et al. 2010), including CVD (Fuhrman 
et al. 2005, Hubbard et al. 2006), specific forms of cancer (Zhou et al. 2016), and 
neurodegenerative disorders (Solanki et al. 2015). In this regard, evidence supports 
the neuromodulatory potential of polyphenols via their ability to protect vulnerable 
neurons and improve neuronal function and regeneration (Spencer 2008). In particular, 
several in vitro studies have confirmed the neuroprotective capacity of polyphenols 
mainly against cytotoxicity induced by both oxidative stress (Yao et al. 2015) and β-
amyloid peptide (Aβ) in neuronal-death models (Godoy et al. 2016).  
There is accumulating data from animal and human studies that support the role of a 
variety of dietary polyphenols in affecting behaviour and mood through anxiolytic and 
antidepressant properties (Dias et al. 2012) (see Table 1.9.1 to see some examples in 
pre-clinical studies). For instance, seminal work in this field-tested a polyphenol-rich 
traditional Chinese herbal medicine, which is used to treat depression, performing 
neurochemical analyses in chronically stressed rats. Their findings showed that 
flavonoid-rich treatment induced an increase in neurogenesis and hippocampal Brain-
derived Neurotrophic Factor (BDNF) expression, indicating one of the cellular 
mechanisms underlying the antidepressant action of this Chinese medicine (An et al. 
2008). Recent studies using resveratrol, a polyphenol found in grape skin and hence 
red wine, showed that the treatment with this polyphenol ameliorated chronic 
unpredictable stress-induced depression-like behaviour in rats. This effect was 
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correlated with a downregulation of the HPA axis hyperactivity and a modulation of 
the Wnt/catenin pathway (Yang et al. 2017).  
Table 1.9.1 Evidence of polyphenol-mediated improvements of depressive-like behaviours 
Polyphenol Dose 
(mg/kg) 
Duration Animal 
model 
Behavioural 
outcomes 
Biochemical 
outcomes 
Reference 
Resveratrol 20 – 80 
i.p. 
5 weeks CUS in Wistar 
rats  
↑Sucrose 
preference  
↓Immobility 
FST 
↓Corticosterone 
↑BDNF, 
pCREB 
(Liu et al. 
2014) 
Resveratrol 15 i.g. 3 weeks CUS in 
Sprague 
Dawley rats 
↑Sucrose 
preference  
↓Immobility 
FST 
↓Corticosterone, 
CRF 
↓IL-6, CRP  
TNF-α 
↑BDNF 
(Yang et al. 
2017) 
Resveratrol 20 i.p. 2 weeks Ovariectomy 
in C57BL/6J 
↑Time in centre 
OFT 
↑Open arms 
time EPM 
↓Immobility 
TST 
↓Immobility 
FST 
↔NPC 
proliferation 
↓Microglia 
activation 
↓NF-κB, ↓IL-1β 
↑Sirt1 
(Liu et al. 
2019) 
Quercetin 20 – 40 
p.o. 
1 hour Albino Swiss 
mice 
↑Social 
interaction 
↓Immobility 
FST 
None (Bhutada et 
al. 2010) 
Quercetin 300 p.o. 3 weeks Wistar rats ↑Open arms 
time EPM 
↑Spatial 
learning 
None (Priprem et 
al. 2008) 
Quercetin 20 i.p. 2 weeks Restrain-
induced 
chronic stress 
in Wistar mice 
↑Time in light 
box  
↑Open arms 
time EPM 
↓Immobility 
FST 
↑SOD, 
↑Catalase 
activity 
↑Brain 
acetylcholine 
(Samad et 
al. 2018) 
Naringenin 10 – 50 
i.g. 
1 hour ICR mice ↓Immobility 
TST 
↔Immobility 
FST 
None (Yi et al. 
2010) 
Naringin 50 – 100 
i.p. 
2 weeks Doxorubicin 
injection 
Wistar rats 
↑Time in centre 
OFT 
↓Immobility 
FST 
↑Sucrose 
preference 
↑Antioxidant 
enzymes 
(Kwatra et 
al. 2016) 
Curcumin 50 – 200 
i.p. 
10 days Wistar Kyoto 
rats 
↓Immobility 
FST 
↑BDNF 
↓IL-1β, TNF-α 
↓Corticosterone 
(Hurley et 
al. 2013) 
Curcumin 20 p.o.  3 weeks Corticosterone
-injection 
↑Sucrose 
preference in 
SPT 
↓Immobility in 
FST 
↑BDNF (Huang et 
al. 2011) 
Catechins 5 – 20 
p.o. 
1 week ICR mice ↓Immobility in 
TST 
↓Immobility in 
FST 
↓Corticosterone 
and ACTH 
(Zhu et al. 
2012) 
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Although the health benefits associated with polyphenol consumption are evident, the 
mechanisms underlying their neuroprotective effects are unclear. Below, evidence 
regarding polyphenol-mediated activation of signalling pathways involved in 
neuroprotection and plasticity is explored. 
1.9.3 Neuroprotective mechanisms associated with polyphenols 
Several polyphenolic compounds have been identified acting as potent effectors of 
cellular processes with a capacity to positively modulate neuroprotective mechanisms. 
Although the molecular mechanism involved in the pathophysiology of neural disease 
and mental disorders are numerous, a number of studies have suggested an important 
role for different pathways involved in neuroplasticity and cytoprotective responses 
that might be linked to polyphenols. 
The Nrf2 signalling pathway 
For example, the nuclear factor E2-related factor 2 (Nrf2) has been associated with 
neuroprotective effects of polyphenols (Scapagnini et al. 2011), and is probably the 
most studied pathway associating polyphenolic consequences in animal and human 
physiology. The Nrf2 transcription factor is a member of the Cap‘n’Collar family of 
transcription factors, which in normal conditions is inactivated by binding to Keap1, 
which promotes Nrf2 proteasomal degradation via interactions with a ubiquitin ligase 
(Sun et al. 2007). Several stress signals, including oxidative stress and electrophiles, 
can disrupt the Nrf2/Keap1 complex and allow Nrf2 to translocate into the nucleus 
(Fig. 1.9.3.1). There, the activated form of Nrf2 is able to interact with the antioxidant 
response element (ARE) in the nucleus (Malhotra et al. 2010), which positively 
modulates antioxidant responses, and triggers the simultaneous expression of 
numerous protective enzymes and scavengers (Scapagnini et al. 2011). 
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Figure 1.9.3.1 The Nrf2 signalling pathway is activated by oxidative stress or polyphenols. 
Intracellular signals like polyphenols or oxidative stress induce the activation of Nrf2, which 
translocates to the nucleus and interact with antioxidant response elements (ARE), triggering the 
expression of cytoprotective and antioxidant enzymes. 
The capacity of polyphenols to activate the Nrf2 pathway has been demonstrated in 
several in vitro models (Table 1.9.2). For instance, naringin, a polyphenolic compound 
mainly found in grapefruit, was shown to protect H9c2 cells (myoblast) against anoxia/ 
reoxygenation-induced apoptosis in vitro via the Nrf2 signalling pathway (Chen et al. 
2015), as well as to reduce the neurotoxic effects of 6-OHDA in a neuroblastoma cell 
line (Lou et al. 2014). 
Table 1.9.2 Evidence of polyphenol-mediated Nrf2 activation in vitro 
Polyphenol Cells Dose Model Effect via Nrf2 Reference 
Naringin H9c2 cell 
line 
10 – 40 
µg/mL 
Anoxia/reoxygenation-
induced apoptosis 
↓Apoptosis 
↑Antioxidant 
capacity 
(Chen et al. 
2015) 
Naringenin SY5Y cell 
line 
20 – 80 
µM 
6-OHDA-induced 
neurotoxicity 
↓Neurotoxicity 
↑Nrf2 
expression 
↑ARE 
activation 
(Lou et al. 
2014) 
Resveratrol Coronary 
arterial 
endothelial 
cells 
0.1 – 100 
µM 
High glucose-induced 
mitochondrial and 
cellular oxidative stress 
↓Oxidative 
stress      
↑Nrf2 target 
genes 
expression 
(Ungvari et 
al. 2010) 
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Resveratrol Neural stem 
cells 
1 – 20 µM Oxygen-glucose 
deprivation/reoxygenat
ion  
↑Survival and 
proliferation 
↓Apoptosis     
↑SOD activity        
↑Nrf2 target 
genes 
expression 
(Shen et al. 
2016) 
Quercetin Human 
hepatocytes 
10 – 200 
µM 
Ethanol-derived 
oxidative stress 
↑HO-1 
expression 
↓toxicity 
↓AST/LDH 
release 
(Yao et al. 
2007) 
Quercetin Primary 
cerebellar 
granule 
neurons 
5 – 100 
µM 
H2O2-induced 
oxidative stress 
↑GSH levels  
↑Nrf2 
translocation 
↑GCLC 
expression 
(Arredondo 
et al. 2010) 
Curcumin MCF-7 cell 
line 
10 – 30 
µM 
Proliferative conditions ↓Proliferation  
↓Fen-1 
expression 
(Chen et al. 
2014) 
EGCG Primary 
vascular 
endothelial 
cells 
25 – 50 
µM 
PCB 126-induced 
inflammation 
↑Nrf2-regulated 
antioxidant 
enzymes   
↓PCB-induced 
CYP1A1 
expression 
↓Superoxide 
(Han et al. 
2012) 
ARE=Antioxidant Response Elements; AST=Aspartate Transaminase; CYP1A1=Cytochrome P450 
1A1; Fen-1=Flap Endonuclease 1; GCLC=Glutamate-Cysteine Ligase Catalytic Subunit; 
GSH=Glutathione; HO-1=Heme Oxygenase 1; LDH=Lactate Dehydrogenase; PCB=Polychlorinated 
Biphenyl; SOD=Superoxide Dismutase. 
On the other hand, accumulating evidence suggests an important role for Keap1/Nrf2 
signalling in mood disorders. Preclinical studies demonstrated that mice subjected to 
chronic stress have lower protein expression of Keap1 and Nrf2 in the prefrontal cortex 
(PFC), CA3 and dentate gyrus (DG) of the hippocampus compared with non-stressed 
animals, which it was correlated with depressive-like behaviours (Yao et al. 2016, 
Zhang et al. 2018). Furthermore, Nrf2 knockout mice exhibited depressive-like 
behaviours accompanied by increased plasma pro-inflammatory cytokines levels and 
reduced BDNF expression in hippocampal regions (Yao et al. 2016). In addition, post-
mortem analysis from patients with MDD and bipolar disorder showed decreased 
expressions of Keap1 and Nrf2 in cortical brain areas (Martin-Hernandez et al. 2018, 
Zhang et al. 2018). Taken together, the evidence suggests an important role for the 
Nrf2 pathway in polyphenol-mediated neuroprotection and mental health.  
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Polyphenols and BDNF 
The role of dietary polyphenols in neuroprotection and brain health has also been 
associated with the modulation of BDNF expression (Venkatesan et al. 2015). BDNF 
belongs to the neurotrophin family of growth factors, which are implicated in  neuronal 
survival support and providing the growth and differentiation of new neurons and 
synapses (Huang et al. 2001). Indeed, neurotrophin levels, especially BDNF, have 
been highly associated with the development and treatment of stress-related mental 
disorders, such as depression and anxiety (Martinowich et al. 2007, Brunoni et al. 
2008). 
Studies using different in vitro neuronal models have demonstrated the potential of 
polyphenols in regulating BDNF, and subsequently the neuroprotection associated 
with these phytochemicals. For instance, tea polyphenols were able to protect neurons 
through activation of the TrkB/CREB/BDNF pathway against oxidative stress-
induced apoptosis (Qi et al. 2017). In a different study testing the neuroprotective 
properties of catechines, a type of polyphenol that belongs to the family of flavonoids, 
discovered that mitochondrial toxin-induced cytotoxicity was prevented by these 
catechines by increasing the protein levels of BDNF in primary hippocampal neurons 
(Nath et al. 2012). 
The relationship between polyphenol consumption and BDNF expression has been 
also demonstrated in vivo. A clear example was shown in a study where administration 
of different doses of resveratrol to naïve rats, resulted in dose-dependently elevated 
mRNA levels of BDNF in hippocampal tissue (Rahvar et al. 2011). To demonstrate 
that this resveratrol-mediated increased expression of BDNF has therapeutic effects in 
neuropsychiatric disorders, in vivo studies using models of chronic stress have been 
assessed. In this regard, it was shown that the resveratrol antidepressant-like effects in 
CUS in rats and LPS-induced depressive-like behaviour in mice could be partly 
mediated by modulation of BDNF expression (Liu et al. 2014, Ge et al. 2015). Taken 
together, these data support the role of BDNF in mechanisms associated with 
neuroprotection by polyphenols. 
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Polyphenols and neuroinflammation 
Brain inflammation, a pathophysiological process characterised by increased 
microglia and astrocyte activation, increases during aging and is a key feature of 
neurodegenerative diseases (Sawikr et al. 2017). In addition, patients diagnosed with 
stress-related disorders, such as depression and anxiety, show increased levels of 
circulating pro-inflammatory cytokines (Brites et al. 2015), suggesting a critical role 
for neuroinflammation in the onset and development of stress-related neuropsychiatric 
disorders.  
In this regard, polyphenols have been reported to exert anti-inflammatory effects in 
acute and chronic animal models of inflammation (Wang et al. 2012, Jhang et al. 2015, 
He et al. 2016). In terms of known mechanisms associated with anti-inflammation, 
polyphenols have been found to regulate immune cells (Shimizu 2017), and to 
modulate the activity and expression of enzymes involved in arachidonic acid 
metabolism, including phospholipase A2 and cyclooxygenase (Yahfoufi et al. 2018). 
For instance, further studies have associated the anti-inflammatory capacity of 
resveratrol with inactivation of the peroxisome proliferator-activated receptor gamma 
(PPAR-α) (Mohar et al. 2012, Barone et al. 2019). Curcumin, another non-flavonoid 
polyphenol, was shown to inhibit the nuclear factor κB (NF- κB) (Chin 2016, Wang 
et al. 2018). 
Particularly, polyphenol treatments have displayed promising effects against 
neuroinflammatory injuries. For example, a study demonstrated that intragastric 
administration of resveratrol was able to ameliorate neuroinflammation by promoting 
microglia polarization to the anti-inflammatory phenotype (Yang et al. 2017). 
Quercetin also has demonstrated to have therapeutic potential against 
neuroinflammation. Oral treatment with quercetin reversed the augmented expression 
of pro-inflammatory cytokines and the affected haematological parameters found in 
the rat brain after manganese-induced neuroinflammation (Bahar et al. 2017). 
Similarly, LPS-induced brain inflammation and synaptic dysfunction was attenuated 
by treatment with quercetin in a mouse model (Khan et al. 2018). This evidence 
highlights the anti-inflammatory capacity of polyphenols as a relevant mechanism of 
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neuroprotection with important implication for neurodegenerative and stress-related 
mental disorders. 
1.9.4 Impact of polyphenol intake on the microbiota-gut-brain axis 
Most of the health benefits of polyphenols are determined by their bioavailability, 
which is dramatically affected by different biochemical factors, including the type of 
bioactive compounds, their polarity, molecular mass, source matrix, digestibility by 
gastrointestinal enzymes, and absorption into the enterocytes (Ozdal et al. 2016). In 
this regard, gut microbiota metabolism plays a critical role in the bioavailability of 
polyphenol-derived compounds once polyphenols pass the small intestine and 
encounter the gut microbiota in the colon (Scalbert et al. 2000). Polyphenols are 
extensively conjugated and metabolized in the small intestine and liver during nutrient 
absorption (Marin et al. 2015). Specifically, they are subject to phase I de-
glycosylation and phase II metabolism processes, which involve methylation, 
sulphation, glucuronidation and hydrolysis. All of these metabolic transformations are 
common to many xenobiotics as a detoxification system and facilitate their elimination 
by increasing their hydrophilicity (Williamson et al. 2017). 
On the other hand, polyphenols are capable of modulate the composition of the gut 
microbial community by inhibiting or stimulating the growth of certain bacteria (Lee 
et al. 2006). Indeed, a number of studies assessing the impact of polyphenols on 
microbiota composition have been published in recent years (Table 1.9.4.1). For 
example, a study analysing the effect of isoflavone supplementation on 
postmenopausal women for two months found an increase in Bifidobacterium species 
in their gut microbiota (Clavel et al. 2005). Another study, using rats on a diet 
intervention with tannins, a class of polyphenolic compounds, detected that 
Bacteroides was significantly increased, while the Clostridium leptum cluster was 
significantly decreased (Smith et al. 2005). 
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Table 1.9.4.1 Evidence of polyphenols modifying gut microbiota composition 
Polyphenol Dose Duration Model Impact on the gut 
microbiota 
Reference 
Resveratrol 200 
mg/kg 
p.o. 
12 weeks Kunming mice 
– High-fat diet 
↑Bacteroides/Firmicutes 
↑Lactobacillus 
↑Bifidobacterium 
↓Enterococcus faecalis 
(Qiao et al. 
2014) 
Resveratrol 1 mg/kg 
p.o. 
25 days F334 rats – 
DDS-induced 
colitis 
↑Lactobacillus 
↑Bifidobacterium 
↓Enterococcus 
(Larrosa et 
al. 2009) 
Resveratrol+ 
Quercetin 
30+15 
mg/kg 
i.g. 
10 weeks Wistar rats – 
High-fat diet 
↓Firmicutes/Bacteroides 
↑Akkermansia 
↑Ruminococcaceae 
↑Bacteroidales 
(Zhao et al. 
2017) 
Quercetin 30 mg/kg 
p.o. 
6 weeks Wistar rats – 
High-fat 
sucrose diet 
↓Firmicutes/bacteroides 
↓Erysipelotrichaceae 
↓Bacillus 
↓Euabcterium 
↓Cylindroides 
(Etxeberria 
et al. 2015) 
Quercetin 0.05% 
w/w p.o. 
16 weeks C57BL/6J mice 
– High-fat diet 
↓Firmicutes/bacteroides 
↓Helicobacter 
↔Lactobacillus 
↔Parabacteroides 
↓Desulfovibrio 
↔Akkermansia 
(Porras et al. 
2017) 
Curcumin 200 
mg/kg 
i.g. 
12 weeks Sprague 
Dawley rats – 
High-fat diet 
↓Richness 
↓α-Diversity 
↑Streptococcus 
↑Collinsella 
↓Ruminococcus 
(Feng et al. 
2017) 
Curcumin 100 
mg/kg 
i.g. 
12 weeks Wistar rats – 
Ovariectomy 
↑α-diversity 
↑Bacteroides/Firmicutes 
↓Helicobacter 
↑Serratia 
↑Pseudomonas 
↑Shewanella 
(Zhang et al. 
2017) 
Condensed 
tannins 
2% w/w 
p.o. 
3 weeks Wistar Furth 
rats  
↑Enterobacteriaceae 
↑Bacteroides 
↑Prevotella 
↑Porphyromonas 
↓Clostridium 
(Smith et al. 
2004) 
EGCG 25 mg/kg 
p.o. 
4 months C57BL/6J mice 
– High-fat diet 
↓Firmicutes/Bacteroides 
↓Lactobacilli 
↑Clostridium 
↑Bacteroidetes 
↓Akkermansia 
(Remely et 
al. 2017) 
Tea 
catechines 
0.1% 
w/w p.o. 
7 weeks db/db mice ↑Richness 
↑Evenness 
↓Barnesiella 
(Chen et al. 
2019) 
Thus, the potential of polyphenolic compounds in modifying the gut microbial 
composition as a strategy to modulate the gut-microbiota-brain axis has attracted great 
interest in novel treatments for neuropsychiatric disorders.  
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1.10 Phospholipids 
The brain contains an incredible mixture of lipids, which represent important 
biochemical components of the CNS in terms of neuronal function and structure 
(Brown et al. 2009). Indeed, disturbances in brain lipid balance have been associated 
with common neurological disorders, including Parkinson’s Disease, Alzheimer’s 
Disease, amyotrophic lateral sclerosis, and glioblastomas (Dawson 2015). In 
particular, phospholipids have attracted great interest due to they represent a major 
component of all cell membranes (Kent 1995), and their potential link with a number 
of health benefits in relation to different illnesses, including coronary health disease, 
inflammation and cancer (Kullenberg et al. 2012). However, more research is needed 
to understand the impact of phospholipid supplementation on brain health, and the 
implication of potential neuroprotective mechanisms involved in the phospholipid-
elicited health benefits. 
1.10.1 Structure and natural sources of phospholipids 
Phospholipid structure generally consists of a hydrophilic “head” formed by a 
phosphate group and two hydrophobic “tails” (see Fig. 1.10.1 A), which can be 
unsaturated fatty acids in the sn-2 position, such as oleic, linoleic or linolenic, 
arachidonic, or eicosapentanoic acid, while the sn-1 position predominantly carries a 
saturated fatty acid, such as stearic or palmitic acid (Kullenberg et al. 2012). This 
structure confers their typical amphiphilic characteristics that allow them to form lipid 
bilayers (Peterson et al. 2006) (see Fig. 1.10.1 B).  
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Figure 1.10.1 (A) Schematic chemical structure of phospholipids and (B) their capacity to form a lipid 
bilayer. G=Glycerol moiety;  –P=Phosphate group.  
Phospholipids differ in not only their hydrophobic tail, but they also show differences 
in their hydrophilic heads where the phosphate group can be modified with organic 
molecules such as choline or serine. In this regard, among the most common 
phospholipids found in food are phosphatidylcholine (PC), phosphatidylethanolamine 
(PE), phosphatidylserine (PS), phosphatidylinositol (PI), and sphingomyelin (SM) 
(Cohn et al. 2010) (see Fig. 1.10.2). 
 
Figure 1.10.2 Chemical structure of PS, PE, PC, PI and SM. 
Naturally occurring phospholipids can be found in plant and animal food sources, 
including eggs, organ and lean meats, fish, shellfish, cereal grains, oilseeds and milk 
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(Cohn et al. 2010). Although, among total milk fat, only 0.32 – 1% represent 
phospholipid compounds, compared to soy lecithin and egg yolk lecithin, milk 
phospholipids have a more balanced distribution in each subclass (Garcia et al. 2012). 
For this reason, dairy-derived phospholipids have become an interesting target for 
research in the field of nutritional therapies and functional foods for enhancing 
cognition (Zheng et al. 2019). In particular, the milk fat globule membrane (MFGM) 
is one unique component, comprised of a tri-layer of polar lipids, glycolipids, and 
proteins, that may be important for brain development (Moukarzel et al. 2018). 
1.10.2 Nutritional impact of phospholipids on brain health 
Phospholipids are structural components of neural tissues, and they have been found 
to be critical for neurodevelopment and neuronal function (Svennerholm et al. 1972, 
Burdge et al. 1995). In addition, some intracellular phospholipids can be converted 
into second messengers, participating in key neuronal signalling pathways, such as 
survival and differentiation (Colombaioni et al. 2004, Huang et al. 2011). In this 
context, studies have demonstrated that phospholipid-enriched diets significantly 
impact behaviour (Kullenberg et al. 2012). For example, clinical studies using PS 
supplementation have demonstrated significant improvements in Age Related 
Cognitive Decline  in terms of cognitive performance (Crook et al. 1991). Other 
clinical study showed that PS supplementation was able to induce an improved mood 
and reduced levels of cortisol in young adults subjected to acute stress (Benton et al. 
2001). Similar effects have been detected in preclinical studies. For instance, Mice fed 
with phospholipid-enriched diet from early life until adolescence exhibited improved 
working memory performance in adolescence, whereas recognition memory was 
unchanged (Schipper et al. 2016). 
On the other hand, fatty acid analysis on the brain of mice subjected to CUS showed 
altered phospholipid content accompanied with elevated immobility time in the FST. 
Chronic stress significantly reduced the levels of PI but increased the levels of PC 
(Faria et al. 2014). Also, an in vitro study using different types of antidepressant drugs 
on a neuronal cell line, supports the role of phospholipids in their antidepressant 
activity. Here, imipramine, paroxetine, and maprotiline increased the levels of 
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diacylglycerol and PI in neuron-like PC12 cells (Aboukhatwa et al. 2010). These and 
other reports (see Table 1.10.1) suggest potential therapeutic effects of phospholipid 
supplementation on human cognitive decline and/or chronic stress. Although, the 
mechanisms underlying the phospholipid-mediated positive effects on behaviour are 
unclear, there are some candidate signalling pathways potentially implicated in 
phospholipid activity. 
Table 1.10.1 Pre-clinical and clinical evidence of phospholipid-mediated improvements in mental 
health 
phospholipid -
based 
supplement 
Dose Duration Model Effects Reference 
Bovine milk-
derived 
phospholipid 
2.7 g/day 
p.o. 
6 weeks Human – Acute 
psychosocial 
stress 
↑Attention-switching 
task 
↔Cortisol response 
↑Mid-stress induction 
energetic arousal 
(Boyle et al. 
2019) 
Phosphatidic 
acid and PS 
complex 
400 mg/day 
p.o. 
3 weeks Human – Trier 
social stress test 
↓ACTH, cortisol 
↔Heart rate 
↓Distress 
 
(Hellhammer 
et al. 2004) 
PC-enriched 
diet 
30 mg/day 
p.o. 
1 week Human – 
Bipolar disorder 
patients 
↓Mania symptoms (Cohen et al. 
1982) 
PS 300 mg/day 
p.o. 
1 month Human – 
Stressful 
arithmetic task 
↓Stress 
↓Cortisol 
(Benton et al. 
2001) 
Phospholipid-
enriched diet 
28% w/w in 
food p.o. 
28 days C57BL/6 –  
Males 
↑Short-term memory 
↔Long-term memory 
(Schipper et 
al. 2016) 
Lacprodan® 
MFGM-10 
100 mg/kg 
i.g. 
19 days Sprague Dawley 
– P2 to P21 
↑BDNF, GluR1 
↔MBP 
↑Spatial memory 
(Brink et al. 
2018) 
Krill PS 100 mg/kg 
p.o. 
30 days Sprague Dawley 
– Young males  
↑Spatial memory 
↑BDNF, IGF 
(Park et al. 
2013) 
1.10.3 Phospholipids and neuronal signalling 
It is well accepted that the composition of distinct phospholipids in eukaryotic 
membranes is essential for maintaining cellular homeostasis, while reception and 
transmission of signals across the plasma membrane has been a function generally 
attributed to transmembrane proteins (Horejsi et al. 2004, Wang et al. 2018). However, 
accumulated evidence support an important contribution of membrane lipids in the 
process of signal transduction (Sunshine et al. 2017). Indeed, alteration of 
phospholipid composition and biochemistry has been involved in allosteric regulation 
of G protein-coupled receptor (GPCR) activity (Dawaliby et al. 2015), modulation of 
Toll-like receptors signalling cascade (Erridge et al. 2008), and proliferative and 
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apoptotic pathways (Colombaioni et al. 2004, Huang et al. 2011). In particular, 
phospholipid-dependent Protein Kinase C (PKC) activation is one of the most studied 
signalling pathways associated to phospholipids (Fig. 1.10.3.1). Upon GPCR 
activation, Phospholipase C (PLC) enzymatically hydrolyses phosphatidylinositol 
diphosphate (PIP2), a structural phospholipid component of the cellular membrane, to 
inositol trisphosphate (IP3) and diacylglycerol (DAG) (Essen et al. 1997). IP3 is a 
soluble second messenger molecule able to diffuse through the cytosol, where it binds 
to its receptor, which is a calcium channel located in the endoplasmic reticulum (ER) 
(Hanson et al. 2004). When IP3 binds its receptor, calcium is released into the cytosol, 
thereby activating various calcium regulated intracellular signals, including PKC and 
muscle contraction mechanisms (Putney et al. 2012). 
  
Figure 1.10.3.1 Phospholipid-dependent activation of protein kinase C signalling. Upon GPCR 
activation, Phospholipase C (PLC) enzymatically hydrolyses phosphatidylinositol diphosphate (PIP2), 
to produce inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 induces the release of Ca++ from 
the endoplasmic reticulum (ER), which activates PKC cascade. 
Phospholipids and inflammation 
Inflammation is considered a critical component involved in the pathophysiology of 
stress-related neuropsychiatric disorders (Brites et al. 2015) (see section 1.4). Indeed, 
anti-inflammatory treatments for depression have demonstrated potential in 
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attenuating depressive symptoms without increased risks of adverse effects (Kohler et 
al. 2014, Miller et al. 2015). Interestingly, some of the beneficial effects of 
phospholipids have been associated to anti/inflammatory processes (Greig et al. 2012). 
Evidence suggests that anti/inflammatory effects of phospholipids involve the 
activation of peroxisome proliferator-activated receptors (PPARs) (Fig. 1.10.3.2). 
PPARs are transcription factors, that when bind to peroxisome proliferator hormone 
response elements (PPREs) in the nucleus, can activate different physiological 
processes including cellular differentiation, development, metabolism, and 
inflammation (Komar 2005). Indeed, activation of some PPARs inhibit the production 
of monocyte inflammatory cytokines (Jiang et al. 1998). For instance, a study 
demonstrated that oxidised phospholipids can activate PPARα in a phospholipase A2-
dependent manner (Delerive et al. 2000). Taken together, these novel insights have 
provided interesting ideas into the role of phospholipids in human inflammatory 
diseases. Moreover, phospholipids are emerging as a class of signalling lipids 
implicated in neuroinflammatory responses, and being seriously considered as a target 
for therapeutic treatment of neurological disorders with inflammation component 
(Kim 2015). 
Phospholipids as modulators of Akt 
Akt, also known as protein kinase B, is a protein identified as playing a role in the 
regulation of diverse physiological effects, including cell proliferation, survival and 
metabolism (Hers et al. 2011). Indeed, dysregulation of Akt has been associated with 
complicated diseases, such as CVD and neurological disorders (Chong et al. 2012). 
For example, interesting insights into treatment for stress-related disorders suggest a 
role for Akt in their antidepressant actions (Zhang et al. 2012, Huang et al. 2013). In 
particular, there is evidence supporting phospholipids as critical modulators of Akt 
(Huang et al. 2011). Since Akt signalling is dependent of lipid membrane balance, 
dietary phospholipids can induce Akt activation by incorporating into the cellular 
membrane and altering its composition. On the other hand, phospholipids can act as 
second messengers in cellular signalling and can activate Akt by interacting directly 
with it (Huang et al. 2011) (Fig. 1.10.3.2).  
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Figure 1.10.3.2 Phospholipids can activate PPAR and Akt signalling pathways. Phospholipids can 
interact with Akt in the cytoplasm to induce proliferative- and survival-related pathways. Similarly, 
phospholipids activate peroxisome proliferator-activated receptors (PPARs), which translocate to the 
nucleus and bind with specific DNA sites named peroxisome proliferator hormone response elements 
(PPREs) and induce the expression of genes involved with anti-inflammatory response. 
Although, more research is needed to define the potential implications of 
phospholipid-Akt interaction as a molecular target for therapeutic strategies for stress-
related disorders, the beneficial in vivo effects of phospholipids are clearly attracting 
interest in developing novel dietary treatments for neuropsychiatric mental disorders. 
1.10.4 Interaction between dietary phospholipids and the gut 
microbiota 
It is well known that diet can produce dramatic changes in gut microbiota composition, 
where these alterations are highly associated with health status (see section 1.4.1). 
However, there is a paucity of information on the effects of dietary phospholipids on 
microbiota, although this is slowly changing. For instance, a diet based in milk 
sphingomyelin improved lipid metabolism and altered gut microbiota composition in 
a mouse model (Norris et al. 2016). Specifically, this diet reduced gram-negative 
bacteria, while relative abundance of Bifidobacterium was significantly increased in 
faecal samples. On the other hand, a dietary intervention study using MFGM 
supplementation in maternally separated rats showed a significant impact on the 
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composition of the gut microbiota, alongside with attenuation of some of the long-
term effects of early-life stress (O'Mahony et al. 2019). 
However, much more research is needed to understand the potential of nutritional 
therapies using phospholipids against stress-related disorders. The purpose of this 
thesis is to give more insights into the therapeutic potential of dietary phospholipids 
in stress-related conditions using in vitro and animal models. 
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1.11 Primary hypothesis and aims of thesis 
Given that nutritional interventions supported on scientific insights have emerged as 
valid and less invasive strategies to treat stress-related neuropsychiatric disorders, it is 
hypothesised that dietary polyphenols and phospholipids will exert positive 
neurobiological effects during stress-related conditions in cellular and animal models. 
As such, this PhD thesis is based on the following overarching objectives: 
• To identify natural polyphenolics compounds with neuroprotective potential 
against CORT-induced cytotoxicity in cortical neurons, and to elucidate the 
molecular components involved in their mechanism. 
• To demonstrate that polyphenol-enriched diets improve the depressive 
phenotype produced by maternal separation, an animal model of early-life 
stress. 
• To determine whether dietary-derived phospholipids are capable of 
modulating neuronal function in vitro, including neuroprotection in cortical 
cells, and proliferation and differentiation in neural progenitor cells. 
• To investigate the potential therapeutic effects of a phospholipid-enriched food 
against cognitive decline and depressive behaviour caused by a chronic 
psychosocial stress animal model. 
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2.1 Abstract 
Polyphenols are phytochemicals that have been associated with therapeutic effects in 
stress-related disorders. Indeed, studies suggest that polyphenols exert significant 
neuroprotection against multiple neuronal injuries, including oxidative stress and 
neuroinflammation, but the mechanisms are unclear. Evidence indicates that 
polyphenol neuroprotection might be mediated by Nrf2 activation, a nuclear factor 
associated with antioxidant and cell survival response. On the other hand, in stress-
linked disorders, Fkbp5 is a novel molecular target for treatment because of its 
capacity to regulate glucocorticoid receptor sensitivity. However, it is not clear the 
role of Fkbp5 plays in polyphenol-mediated stress modulation. In this study the 
neuroprotective effects and mechanisms of the naturally-derived polyphenols 
xanthohumol and quercetin against cytotoxicity induced by corticosterone (CORT) 
were investigated in primary cortical cells. 
Primary cortical cells containing both neurons and astrocytes were pre-incubated with 
different concentrations of quercetin and xanthohumol in order to examine the 
neuroprotective effects of polyphenols on cell viability, morphology and gene 
expression following CORT insult. Both polyphenols tested prevented the reduction 
of cell viability and alterations of neuronal/astrocytic numbers due to CORT exposure 
as assessed by the MTT assay and immunocytochemistry. Basal levels of Bdnf mRNA 
were also decreased after CORT insult, however this was reversed by both polyphenol 
treatments. Interestingly, the Nrf2 inhibitor blocked xanthohumol, but not quercetin-
mediated neuroprotection. In contrast, we found that Fkbp5 expression was 
exclusively modulated by quercetin. These results suggest that naturally-derived 
polyphenols protect cortical cells against CORT-induced cytotoxicity, and enhance 
cell survival, via modulation of the Nrf2 pathway and expression of Fkbp5. 
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2.2 Introduction 
Alterations in hypothalamic-pituitary-adrenal (HPA) axis function have been 
associated with many neuropsychiatric disorders including depression, anxiety, 
anorexia nervosa and post-traumatic stress disorder (de Kloet et al. 2006, Pariante et 
al. 2008). It is well known that the HPA axis is activated in response to stress leading 
to increased concentration of glucocorticoids in the circulation. These steroid 
hormones are critical involved in the homeostatic regulation of metabolism, 
development and immune function (Sapolsky 2000). Moreover, preclinical studies 
have shown that chronic exposure to glucocorticoids produces deleterious effects to 
the structure and functional plasticity of the hippocampus and amygdala of adult rats 
(Mitra et al. 2008, Zhu et al. 2013). In addition, stress-induced increase of 
glucocorticoids has also been associated with impairment in the structure and function 
of the prefrontal cortex (PFC), a brain region that has been implicated in executive 
function (Arnsten 2009). Indeed, chronic stress exposure induces loss of dendrites and 
spines in pyramidal cells of PFC in rodents, which correlates with impaired working 
memory on the delayed alternation task (Hains et al. 2009, Shansky et al. 2009). In 
humans, chronic stress has been shown to weaken PFC functional connectivity and 
PFC regulation of the amygdala, which correlates with loss of grey matter (Arnsten 
2015). Moreover, brain-derived neurotrophic factor (BDNF), which maintains 
neuronal survival and plasticity, is decreased in chronically stressed animals and 
patients with major depressive disorder and stress-related disorders (Murakami et al. 
2005, Brunoni et al. 2008). Based on these observations, a drug that can attenuate the 
effects of chronic exposure to glucocorticoids on brain function may have a therapeutic 
potential in preventing and treating stress-related disorders. 
Polyphenolic compounds are natural phytochemicals found abundantly in plant food 
sources, and characterised by the presence of multiple hydroxyl structural units on 
aromatic rings (Vauzour 2012). Several in vivo studies have focused on the potential 
of dietary polyphenols in protecting cognitive function and reducing risk for 
developing neurodegenerative and neuropsychiatric disorders, including depression 
and anxiety (Bhutada et al. 2010, Hurley et al. 2014, Lopresti et al. 2014). Indeed, 
increasing data support the neuromodulatory potential of polyphenols via their ability 
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to protect vulnerable neurons, improve neuronal function and regeneration (Spencer 
2008). In particular, several in vitro studies have confirmed the neuroprotective 
capacity of polyphenols mainly against cytotoxicity by both oxidative stress and 
amyloid peptide (Aβ) neuronal insult (Godoy et al. 2016).  
Polyphenols vary in their chemical structure and functional activity (Vauzour et al. 
2010). Xanthohumol for example is a prenylated chalcone isolated from the female 
hop plant, Humulus lupulus and shown to possess anti-cancer, anti-inflammatory and 
neuroprotective effects in vitro (Liu et al. 2015, Yao et al. 2015). On the other hand, 
quercetin, a member of the flavonoid family, is one of the most prominent and widely 
distributed polyphenols in nature, and is found in many fruits, vegetables, leaves and 
grains (Manach et al. 2004). Quercetin has been associated with countless beneficial 
health effects such as protection against certain types of cancer, CVD and 
neurodegenerative disorders (Boots et al. 2008, Godoy et al. 2016). 
It is well known that polyphenols can activate the nuclear factor erythroid 2-related 
factor-2 (Nrf2), a redox-sensitive transcription factor related to cell survival and 
antioxidant responses (Ungvari et al. 2010, Gopinath et al. 2012). On the other hand, 
there is evidence showing that polyphenols are able to modulate the glucocorticoid 
receptor (GR) function. Indeed, the polyphenolic flavonoid icariin is able to alter the 
expression of the GR and the FK506 binding protein 5 (FKBP5), which promotes GR 
stability and reduces GR sensitivity to GC in vivo (Wei et al. 2016). Actually, 
modulation of the GR regulatory system is currently an interesting target for treatment 
for stress-related disorders, therefore more research is needed in this area (O'Leary et 
al. 2013). 
Taken together, the purpose of the present study was to explore through an in vitro 
approach new pharmacological strategies to treat stress-related disorders. In particular, 
we examined whether xanthohumol and quercetin, two naturally-derived polyphenols, 
protect against corticosterone-induced toxicity in neurons derived from the brain 
cortex, a key brain area involved in the pathophysiology of stress-related disorders. In 
addition, we explored the molecular mechanisms potentially implicated in such an 
effect.  Specifically, we examined the interaction between the Nrf2 pathway and the 
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GR signalling pathway to elucidate the key molecular mechanisms through which 
polyphenols may protect neuronal integrity and improve stress-related disorders.  
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2.3 Methods 
2.3.1 Chemicals and reagents 
Dulbecco’s modified Eagle’s medium (DMEM), foetal bovine serum (FBS), poly-L-
lysine, corticosterone (CORT), trypsin, L-glutamine, penicillin/streptomycin, D-
glucose, 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), 
dimethyl sulfoxide, Triton™ X-100, RU486, HEPES, NaCl, trigonelline and quercetin 
were purchased from Sigma. B-27 supplement was obtained from Thermo Fisher 
Scientific. Xanthohumol (purity 65 – 85%) was provided by Hopsteiner. 
2.3.2 Animals 
All procedures on live animals were performed under licence from the Government of 
Ireland Department of Health (B100/3774) in accordance with National and European 
Union directive 2010/63/EU, with prior ethical approval by University College Cork 
(AEEC #2012/045). Experiments were conducted in accordance with guidelines 
established by University College Cork's Animal Welfare Body. 
2.3.3 Cell culture 
Primary cortical cell cultures, consisting of both neurons and astrocytes, were prepared 
as described previously (Pusceddu et al. 2016) with some modifications. Briefly, 
PND1 Sprague Dawley male rats were sacrificed, brain removed and cerebral cortices 
dissected. Tissue was enzymatically dissociated with trypsin (0.25 µg/mL) and then 
triturated using a glass Pasteur pipette in warmed DMEM-F12 with 10% FBS and 100 
µg/mL DNase. Cell suspension was passed through 40 µm strainer and then 
centrifuged at 1000 rpm for 10 min at room temperature. The pellet was re-suspended 
in warm culture media (DMEM-F12 supplemented with B-27, 1% FBS, 100 U/mL 
penicillin, 100 µg/mL streptomycin, L-glutamine 2 mM and D-glucose 55 mM). The 
suspended cells were cultured at 37 °C with 5% CO2. 
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2.3.4 Cell treatment 
Quercetin and xanthohumol were selected after we detected their positive effects in a 
preliminary in vitro screen testing the potential of several polyphenolic compounds, 
including resveratrol, naringin and astaxanthin against CORT cytotoxicity in cortical 
cells (data not shown). Quercetin (0.03, 0.3 and 3 µM) and xanthohumol (0.2, 1 and 5 
µM) were added to primary cortical cell cultures at day in vitro (DIV) 5, and 
maintained for 24 hours. The media was replaced with fresh media containing 200 µM 
CORT at DIV6 and kept for 96 hours (Fig. 2A). The doses of polyphenols were chosen 
based on previous publications, which showed neuroprotective effects in vitro (Yao et 
al. 2015, Godoy et al. 2016). To investigate the involvement of Nrf2 signalling in 
quercetin and xanthohumol-mediated neuroprotective effects, cells were co-treated 
with a specific Nrf2 inhibitor (5 µM trigonelline) along with quercetin or xanthohumol 
prior to CORT treatment. The dose of trigonelline is based on previous studies of Nrf2 
inhibition in cellular models (Arlt et al. 2012, Rizza et al. 2015). 
2.3.5 Cell viability measurement 
Cell viability was determined by MTT assay based on mitochondrial dehydrogenase 
activity of viable cells as previously described (Mosmann 1983). Briefly, cortical cells 
were cultured in 24 well plate at a density of 4×10P4P cells per well. After treatment, 
medium was removed and replaced with fresh culture medium containing MTT (500 
µg/mL), and then incubated at 37 °C for 3 hours. Afterwards, 100 µL of dimethyl 
sulfoxide were added to each well to dissolve the resulting formazan. The absorbance 
values were measured by spectrophotometry at 570 nm with a microplate reader 
(BioTek Synergy HT). The results were expressed as a percentage of vehicle control 
group. 
2.3.6 LDH determination 
Lactate dehydrogenase (LDH) release is usually quantified as a marker for cell lysis 
and necrosis (Brito et al. 2006). Detection of LDH was measured using the 
Cytotoxicity Detection Kit LDH (Roche) according to manufacturer instructions. 
Briefly, cortical cells were cultured in 24 well plate at a density of 4×10P4 P cells per well. 
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After treatment, medium was transferred to a 96 well plate. Mix solution from kit 
containing both Catalyst and Dye solution was added to the wells and incubated for 
30 min at room temperature protected from light. The absorbance values were 
measured by spectrophotometry at 490 nm with a microplate reader (BioTek Synergy 
HT). 
2.3.7 Immunocytochemistry 
Cellular staining for βIII-tubulin and Glial Fibrillary Acidic Protein (GFAP) proteins, 
molecular markers for neurons and astrocyte respectively, was assessed as through 
immunofluorescence detection as previously described (Pusceddu et al. 2016). 
Briefly, cortical cells were fixed with ice-cold methanol for 10 min and then blocked 
overnight in 5% horse serum at 4 °C. Subsequently, the cells were incubated in primary 
antibody solution (mouse anti-βIII-tubulin 1:300, Promega; rabbit anti-GFAP 1:300, 
Dako) overnight at 4 °C. The following day, the cells were incubated with the 
appropriate secondary antibody (Alexa Fluor 594 donkey anti-mouse 1:2000, Thermo 
Fisher; Alexa Fluor 488 donkey anti-rabbit 1:2000, Thermo Fisher) for 1 hour at room 
temperature. Finally, cellular counterstaining was assessed with Hoechst 33258 
(Sigma) during 5 min. The cells were viewed using an Olympus BX53 upright 
fluorescence microscope.  
2.3.8 Quantitative RT-PCR 
Total RNA was isolated from primary cortical cells using the High Pure RNA isolation 
kit (Roche). Briefly, cells were seeded at density of 1.5×106 cells per well in 6-well 
plates, followed by pre-treatments with quercetin and xanthohumol before CORT 
insult. Cells were harvested and the lysate transferred into a filter tubes. RNA 
concentration was assessed using the ND-1000 spectrophotometer. Subsequently, 
isolated RNA was reverse transcribed into cDNA using the ExiLERATE LNA™ 
qPCR, cDNA synthesis kit (Exiqon). Following reverse transcription, mRNA 
expression levels of respective genes were measured using a lightcycler 480 II 
(Roche). Amplification was performed using ExiLERATE LNA™ qPCR, SYBR® 
Green master mix kit (Exiqon). Each sample was analysed in triplicate for both target 
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gene and reference gene (β-actin), and the relative mRNA expressions were calculated 
using the 2-ΔΔCt method (Livak et al. 2001). 
Table 2.3.8.1 Real time PCR primers 
Target 
mRNA 
Forward primer 5’-3’ Reverse primer 5’-3’ RefSeq 
β-actin TGTCACCAACTGGGACGATA GGGGTGTTGAAGGTCTCAAA NM_031144.3 
Bdnf GGACATATCCATGACCAGAAAGAAA GCAACAAACCACAACATTATCGAG XM_006234684.3 
Creb1 CGTCATCTGCTCCCACTGTA CCTTCGTTTTTGGGAATCAG XM_017596652.1 
Nqo-1 TCACCACTCTACTTTGCTCCAA TTTTCTGCTCCTCTTGAACCTC NM_017000.3 
Ho-1 GCCCTGGAAGAGGAGATAGAG TAGTGCTGTGTGGCTGGTGT NM_012580.2 
Gclc CAAGGACAAGAACACACCATCT CAGCACTCAAAGCCATAACAAT NM_012815.2 
Nr3c1 GAAAAGCCATCGTCAAAAGGG TGGAAGCAGTAGGTAAGGAGA XM_008772065.2 
Gilz CAGGCCATGGATCTAGTGAA AGCGTCTTCAGGAGGGTATT XM_008773446.2 
Fkbp5 ACATGCAGGCCGTGATTCAGTA TTGTCACAGCACTCGACAGCTT XM_006256224.3 
Sgk1 TGAAATAGCCAGTGCCTTGGGT AAGGTGGACGTTGTCCCATTGT XM_006227723.1 
Foxo3 TGTCAGCAACATGGGCTTGAGT GGGAAGGTTTGCACTGGCTGAATA NM_001106395.1 
Btg1 TTCAGGCTTCTCCCAAGTGAACTC CCATTTGCACGTTGGTGCTGTT NM_017258.1 
2.3.9 Reverse-phase protein array (RPPA) 
High-throughput RPPA for 249 proteins (antibody list provided in Supplementary 
Information in Appendix) was performed following the protocol and directions of MD 
Anderson Center (Houston, Texas 77030, USA), where RPPA was performed. Briefly, 
cells were seeded at density of 1.5×106 cells per well in 6-well plates, followed by pre-
treatments with quercetin and xanthohumol before CORT insult. Cells were harvested 
and then lysed using the lysis buffer suggested by MD Anderson (1% Triton™ X-100, 
50 mM HEPES, pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 100 mM NaF, 
10 mM Na pyrophosphate, 1 mM Na3VO4 and 10% Glycerol). Total protein 
concentration in lysates was determined by performing a BCA assay (Thermo 
Scientific), and samples were adjusted to a concentration of 1–1.5 μg/μl. Samples were 
then denatured using the SDS sample buffer recommended by the core facility, boiled 
for 5 min and then stored at −80 °C before being shipped to MD Anderson on dry ice. 
Samples were then serially diluted and arrayed onto nitrocellulose-coated slides. 
Slides were then probed with the core facility’s collection of antibodies, and signal 
was generated using a 3, 3′-diaminobenzidine colorimetric reaction-based system. 
Results provided by MD Anderson were then analysed using the functional annotation 
tool DAVID 6.8 in order to detect up- or down-regulation of signalling pathways 
within the KEGG database. 
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2.3.10 Statistical analysis 
Statistical analysis was performed using the software SPSS 24.0, and the results were 
presented as mean ± SEM. Data were analysed using one- or two-way analysis of 
variance (ANOVA) as appropriate. A p-value of 0.05 was considered statistically 
significant. 
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2.4 Results 
2.4.1 CORT-induced changes in cortical cells are mediated by the 
GR 
To investigate the role of the GR in CORT-elicited cytotoxicity in cortical cells, dose 
and time curve response of CORT were determined by MTT assay. At DIV6 the cells 
were treated with CORT stimulus for 72 and 96 hours (Fig 1A). As expected, 
stimulation with CORT caused a significant reduction in cell viability at 96 h (Fig 1B 
and C). Pre-incubation for 24 hours with the GR antagonist RU486 (50 nM) 
ameliorated the reduction of cell viability caused by CORT (Fig. 1D). 
 
Figure 1 CORT-induced cytotoxicity in cortical cells is mediated by the GR. (A) Schematic 
representing the experiment timeline. (B – C) Cortical cells were treated with various concentrations 
of CORT for 72 and 96 h. (D) Cortical cells were pre-treated with 50 nM of RU486 for 24 h and then 
with 200 µM CORT for 96 hours. Cell viability was measured by MTT assay. Results are expressed as 
the mean ± SEM of three independent experiments performed in triplicate (***p < 0.001 versus 
‘vehicle’ groups; #p < 0.05 versus ‘CORT’ groups). 
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2.4.2 Xanthohumol and quercetin prevented CORT-induced 
cytotoxicity in cortical cells 
To determine the protective effects of xanthohumol and quercetin from CORT-
induced cytotoxicity, cortical cells were pre-incubated with different concentrations 
of xanthohumol and quercetin. The reduction of cell viability in cortical cells induced 
by 96 hours of incubation with 200 µM CORT was significantly prevented by 24-hour 
pre-treatment with both xanthohumol (1 or 5 µM) and quercetin (3 µM) (Fig. 2 B-C). 
2.4.3 Xanthohumol and quercetin prevented CORT-induced 
alterations in neuron and astrocyte proportion 
To further determine the potential protective effects of xanthohumol and quercetin 
against CORT-induced cytotoxicity, we explored whether these polyphenols 
prevented the alteration in neuron and astrocyte composition caused by CORT in 
cortical cells. As illustrated in Fig 2D-H, pre-treatment with both xanthohumol and 
quercetin prevented the decrease in the number of neurons and the increase in 
astrocytes induced by treatment with 200 µM CORT. 
2.4.4 Xanthohumol and quercetin prevented CORT-induced 
apoptotic morphological changes in cortical cells 
To define the type of cell death triggered by CORT, apoptotic and necrotic features 
were measured in cortical cells after CORT exposure. Apoptosis is characterised by 
morphological changes including chromatin condensation and reduction of cell 
membrane permeability. On the other hand, membrane integrity is completely lost 
during necrosis (Brito et al. 2006). 24-hour pre-incubation with 5 µM xanthohumol 
and 3 µM quercetin reduced the number of condensed nuclei in cortical cells after 200 
µM CORT treatment for 96 hours (Fig. 2I-K). Extracellular LDH activity was not 
increased after CORT treatment suggesting that plasmatic membrane did not lose 
integrity, similarly to apoptosis. In contrast, the necrotic/cell lysis inductor Triton™ 
X-100 produced a significant increase of extracellular LDH activity. 
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2.4.5 Xanthohumol and quercetin prevented CORT-induced down-
regulation of Bdnf gene expression in cortical cells 
Modulation of BDNF expression is one of the mechanisms which neuroprotective 
agents exert their effects (Zhao et al. 2017). Thus, the effect of xanthohumol and 
quercetin on CORT-induced reduction in mRNA Bdnf levels was investigated in 
cortical cells. After 96 hours of treatment, 200 µM CORT triggered a considerable 
reduction of Bdnf gene expression in cortical cells as previously reported (Pusceddu 
et al. 2016). However, this Bdnf reduction was prevented by a pre-incubation with 5 
µM xanthohumol and 3 µM quercetin for 24 hours (Fig. 2N-O). To investigate whether 
CORT-induced reduction of Bdnf expression is mediated by down-regulation of 
Creb1, we first explored whether CORT regulates the Creb1 mRNA expression in 
cortical cells (Fig. 2P-Q). Treatment with 200 µM CORT for 96 hours did not induce 
changes in Creb1 expression in cortical cells. Moreover, neither 5 µM xanthohumol 
nor 3 µM quercetin were able to up-regulate Creb1 gene expression. 
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Figure 2 Xanthohumol and quercetin prevented CORT-induced changes in cortical cells. (A) 
Schematic representing the experiment timeline. (B – C) Cortical cells were pre-treated with the 
indicated concentrations of xanthohumol and quercetin for 24 h and then with 200 µM CORT for 96 
hours. Cell viability was measured by MTT assay. (D – H) Quantitative analysis of neurons and 
astrocytes was assessed by immunostaining of βIII-tubulin+ and GFAP+ cells. Scale bar = 50 µm. (I – 
K) Cortical cells were pre-treated with 5 µM xanthohumol or 3 µM quercetin for 24 hours, and then 
exposed 96 hours to 200 µM CORT. Morphological changes of the nuclei were determined by Hoechst 
33258 staining. Scale bar = 50 µm. Red arrows indicate representative condensed nuclei. (L – M) 
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Lactate dehydrogenase (LDH) activity was measured in cell culture media after polyphenol and CORT 
treatment. (N – Q) The gene expression was quantitatively measured using real time RT-PCR for Bdnf 
and Creb1 mRNA relative expression. Results are expressed as the mean ± SEM of three independent 
experiments performed in triplicate (*p < 0.05; **p < 0.01; ***p < 0.001 versus ‘vehicle’ groups; #p 
< 0.05; ##p < 0.01 versus ‘CORT’ groups). 
2.4.6 Inhibiting the Nrf2 pathway attenuated only the protective 
effect of xanthohumol against CORT-induced cytotoxicity in 
cortical cells 
The activation of Nrf2 pathway has been shown to be involved in the protective 
mechanisms of polyphenols against CORT inducing its deleterious effects on neuronal 
models (Freitas et al. 2015, Sun et al. 2018). Thus we used a pharmacological 
approach to determine the mediatory role of Nrf2 pathway in the protective effects of 
xanthohumol and quercetin against CORT-elicited cytotoxicity. We investigated 
whether trigonelline, an inhibitor of Nrf2 nuclear import (Arlt et al. 2012), could 
abolish the cytoprotective effect of these polyphenols against CORT-dependent 
reduction in cell viability in cortical cells. At DIV5 the cells received a treatment with 
both polyphenols and 5 µM trigonelline for 24 hours and subsequently CORT stimulus 
for 96 hours (Fig. 3A). Trigonelline treatment ameliorated the increase in cell viability 
induced by treatment with xanthohumol, which suggested that inhibition of Nrf2 
pathway blocked the protective effects of xanthohumol against CORT-induced 
cytotoxicity in cortical cells. In contrast, trigonelline did not affect the protective 
effects of quercetin against CORT-induced cytotoxicity (Fig. 3B-C). 
2.4.7 Xanthohumol induced the expression of Nrf2 target genes in 
cortical cells 
We further investigated whether xanthohumol or quercetin induced the expression of 
Nrf2-driven cytoprotective/antioxidant genes in cortical cells. At DIV5 the cells 
received a treatment with either xanthohumol or quercetin along with 5 µM 
trigonelline for 24 hours (Fig. 3D). After 24-hour treatment with 5 µM xanthohumol, 
the mRNA expression of Nrf2-activated genes (Ho-1, Nqo-1 and Gclc) was 
significantly increased. Moreover, 5 µM trigonelline co-treatment blocked 
xanthohumol-induced up-regulation of Nrf2-activated genes, which confirmed the 
activation of Nrf2-pathway by xanthohumol (Fig. 3E-G). On the other hand, 3 µM 
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quercetin treatment did not induce expression of Nrf2-driven genes in cortical cells 
(Fig. 3J-L). 
2.4.8 Xanthohumol-induced Bdnf gene expression is dependent of 
Nrf2 activation 
The effect of xanthohumol and quercetin on gene expression of Bdnf before CORT 
exposure was studied in cortical cells. Treatment with 5 µM xanthohumol for 24 hours 
remarkably induced the gene expression of Bdnf and Creb1. Interestingly, 5 µM 
trigonelline prevented the increase in Bdnf and Creb1 gene expression induced by 
treatment with xanthohumol (Fig. 3H-I). In contrast, 3 µM quercetin treatment for 24 
hours did not induce gene expression of Bdnf and Creb1 (Fig. 3M-N). These data 
indicate that xanthohumol-induced Creb1 and Bdnf gene expression may be mediated 
by the Nrf2-pathway. 
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Figure 3 Xanthohumol neuroprotection is mediated by the Nrf2 pathway. (A – C) Cortical cells were 
co-treated with 5 µM trigonelline and polyphenols (5 µM xanthohumol or 3 µM quercetin) for 24 hours 
before 96-hour exposure to 200 µM CORT. Cell viability was detected by MTT assay. (D) Cortical cells 
were co-treated with 5 µM trigonelline and 5 µM xanthohumol or 3 µM quercetin for 24 hours. Relative 
expression of Nrf2-activated genes (Ho-1, Nqo-1 and Gclc), Creb1 and Bdnf induced by (E – I) 
xanthohumol and (J – N) quercetin was determined through real time RT-PCR. Data were expressed 
as the mean ± SEM of three independent experiments performed in triplicate (***p < 0.001; **p < 
0.01; ***p < 0.001). Note: Ho-1 heme oxygenase, Nqo-1 NAD(P)H dehydrogenase (quinone 1), Gclc 
glutamate-cysteine ligase catalytic subunit. 
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2.4.9 Quercetin improved Fkbp5 gene expression after CORT 
stimulus in cortical cells 
Given that the Nrf2 pathway might not be involved in quercetin neuroprotection, we 
examined the GR signalling. The effect of xanthohumol and quercetin on GR-
regulated genes expression after CORT treatment was studied in cortical cells. 
Although, we did not find changes in Btg1, N3c1 and Sgk1 mRNA levels after CORT 
exposure, the gene expression of Fkbp5, Foxo3 and Gilz was significantly increased 
(Fig. 4). All of these genes have been associated with modulation and regulation of 
the GR signalling pathway (27030168, 16110340, 27288728). Moreover, Fkbp5 
expression was increased by pre-incubation with 3 µM quercetin followed CORT 
treatment for 96 h compared to CORT group alone (Fig. 4H). Pre-treatment with 5 µM 
xanthohumol did not affect the gene expression of any GR-regulated gene (Fig. 4A-
F). 
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Figure 4 Quercetin enhanced the expression of Fkbp5 after CORT treatment in cortical cells. After 
24-hour exposure to (A – F) 5 µM xanthohumol or (G – L) 3 µM quercetin, cortical cells were treated 
during 96 hours with 200 µM CORT. The gene expression of Btg1, Fkbp5, Foxo3, Gilz, Nr3c1 and Sgk1 
was quantitatively measured using real time RT-PCR. Results are expressed as the mean ± SEM of 
three independent experiments performed in triplicate (***p < 0.001; **p < 0.01; *p < 0.05 versus 
‘vehicle’ groups; #p < 0.05 versus ‘CORT’ groups). Note: Btg1 B-cell translocation gene 1, Fkbp5 
FK506 binding protein 5, Foxo3 forkhead box O3, Gilz glucocorticoid-induced leucine zipper, Nr3c1 
nuclear receptor subfamily 3 group C member 1, Sgk1 serum and glucocorticoid-regulated kinase 1. 
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2.4.10 CORT induced changes in Akt/mTOR/AMPK signalling 
pathways 
In order to investigate the impact of CORT treatment in signalling pathways associated 
with proliferation, cell growth and apoptosis in cortical cells we studied the activation 
or downregulation of proteins involved in these physiological processes using the 
RPPA approach. After treatment with 200 µM CORT for 96 hours we found 46 
proteins with altered expression (Fig. 5A), and further analysis revealed that Akt, 
FOXO, mTOR, AMPK and Neurotrophin signalling pathways were significantly 
affected (Fig. 5B; KEGG codes: Akt map04151, FoxO map04068, mTOR map04150, 
AMPK map04152 and Neurotrophin map04722). 
2.4.11 Impact of xanthohumol and quercetin on CORT-induced 
changes in Akt/mTOR, AMPK and Erk1/2 signalling pathways 
The effect of xanthohumol and quercetin on CORT-induced alteration in signalling 
pathways associated with proliferation and apoptosis were next investigated in cortical 
cells. Pre-incubation with xanthohumol or quercetin did not interfere significantly 
against CORT-induced changes in Akt, mTOR and Erk1/2 signalling pathways (Fig. 
5D, 5F and 5G). Nevertheless, xanthohumol treatment prevented the abnormal 
increase of pAMPK/AMPK ratio caused after CORT insult (Fig. 5C). Surprisingly, 
xanthohumol abolished CORT-induced protein overexpression of connexin 43 
(Cx43), which is not involved directly with these signalling pathways (Fig. 5H). 
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Figure 5 Impact of xanthohumol and quercetin on CORT-induced changes in Akt/mTOR, AMPK 
and Erk1/2 signalling pathways. (A) Schematic interaction map of proteins altered by CORT; 
upregulated expression of proteins is showed in green while downregulated proteins are highlighted in 
red. Cortical cells were treated with 200 µM CORT for 96 hours. The relative expression of proteins 
involved in proliferation, cell growth and apoptosis was determined using the RPPA approach. (B) 
KEEG signalling pathways affected by CORT were detected using the functional annotation tool 
DAVID 6.8. (C – H) After 24-hour exposure to 5 µM xanthohumol or 3 µM quercetin, cortical cells 
were treated during 96 hours with 200 µM CORT. The levels of protein expression of AMPK, pAMPK, 
total Akt, FOXO3, pFOXO3, mTOR, pErk1/2 and connexin 43 were quantitatively measured using 
RPPA and provided by MD Anderson. Results are expressed as the mean ± SEM of three independent 
experiments (***p < 0.001; **p < 0.01; *p < 0.05 versus ‘vehicle’ groups; ###p < 0.001; #p < 0.05 
versus ‘CORT’ groups). 
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2.5 Discussion 
In the present study, we demonstrated that administration of naturally-derived 
polyphenols xanthohumol and quercetin significantly protects primary cortical cells 
against CORT-elicited cytotoxicity, altered neuronal/astrocytic ratio and reduced Bdnf 
expression. In addition, our results establish that trigonelline, an inhibitor of Nrf2, 
abolishes the neuroprotective effects of xanthohumol, but not quercetin against 
CORT-induced cell death. Taken together, our findings reveal that although both 
xanthohumol and quercetin are neuroprotective agents, they recruit different cellular 
signalling pathways to induce such effects. 
Several reports have demonstrated that the glucocorticoid hormone corticosterone 
exerts toxic effect on neurons (Gao et al. 2015, Zhao et al. 2018). Additionally, 
increasing levels of CORT are associated with depressive and anxious-like behaviours 
in rodent models (Rosa et al. 2014, Mendez-David et al. 2017). Therefore, preventing 
the neurotoxic effects of glucocorticoids could represent a novel therapeutic approach 
for treatment of stress-related disorders. On the other hand, polyphenols have attracted 
considerable interest due to their multiple health benefits including anti-oxidant, anti-
cancer and neuroprotective effects (Vauzour et al. 2010). However, the molecular 
mechanisms underlying polyphenol-mediated neuroprotection in neurons are not fully 
understood. Thus, the aim of the present study was to investigate whether the 
naturally-derived polyphenolic compounds xanthohumol and quercetin prevent 
CORT-induced neurotoxicity in cortical cells. 
Mixed cortical cell cultures containing both neurons and astrocytes have been 
extensively used as a model to study the neurotoxic effects of numerous stimulants in 
vitro (Wie et al. 1997, Trackey et al. 2001, Huang et al. 2009). As expected, our data 
shows that CORT treatment decreased the cell viability of cortical cells. In addition, 
further analysis indicated that CORT-exerted cell death is mediated through activation 
of the GR resulting in the induction of apoptosis. In accordance with our findings, it 
has been shown before that CORT induces apoptosis via activation of the GR cascade 
in different neuronal models such as hippocampal neurons (Latt et al. 2018), PC12 
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cells (Li et al. 2014), hypothalamic neurons (Zhang et al. 2012), and cortical cells 
(Pusceddu et al. 2016). 
We next demonstrated that treatment with xanthohumol and quercetin significantly 
reduced CORT-induced cytotoxicity. In addition, these compounds reduced the 
alteration of cellular composition in cortical cells produced by CORT. Indeed, our 
study shows that the reduction in neuronal percentage and increased astrocytic 
concentration caused by CORT treatment is prevented by these polyphenols. In neural 
tissue, astrocytes play an important role in regulation of synapse, energy and 
neurotransmitter balance (Sofroniew et al. 2010). Accordingly, astrocytic overgrowth 
or astrogliosis has been described as a physiological process critical for neural 
protection and repair (Zhang et al. 2007). This is in line with previous studies showing 
similar effects on astrocytes after CORT insult (Bridges et al. 2008, Pusceddu et al. 
2016). 
To further investigate the possible mechanisms underlying the protective effect of 
xanthohumol and quercetin against CORT-induced cytotoxicity we next examined the 
BDNF gene expression. BDNF is a neurotrophin involved in neuroplasticity and 
neuronal survival, which has been associated with neuroprotective effects in in vitro 
and in vivo (Almeida et al. 2005, Motaghinejad et al. 2017).  Here we demonstrated 
that both polyphenols prevent CORT-induced reduction of Bdnf mRNA levels. 
Previous studies have demonstrated that several polyphenols, including xanthohumol 
and quercetin, induce the activation of Nrf2, which contributes significantly to 
cytoprotective and antioxidant responses in different cellular models (Tanigawa et al. 
2007, Ungvari et al. 2010, Gopinath et al. 2012, Yao et al. 2015). We found that 
trigonelline, an inhibitor of Nrf2, significantly reversed the protective effect of 
xanthohumol but not quercetin. Moreover, blocking Nrf2 activation abolished the 
xanthohumol-mediated increase of Bdnf mRNA levels confirming previous studies 
that also highlight the crosstalk between BDNF and Nrf2 signalling (Mendez-David 
et al. 2015, Bouvier et al. 2017, Ishii et al. 2018). 
Surprisingly, quercetin treatment did not induce Bdnf gene expression, suggesting that 
quercetin prevented CORT-induced depletion of BDNF in cortical cells through an 
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alternative mechanism. Interestingly, there is some evidence indicating that quercetin 
is able to activate Nrf2 signalling in other in vitro studies (Tanigawa et al. 2007, 
Granado-Serrano et al. 2012). However, the reason as to why quercetin fails to activate 
Nrf2 in cortical cells remains unknown. 
To elucidate the mechanisms underlying the neuroprotection of quercetin, we 
examined whether quercetin attenuates activation of the GR cascade following CORT 
stimulation. We hypothesised that downregulation of the GR signalling pathway could 
decrease CORT-induced cytotoxicity and eventually reverse BDNF depletion in 
cortical cells. GR blockade strategies have been proposed to be a novel therapeutic 
approach to prevent the negative effects of chronic stress (Oomen et al. 2007, Revsin 
et al. 2009). In this regard, analysis of FK506 binding protein 51 (FKBP5) a protein 
which regulates GR sensitivity, is considered an interesting target for the prevention 
and treatment of stress-related psychiatric disorders (Guidotti et al. 2013). When 
FKBP5 is bound to the receptor complex, glucocorticoids bind with lower affinity and 
the nuclear translocation of the receptor is less efficient (Binder 2009). Our data 
demonstrates that quercetin treatment significantly increased expression of Fkbp5 
after CORT stimuli in cortical cells, suggesting that the GR negative feedback system 
could be activated, thus preventing BDNF depletion. 
BDNF-mediated neuroprotective mechanisms are associated with the activation of 
different molecular pathways related to proliferation and cell growth processes such 
as Akt, mTOR and Erk1/2 (Han et al. 2000, Chen et al. 2013). Therefore, we analysed 
components of these signalling pathways in cortical cells upon CORT stimulation. In 
this study, we established that CORT treatment significantly influence the proliferative 
pathways Akt and mTOR, as well as metabolic signalling pathways that possibly 
trigger apoptosis, such as AMPK and FOXO3. Indeed, downregulation of Akt and 
mTOR is associated with decreased proliferation in neuronal models (Peltier et al. 
2007, Bhaskar et al. 2009), while activation of AMPK/FOXO3 pathways indirectly 
lead to apoptotic signalling (Davila et al. 2012). Our results demonstrate that 
xanthohumol treatment reduced AMPK phosphorylation after CORT stimulus, 
indicating down regulation of this pathway. However, treatment with either 
xanthohumol or quercetin did not prevent CORT-induced changes at protein levels of 
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Akt, mTOR and Erk1/2. These data suggest that activation of these proliferative 
pathways are not critical for BDNF-mediated neuroprotection in cortical cells.  
Additionally, we have demonstrated that xanthohumol significantly blocked CORT-
induced overexpression of Cx43 in cortical cells.  The evidence suggests that Cx43 
plays a pro-apoptotic role in different cytotoxic stimuli, which has been suggested 
before (Huang et al. 2001, Dong et al. 2015, Yahiro et al. 2015), although the 
mechanisms responsible for Cx43-mediated apoptosis are unknown. Since Cx43 is the 
structural component of gap junctions and it is responsible for the transfer of water‐
soluble molecules directly from one cell to another without passing through the 
membrane, the enhancement of cytotoxic effects on Cx43‐transfected cells may be due 
to increased transfer of drugs or pro-apoptotic molecules from one cell to another 
(Kameritsch et al. 2013). 
In conclusion, our present work confirmed that naturally-derived polyphenols 
xanthohumol and quercetin attenuated CORT-exerted neurotoxicity in primary 
cortical cultures. We further found that blocking the Nrf2 pathway could abolish the 
protective effect of xanthohumol, while quercetin neuroprotection may be mediated 
by FKBP5 modulation. Our data reveal that xanthohumol and quercetin differentially 
mediate BDNF restoration upon CORT treatment in cortical cells, indicating the 
possible role of this neurotrophin in the neuroprotective mechanisms of these 
polyphenols. In addition, our findings provide a novel insight into the mechanisms 
underlying polyphenol-mediated neuroprotective effect in vitro and potential health 
benefits for stress-related disorders. 
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3.1 Abstract 
There is a growing emphasis on the role of the microbiota-gut-brain axis as modulator 
of host behaviour and as therapeutic target for neuropsychiatric disorders. In addition, 
accumulating evidence suggests that early-life stress can exert long-lasting changes on 
the brain and microbiota, and this early adversity is associated with increased risk for 
developing depression in later life. The maternal separation (MS) model in rats is a 
robust paradigm to study the effects of early-life stress on the microbiota-gut-brain 
axis. Recently, we have shown that   polyphenols, naturally occurring compounds 
associated with several health benefits, have anti-stress effects in in vitro models. In 
this study, we assess the therapeutic potential of a variety of both flavonoid and non-
flavonoid polyphenols in reversing the impact of MS on behaviour and the microbiota-
gut-brain axis. 
Rats underwent a dietary intervention with the naturally-derived polyphenols 
xanthohumol and quercetin, as well as with a phlorotannin extract for 8 weeks. 
Treatment with polyphenols prevented the depressive and anxiety-like behaviours 
induced by MS, where xanthohumol effects were correlated with rescue of BDNF 
plasma levels. In addition, MS resulted in altered brain levels of 5-hydroxyindoleacetic 
acid (5-HIAA) and dopamine, accompanied by abnormal elevation of plasma 
corticosterone. Although polyphenols did not reverse neurotransmitter imbalance, 
xanthohumol normalised corticosterone levels in MS rats. Finally, we explored the 
impact of MS and polyphenolic diets on the gut microbiota. We observed profound 
changes in microbial composition and diversity produced by MS condition and by 
xanthohumol treatment. Moreover, functional prediction analysis revealed that MS 
results in altered enrichment of pathways associated with microbiota-brain interactions 
that are significantly reversed by xanthohumol treatment. These results suggest that 
naturally-derived polyphenols exert antidepressant-like effects in MS rats, which 
mechanisms could be potentially mediated by HPA regulation, BDNF levels rescue 
and modulation of the microbiota-gut-brain axis. 
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3.2 Introduction 
Stress-related psychiatric disorders including depression and anxiety are currently a 
major public health concern. In 2015, depressive disorders were estimated to be the 
third leading cause of disability worldwide. Now, the WHO indicates that depression 
is a leading cause of disability worldwide and is a major contributor to the overall 
global burden of disease (Johnston et al. 2019, Park et al. 2019). On the other hand, 
major depressive disorder is thought to result from the complex interplay of multiple 
inherited genetic factors and subsequent exposure to a wide range of environmental 
variables throughout life (aan het Rot et al. 2009); therefore, the search for adequate 
treatments is a great challenge as no established mechanisms have yet been determined 
(Berton et al. 2006). Based on these observations and considering that depression has 
an inconsistent response to treatment, the development of new antidepressant 
strategies is increasingly being considered as a critical focus of research. 
It is well known that stressful events in early life can exert long-lasting changes in 
brain structure and function later on (Cryan et al. 2013) and accumulating evidence 
indicates that this early life adversity is associated with an increased risk for 
developing depression (Chapman et al. 2004, Heim et al. 2012). For instance, 
inadequate maternal care has been linked to developmental, emotional and social 
deficits in humans (Field 1998). In rodents, the maternal separation (MS) model is a 
well-described paradigm used to investigate the biological and behavioural 
consequences of early life stress (O'Mahony et al. 2011, Nishi et al. 2014, Rincel et 
al. 2019). For this reason, the MS model has been used for various psychiatric 
conditions, especially depression (Vetulani 2013). For example, evidence supports 
that MS in rats is capable of inducing a depressive phenotype comparable to adult 
humans including hyperactivity of the HPA axis (Meaney et al. 1996) and increasing 
pro-inflammatory cytokines in plasma (Wieck et al. 2013). 
The microbiota-gut-brain axis describes the complex bidirectional communication 
system that exists between the central nervous system (CNS) and enteric microbiota; 
involving endocrine, immune and neural pathways (Rhee et al. 2009, Foster et al. 
2017, Cryan et al. 2019). Accumulating research has focused on the impact of the 
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microbiota on CNS function and stress perception, and its consequences for behaviour 
(Cryan et al. 2012). Indeed, top down activation of the CNS can influence gut 
neuromotor and secretory function, immunity and microbiota composition during 
stress (De Palma et al. 2014). In this regard, early-life stress models such as MS have 
long-term impact on the gut microbiota, which correlate with increased HPA axis 
activity and behaviour (Bailey et al. 1999, O'Mahony et al. 2009). Moreover, the MS 
model is sensitive to reversal treatments that target the gut microbiota (Gareau et al. 
2007, Fukui et al. 2018, Cowan et al. 2019, McVey Neufeld et al. 2019, O'Mahony et 
al. 2019). 
The emerging and compelling evidence for nutrition as a crucial factor in the high 
prevalence and incidence of mental disorders suggests that changes in diet are a viable 
strategy for improving mental health and treatment of psychiatric disorders including 
anxiety and depression (Jacka et al. 2014, Lai et al. 2014, Adan et al. 2019). For 
instance, dietary polyphenols are a group of naturally occurring phytochemicals which 
are present in high amounts in fruits and vegetables and are characterised by the 
presence of multiple hydroxyl groups on aromatic rings (Vauzour 2012). Several 
studies have focused on the potential of polyphenolic compounds in protecting 
cognitive function and reducing risk for developing neurodegenerative disorders 
(Spencer 2008). In particular, some pre-clinical studies have confirmed the 
antidepressant capacity of polyphenols in different animal models (Anjaneyulu et al. 
2003, Kulkarni et al. 2008, Yi et al. 2008). Moreover, dietary polyphenols are capable 
of modulating the composition of the gut microbial community by inhibiting or 
stimulating the growth of certain bacteria (Lee et al. 2006). Hence, there is increasing 
interest in using polyphenols to target the microbiota-gut-brain axis to treat mental 
disorders (Filosa et al. 2018, Matarazzo et al. 2018). 
Polyphenolic compounds are characterised as having different functional activity 
depending on their chemical structure (Manach et al. 2004, Vauzour et al. 2010). For 
instance, phlorotannins are a type of polyphenolic tannin found in marine brown algae, 
and have been shown to possess anti-oxidant activity, as well as beneficial effects for 
different diseases such as cancer, cardiovascular problems and diabetes (Kim et al. 
2011). Other polyphenols can only be isolated from specific sources. Xanthohumol, 
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for example, is described as a prenylated chalcone, a principal component from the 
female hop plant, Humulus lupulus (Stevens et al. 2004). Some health benefits 
associated with xanthohumol intake include anti-inflammatory and neuroprotective 
effects (Liu et al. 2015). In contrast, some members of the flavonoid family like 
quercetin are widely distributed in nature (Manach et al. 2004). Quercetin is one of 
the most studied polyphenols and has been demonstrated to confer protection against 
certain types of cancer, cardiovascular and neurodegenerative disorders (Boots et al. 
2008). 
Recently, we showed that across a wide number of polyphenols, xanthohumol and 
quercetin were able to reverse the impact of corticosterone exposure in primary 
cortical neurons (Donoso et al. 2019). Moreover, although the antidepressant effects 
of several polyphenols have been studied in different preclinical studies (Xu et al. 
2005, Bhutada et al. 2010, Liu et al. 2014), their therapeutic effects have not yet been 
examined in models of early life stress yet, nor the mechanisms underlying the 
polyphenol-mediated alleviation of mood. Therefore, the purpose of this study was to 
explore the antidepressant effects of different naturally-derived polyphenols, including 
phlorotannins, xanthohumol and quercetin in the MS model in rats. In addition, the 
consequences of MS and polyphenol diet intervention on plasma BDNF levels and 
monoamine neurotransmitter concentration in brainstem, and the potential implication 
for the HPA axis and the gut microbiome, were explored. 
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3.3 Methods 
3.3.1 Animals 
All experimental procedures involving animals were approved by the Ethics 
Committee of University College Cork. Pregnant Sprague Dawley dams weighing 
250–300 g were bred in-house in the Biological Services Unit facility, University 
College Cork. The pups were housed with their mothers in plastic cages (15 × 22 × 9 
cm) in a temperature and humidity controlled room on a 12-h light, 12-h dark cycle 
(lights on from 7.00–19.00 h). Food and water were available ad libitum. 
3.3.2 Drugs 
Quercetin (Q4951) was purchased from Sigma. Xanthohumol (A-4-2014) was 
provided by Hopsteiner, GmbH (Mainburg, Germany). Phlorotannin-rich extract from 
Fucus vesiculosus (Gite et al. 2019) was obtained from National University of Ireland, 
Galway (Galway, Ireland). All diets were prepared by ssniff Spezialdiäten (Ferdinand-
Gabriel-Weg, Germany). The resulting chows were isoenergetic and had the same 
proportion of macronutrients (carbohydrates, proteins and lipids). 
3.3.3 Maternal separation procedure 
MS was performed as previously described (O'Mahony et al. 2009, Pusceddu et al. 
2015). Briefly, pups were separated from their mother as a whole litter and placed into 
plastic cages maintained at 30 – 33 °C in a separate room to prevent communication 
through ultrasonic vocalisation (Hofer et al. 1994). Following the 3-hour separation, 
pups were returned to their original home cage with their mother. This procedure was 
repeated each day (9.00am–12.00pm) from post-natal day (PND) 2 through PND12. 
NS-Control rats consisted of non-handled pups, left untouched by the experimenter, 
and with their respective mothers. After postnatal day 12, pups were left undisturbed 
except for routine cage cleaning every two days. At weaning, male rats were group-
housed (2 – 4) in large cages. 
87 
 
3.3.4 Treatments 
The rats were randomly assigned into nine different experimental groups, of which 
five were relevant to this study. Dose of polyphenols are expressed as a percentage in 
food (% m/m). [1] NS-Control diet (n = 12); [2] MS-Control diet (n = 12); [3] MS-
Phlorotannins 0.03% (n = 10); [4] MS-Xanthohumol 0.015% (n = 10); [5] MS-
Quercetin 0.03% (n = 10). Dietary intervention of polyphenols, delivered ad libitum 
in food, began once the animals were eight weeks old and continued for eight weeks. 
The concentrations for the polyphenols tested were calculated based on doses 
previously reported in animal models and considered the average daily food intake and 
body weight of Sprague Dawley rats aged between 9 and 16 weeks (Laaksonen et al. 
2013). Estimated doses are as follows; quercetin 20 mg/kg/day (Haleagrahara et al. 
2009); xanthohumol 10 mg/kg/day (Ceremuga et al. 2013); phlorotannins 20 
mg/kg/day (Ahn et al. 2017). In the interest of reduction in the 3 Rs the control groups 
used here were also used to assess the impact of a number of other interventions that 
were run at the same time (Egerton et al. unpublished). 
3.3.5 Elevated plus maze 
The elevated plus maze (EPM) is one of the most commonly used rodent tests for 
assessing anxiety and was performed as previously described (Cryan et al. 2004, 
Pusceddu et al. 2015). Briefly, the maze consisted of two open arms (51 × 10 cm; 5 
lux) and two enclosed arms (51 × 10 × 41 cm) that all extended from a common central 
platform (10 × 10 cm). The apparatus was elevated 55 cm above the floor on a central 
pedestal. Animals were habituated to the testing room for 30 min prior experiment. At 
week 12, animals were placed in the centre of the maze facing an open arm to begin. 
Animal behaviour was recorded for 5 min. Frequency of open and closed arms entries 
were scored, as well as percentage time spent in each arm. 
3.3.6 Open field test 
The open field test (OFT) is commonly used as a mechanism to assess anxiolytic 
effects of compounds (Seibenhener et al. 2015). Briefly, at week 13 rats were placed 
in the centre of a white open field arena (60 × 40 cm; 60 lux) and observed for 10 min. 
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Animals were habituated to the test room for 30 min prior to the experiment. All trials 
were conducted between 9.00am and 1.00pm. The arena was cleaned with 70% 
ethanol to avoid smell cues between each trial. At the end of each trial, animals were 
returned to their cages. Distance moved, velocity, percentage of time spent in inner 
zone, and frequency of inner zone entries were analysed and recorded using a tracking 
system (Ethovision XT 13, Noldus). 
3.3.7 Forced swim test 
The forced swim test (FST) is the most widely used model for predicting 
antidepressant activity in rodents, and increased immobility in this test is generally 
considered to reflect a state of behavioural despair (Porsolt et al. 1978). Briefly, at 
week 15 a modified rat FST protocol (Slattery et al. 2012) was used to determine the 
antidepressant effects of polyphenols in rats. On day one, rats were placed individually 
in glass cylinders (H: 45 cm; D: 20 cm) filled with water to a depth of 30 cm at 24±1 
°C for a 15 min pre-test period. The rats were removed from the water, dried and 
placed in their home cage. The cylinders of water were changed between each trial. 24 
hours after the pre-test, the rats were again placed in the swim apparatus for 5 min and 
behaviours were monitored from above with a video camera for subsequent analysis. 
Behaviours rated include immobility, climbing and swimming (scoring of behaviours 
was blind to the experimental conditions). The 5-min session was scored using a time-
sampling technique, whereby the predominant behaviour in each 5-s period of the 300-
s trial was recorded. Climbing behaviour consisted of upward-directed movements of 
the forepaws along the side of the cylinder. Swimming behaviour was defined as 
movement (usually horizontal) throughout the cylinder. The rat was considered to be 
immobile when the only activity observed was that which was required by the rat to 
keep its nose above water. 
3.3.8 Plasma corticosterone determination 
Blood sample collection was performed as previously described (Pusceddu et al. 
2015). Briefly, blood samples were collected on day one of FST via a tail-tip incision 
at five different time points: immediately before (baseline), 30 min, 60 min, 90 min 
and 120 min after the test was started. Approximately 200 µl of blood was collected 
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in a tube containing 10 µL of EDTA 0.1 M to avoid coagulation. Blood plasma was 
obtained by centrifugation at 3500 × g at 4 °C for 15 min. Corticosterone levels were 
measured using the Corticosterone EIA kit (Enzo) according to the manufacturer 
instructions, and absorbance signal was detected with a conventional plate reader 
(Synergy HT, Biotek). 
3.3.9 Plasma BDNF measurement 
Immediately after sacrifice, trunk blood was collected in EDTA Vacutainer tubes. 
Blood plasma was obtained by centrifugation at 3500 × g at 4 °C for 15 min. Protein 
levels of brain-derived neurotrophic factor (BDNF) were determined using an 
electrochemiluminescence multiplex system (MSD, Gaithersburg, MD, USA) 
according to the manufacturer’s protocol. BDNF levels were determined and analysed 
using the MSD QuickPlex SQ 120 Instrument. 
3.3.10 Brain monoamines concentration 
The monoamine neurotransmitters noradrenaline (NA), serotonin (5-HT), dopamine 
(DA) and their metabolites 5-HIAA and 3,4-dihydroxyphenylacetic acid (DOPAC) 
were determined in the brainstem using high-performance liquid chromatography 
(HPLC) with electrochemical detection as described previously (Clarke et al. 2012, 
Pusceddu et al. 2015). Briefly, samples were homogenised in mobile phase (consisting 
in 0.1 M citric acid, 0.1 M sodium dihydrogen phosphate monohydrate, 5.6 mM 1-
octanesulfonic acid, 0.01 mM EDTA, 11.1% (v/v) methanol, and 0.1 µg/mL of N-
Methyl 5-HT as internal standard and adjusted to pH 2.8). Then samples were 
centrifuged 14000 g for 15 min at 4 °C, and 20 µL of this supernatant was injected 
onto the HPLC system (consisting in a CBM-20A system controller, a EC3000 Recipe 
amperometric detector, a LC-20AD XR pump, a CTO-20A column oven at 30 ⁰C, a 
SIL-20AC XR autosampler, and a Prominence DGU-20A3 degasser). A reverse-phase 
column (Kinetex 2.6u C18 100A 100 mm X 4.6 mm, Phenomenex) was employed in 
the separation using a flow rate of 0.9 mL/min. Each neurotransmitter was identified 
through their characteristic retention times and their concentration was determined 
using the ratios of peak heights of analyte versus internal standard provided by the 
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LabSolutions software (Shimadzu). Results were expressed as nanograms of 
neurotransmitter per grams of fresh tissue. 
3.3.11 Gut microbiota 16S rRNA sequencing 
Microbial DNA was isolated from frozen faecal samples using the QIAGEN QIAamp 
Fast DNA Stool Mini Kit (Qiagen) according to the manufacturer’s directions. DNA 
concentration and quality was determined using the NanoDrop® ND-1000 UV-Vis 
Spectrophotometer (Thermo Fisher Scientific). The V3-V4 variable region of the 16S 
rRNA gene was amplified from the DNA extracts using the Illumina 16S metagenomic 
sequencing library protocol, and PCR reactions were performed with the KAPA HiFi 
HotStart PCR Kit (KAPA Biosystems). PCR products were cleaned using AMPure 
XP magnetic bead-based purification (Beckman Coulter Life Sciences). This was 
followed by indexing PCR which attached Nextera XT barcodes and Illumina 
sequencing adapters to the 5′ overhangs and another round of AMPure XP clean-up. 
Finally, samples were sequenced on the MiSeq™ System (Illumina®), using a 2 x 
250bp cycle kit, following standard Illumina sequencing protocols. 
3.3.12 Short chain fatty acid determination 
The short chain fatty acids (SCFAs) acetate, propionate, butyrate, and valerate, as well 
as the total branched chain fatty acids (BCFAs) were measured in caecal content using 
gas chromatography flame ionisation detection (GC-FID) as previously reported (van 
de Wouw et al. 2018). Briefly, samples were vortexed with Milli-Q water (1:10 w/v), 
left to stand for 10 min at room temperature, and then centrifuged at 14000 g for 5 
min. The supernatant was filtered (0.2 µm) before transfer to a GC glass vial, and 2-
ethylbutyric acid (Sigma) was added as internal standard.  SCFA concentrations were 
measured using a Varian CP-3800 GC flame-ionization system, fitted with a Zebron 
ZB-FFAP column (30 m × 0.32 mm × 0.25 µm; Phenomenex) and a flame ionisation 
detector with a CP‐8400 auto‐sampler. Helium was used as the carrier gas at a flow 
rate of 1.3 ml/min. The initial oven temperature was set at 100 °C for 0.5 min, raised 
to 180 °C at 8 °C/min and held for 1 min, then increased to 200 °C at 20 °C/min, and 
finally held at 200 °C for 5 min. The temperature of the injector and the detector were 
set at 240 °C and 250 °C respectively. A standard curve made from a standard mix of 
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acetic acid, propionic acid, n-butyric acid and iso-butyric acid (Sigma) at seven 
concentrations. Peaks were integrated by using the Varian Star Chromatography 
Workstation version 6.0 software. Standards were included in each run to maintain 
calibration. 
3.3.13 Statistical analysis 
Statistical analysis was performed using the software SPSS 24.0, and the results were 
presented as mean ± SEM. MS-control group and NS-control group were compared 
using independent T-test to assess the MS effect. All MS groups were analysed using 
one-way analysis of variance (ANOVA) followed by Dunnett’s post hoc test, where 
NS-control group was considered as control for the test. A p-value of 0.05 was 
considered statistically significant. FLASH was used to assemble paired-end reads. 
Further processing of paired-end reads including quality filtering based on a quality 
score of >25 and removal of mismatched barcodes and sequences below length 
thresholds was completed using QIIME (version 1.9.0). Denoizing, chimera detection 
and clustering into operational taxonomic unit (OTU) grouping were performed using 
USEARCH v7 (64-bit). OTUs were aligned using PyNAST, and taxonomy was 
assigned using BLAST against the SILVA SSURef database release 123. Statistical 
microbiome analysis was carried out in R (version 3.6.1) with Rstudio (version 
1.2.1335). OTUs unknown on a genus level were excluded, as well as OTUs available 
in two or fewer samples. The ALDEx2 library (Fernandes et al. 2014) was used to 
compute the centred log-ratio transformed values of the remaining taxa. For principal 
component analysis, a pairwise implementation of the adonis() PERMANOVA 
function in the vegan library (Oksanen et al. 2017) followed by the Bonferroni-Holm 
correction was used to test for difference in β-diversity in terms of Aitchison distance. 
Differential abundance was assessed using a pairwise implementation of the 
aldex.test() function, followed by Benjamini-Hochberg correction. In these cases, a q-
value < 0.1 was considered significant. α-diversity was computed using the iNEXT 
library (Hsieh et al. 2016). 
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3.3.14 Functional prediction of Gut-Brain modules 
The Piphillin webservice (Iwai et al. 2016) was used to infer the functional 
metagenome per sample in terms of KEGG orthologues. Next, these KEGG 
orthologues were processed using the omixer library in R (Darzi et al. 2016) in order 
to calculate abundance of gut-brain modules (GBMs) (Valles-Colomer et al. 2019) 
and gut-metabolic modules (GMMs) in these samples. Then, the same implementation 
from ALDEx2 was used to assess differential abundance. Scripts are publicly available 
on GitHub: https://github.com/thomazbastiaanssen/Tjazi doi: 
10.5281/zenodo.1480804. 
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3.4 Results 
3.4.1 Quercetin and phlorotannins reversed MS-induced 
depressive-like behaviours 
To investigate the therapeutic effects of the dietary interventions with polyphenols 
from MS-induced behavioural despair, animals were subjected to a battery of 
behavioural tests to examine depressive- and anxiety-like behaviours. Firstly, animals 
did not differ in terms of body weight across the different experimental groups 
throughout the duration of the treatment (Fig. 1B and C). In FST, analysis yielded a 
significant effect of MS compared to NS-control group on the time spent immobile 
(t22 = -2.349; p = .028) and swimming (t22 = 2.611; p = .016) (Fig. 2A). MS animals 
exhibited improved depressive-like behaviours with xanthohumol; moreover, 
quercetin (p = .05) and phlorotannins (p = .002) significantly decreased immobility 
time in the FST (F3,36 = 4.425; main effect p = .010). In addition, treatment with 
phlorotannins increased (p = .008) swimming time compared to the MS-control group 
(F3,36 = 2.984; main effect p = .044) (Fig. 2A). 
 
Figure 1 Diet intervention with polyphenols did not affect body weight. (A) Schematic representing 
the experimental timeline. (B) Body weight was measured weekly from 6-week old until the end of the 
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diet intervention. (C) The weight gain was calculated as the difference between the first body weight 
record (6 weeks) and the last measurement (15 weeks). 
3.4.2 Polyphenols exerted potential anxiolytic effects in MS animals 
MS-induced anxiety-like behaviour in the OFT by significantly reducing the time 
spent in the centre (t21 = 2.156; p = .025), as well as in the number of entries in the 
centre of the arena (t21 = 2.855; p = .009) (Fig.2D and E). Administration of quercetin 
in MS rats resulted in an apparent increase in the number of entries in the centre of the 
arena compared to the MS-control group (F3,37 = 2.405; main effect p = .083), which 
was associated with a potential anxiolytic effect (Fig. 2E). Interestingly, treatment 
with phlorotannins seems to ameliorate MS-induced anxiogenic effects in both, time 
in centre (F3,37 = 2.297; main effect p = .094) and in entries into the centre. However, 
no differences were found between NS-control and MS animals during the EPM (Fig. 
2F and G). 
 
Figure 2 Treatment with polyphenols induced antidepressant- and potential anxiolytic-like effects in 
MS rats. (A) MS-induced increased immobility in the FST is prevented through treatment with quercetin 
and phlorotannins, while reduced swimming time caused by MS is reversed only by phlorotannins 
treatment. (B – C) Polyphenolic diets nor MS produced changes in locomotor activity. (D – E) 
Phlorotannins treatment produced a significant increase in the time spent in centre and number of 
centre entries when is compared to MS-control group in the OFT. (F – G) However, MS animals did 
not show anxiety-like behaviours in the EPM. Results are expressed as the mean ± SEM (*p < 0.05; 
**p < 0.01 versus ‘vehicle’ groups; #p < 0.05; ##p < 0.01 versus ‘CORT’ groups). 
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3.4.3 Xanthohumol prevented exacerbated corticosterone 
production in MS rats after acute stress 
To determine the role of the HPA axis in MS-induced depressive- and anxiety-like 
behaviours, the concentration of corticosterone in plasma was measured at different 
time points after an acute stress (Fig. 3A). Indeed, the corticosterone production was 
close to being statistically increased in MS-control relative to the NS-control group as 
revealed by the area under the curve (AUC) of corticosterone response (t20 = -1.949; 
p = .065) (Fig. 3B). Interestingly, dietary intervention with xanthohumol in MS 
animals induced a significant reduction (p = .010) in corticosterone AUC compared to 
the MS-control group (F3,34 = 3.827; main effect p = .018) (Fig. 3B). In addition, all 
polyphenolic treatments induced lower baseline levels of plasma corticosterone 
compared to MS-control group (F3,36 = 3.979; xanthohumol p = .006; phlorotannins p 
= .011), while quercetin showed a trend towards significance (p = .080). 
3.4.4 MS produced significant reduction in plasma BDNF 
BDNF is a critical modulator of neuroplasticity and survival, abundant in the brain and 
periphery, including serum and plasma (Lee et al. 2010). Preclinical and clinical 
studies have demonstrated that chronic stress and depressive status reduces BDNF 
expression (Russo-Neustadt et al. 2001, Gonul et al. 2005). Indeed, MS rats showed 
lower levels of plasma BDNF compared to NS animals (t19 = 2.672; p = .015). 
Although not significant, this effect was partially ameliorated by xanthohumol 
treatment (F3,36 = 1.748; main effect p = .175) (Fig. 3D). 
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Figure 3 Xanthohumol treatment prevented corticosterone elevation and BDNF reduction in MS 
rats. (A) Corticosterone levels in plasma rise after rats are exposed to an acute stress. (B) MS-induced 
increase in corticosterone release is abolished by treatment with xanthohumol. (C) Baseline levels of 
corticosterone of rats treated with xanthohumol and phlorotannins are significantly lower compared to 
MS animals. (D) Rats treated with xanthohumol displayed higher levels of plasma BDNF compared to 
the MS-control group. Plasma corticosterone was determined using ELISA, and BDNF determination 
was performed with MSD system. Results are expressed as the mean ± SEM (*p < 0.05 versus ‘vehicle’ 
groups; #p < 0.05; ##p < 0.01 versus ‘CORT’ groups). 
3.4.5 MS induced decreased levels of DA and 5-HIAA in brainstem 
To further determine the effects of early life stress on neurochemistry, and its potential 
implication on the antidepressant and anxiolytic effects of polyphenols, monoamine 
neurotransmitter concentration was measured in the brainstem. MS produced a 
significant reduction of DA and 5-HIAA levels (t20 = 6.121; p = .000 and t22 = 3.934; 
p = .001 respectively) (Fig. 4B and D), reduced 5-HT turnover (t21 = 3.519; p = .002) 
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(Fig. 4C), and increased DA turnover (t22 = -2.153; p = .047) (Fig. 4F). In contrast, 
treatment with phlorotannins showed a slight increase in the levels of NA (p = 0.177), 
and 5-HT (p = .066) compared to the MS-control group, although not significant 
effects were found (Fig. 4A and G). 
 
 
Figure 4 Polyphenols did not prevent MS-induced reductions in brainstem dopamine and 5-HIAA. 
Monoamine neurotransmitters were measured in the brainstem via HPLC. MS animals show depleted 
concentrations of dopamine and 5-HIAA compared to NS-control rats. Phlorotannins diet intervention 
exerted an increase of noradrenaline and 5-HT MS animals, although not significant. Results are 
expressed as the mean ± SEM (*p < 0.05; **p < 0.01; ***p < 0.001 versus ‘vehicle’ groups; #p < 0.05 
versus ‘CORT’ groups). 
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3.4.6 MS and dietary treatments induced changes in gut bacterial 
diversity 
To define whether the experimental treatments also altered gut microbiota diversity 
and bacterial abundance, α- and β-diversity analyses were performed. Although no 
differences in richness were found using the Chao1 α-diversity metric (Fig. 5A), 
Shannon entropy and Simpson index both indicate that MS rats treated with 
phlorotannins showed reduced diversity within this group compared to the MS-control 
experimental group (p = .072 and p < .05, respectively) (Fig. 5B and C). In other 
words, while the total estimated amount of OTUs did not differ, the microbial 
ecosystem of animals treated with phlorotannins were distributed less evenly. On the 
other hand, principal component analysis (PCA) to measure the diversity among 
groups, indicated that MS and NS control groups were significantly different from 
each other (F4,47 = 2.012; p = .046) (Fig. 5D). In addition, treatments with quercetin, 
xanthohumol and phlorotannins also produced significant changes in β-diversity in 
terms of Aitchison distance compared to MS-control group (F4,47 = 2.012; p = .004; p 
= .045; p = .046, respectively) (Fig. 5D). 
3.4.7 Changes in the gut microbiota composition correlated with 
MS status and polyphenolic diets 
Alteration of the gut microbiota composition has been associated with different mental 
disorders, including major depression and other stress-related psychiatric disorders 
(Cryan et al. 2012). Thus, we examined the differences in the gut microbiota 
composition of maternally separated rats. Significant differences in terms of the 
relative abundance between MS-control and NS-control animals were found in 5 
specific bacteria based on effect size (Streptococcus; Ruminococcus; 
Parabacteroides; Rothia; Christensenellaceae; q < .1) (Fig. 5E). On the other hand, 
dietary interventions with quercetin and xanthohumol in MS rats induced significant 
changes in the abundance of other bacteria genera when compared to the MS-control 
group. Specifically, quercetin produced a significant increase of Enterorhabdus (q < 
.1), while xanthohumol exerted changes in the abundance of Asteroplasma, 
Lachnospiraceae, and Coprococcus (q < .1) (Fig. 5E). 
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3.4.8 Treatment with phlorotannins and xanthohumol restore MS-
induced changes in bacteria associated with microbiota-gut-
brain pathways 
To investigate the implications of MS-induced changes in gut microbiota composition 
on metabolic pathways associated with the microbiota-gut-brain axis, we performed a 
functional prediction based in previously described GBMs (Valles-Colomer et al. 
2019). MS significantly changed the abundance of bacteria linked to 8 GBMs in terms 
of effect size, including tryptophan degradation, quinolinic acid metabolism, nitric 
oxide metabolism, and p-cresol synthesis compared to NS-control group (q < .1) (Fig. 
5F). Intriguingly, although quercetin did not alter any relevant bacteria, xanthohumol 
and phlorotannins treatment restored most of the changes produced by MS in these 
bacteria. 
 
Figure 5 MS and polyphenolic diets induced significant changes in gut microbiota composition and 
diversity. (A – C) Chao1, Simpson index and Shannon entropy were used as estimators of bacterial α-
diversity. (D) Principal component analysis of genus level was performed to estimate the β-diversity 
between experimental groups. (E) Bacterial abundances were significantly altered in MS rats in terms 
of effect size (q < 0.1). In contrast, xanthohumol and quercetin changed other bacteria compared to 
MS animals. (F) Functional prediction of GBMs was utilised to detect potential microbiota-gut-brain 
pathways affected by MS or dietary treatments. Colours represent effect size, only microbiome features 
found to be significantly different in at least one comparison are shown (*q < .1; **q < .05; ***q < 
.01 vs MS-control group). 
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3.4.8 Xanthohumol prevented MS-induced reduction of intestinal 
SCFAs 
To determine whether the observed changes in the gastrointestinal microbiota 
composition and diversity correlate with alteration in SCFA production, the levels of 
acetate, propionate, butyrate, valerate were determined in caecal content. Interestingly, 
maternal separation induced a significant reduction of acetate (t22 = 2.409; p = .025), 
propionate (t22 = 2.988; p = .01), isobutyrate (t21 = 3.354; p = .006), isovalerate (t21 = 
2.779; p = .016), total SCFAs (t21 = 2.228; p = .037), and total BCFAs (t21 = 3.181; p 
= .008). In contrast, phlorotannin treatment significantly reversed the MS-induced 
propionate reduction (F3,38 = 4.646; p = .022), and exerted positive effects on 
isobutyrate, valerate and total levels of BCFAs. 
 
Figure 6 MS rats exhibited lower levels of gut microbiota-derived metabolites (A – H). MS induced 
significant reduction of gut microbiota-derived metabolites including acetate, propionate, isobutyrate 
and isovalerate, as well as decreased total short-chain fatty acids (SCFA) and branched-chain fatty 
acids (BCFA). Xanthohumol treatment ameliorated MS-induced propionate decrease and tends to 
improve isobutyrate and valerate levels. Fatty acid determination was performed through HPLC in 
caecal content. Results are expressed as the mean ± SEM (*p < 0.05; **p < 0.01 versus ‘vehicle’ 
groups; #p < 0.05 versus ‘CORT’ groups). 
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3.5 Discussion 
There has been increasing attention given to the potential of nutritional approaches to 
ameliorate the effects of stress (Lakhan et al. 2008, Marzola et al. 2013, Rechenberg 
et al. 2013). In the present study, we tested different naturally-derived polyphenols as 
potential therapeutic strategies for depression and anxiety associated with early life 
trauma. Indeed, the polyphenols quercetin, xanthohumol and phlorotannins exert 
varying degrees of antidepressant and anxiolytic -like responses in rats subjected to 
MS. Moreover, dietary interventions also modified gut microbial composition and 
diversity, suggesting that their therapeutic effects could be associated with the 
microbiome-gut-brain axis.  
The MS rat is an excellent model to study the negative effects of early life stress on 
brain function and structure, which are associated with the development of depression 
and anxiety (O'Mahony et al. 2011, Vetulani 2013). MS in rats induce a robust 
depressive-like phenotype in adult animals, including changes in gut microbiota, 
dysregulation of the HPA axis, and an imbalance in neurotransmitter levels (Daniels 
et al. 2004, O'Mahony et al. 2009, Liao et al. 2019). Furthermore, we demonstrated 
that all polyphenolic treatments tend to reverse these depressive-like behaviours. In 
particular, the phlorotannin-enriched diet produced a significant improvement in 
immobility and swimming behaviour in the FST compared to the MS-control group. 
Regarding anxiety, quercetin administration exerted a potential anxiolytic effect in MS 
animals, resulting in an increase in the number of entries into the open arms of the 
EPM. Similarly, quercetin- and xanthohumol-enriched diets tend to induce anxiolytic 
effects in the OFT, while phlorotannin treatment revealed also a potential 
improvement. Although the concept of a potential therapeutic effect of polyphenols in 
animal models of stress is not completely new (Anjaneyulu et al. 2003, Hurley et al. 
2014, Aubry et al. 2019). 
We further investigated the role of the HPA axis in the therapeutic effects of 
polyphenol administration. Accumulated lines of evidence indicate that depressive or 
chronically stressed patients have an over activated HPA axis (Pariante et al. 2008, 
Keller et al. 2017). Similarly, animals subjected to chronic stress possess a 
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dysregulated HPA axis and increased baseline levels of glucocorticoids (O'Mahony et 
al. 2011, Uschold-Schmidt et al. 2012). Indeed, we demonstrated that the dietary 
intervention with xanthohumol significantly reduced the exacerbated production of 
corticosterone in MS animals. 
Next, we observed that treatment with xanthohumol shows therapeutic potential in 
preventing the MS-induced reduction in plasma BDNF, although this effect was found 
to be not statistically significant. BDNF has strongly been implicated in antidepressant 
activity and plasma BDNF has been shown to reflect aspects of that centrally and to 
be a biomarker of antidepressant activity (Sen et al. 2008, Lee et al. 2010). Although 
the possible pathways involved in BDNF rescue must be further investigated, it is 
tempting to speculate that the positive effects of xanthohumol on behaviour could be 
partly mediated by normalising BDNF expression. 
The relationship between stress and the gut microbiota is gaining a lot of attention 
(Foster et al. 2017). Additionally, we have demonstrated that MS is able to induce 
strong changes to the gut microbiota in terms of composition and diversity which is in 
line with previous reports (O'Mahony et al. 2009, Moussaoui et al. 2017). Although, 
we did not detect changes at the α-diversity level, analysis of β-diversity revealed that 
MS groups treated with polyphenols differ from the MS control group. We followed 
this up by assessing differential abundance of bacterial genera between the treatment 
groups. Notably, only xanthohumol and quercetin treatments produced significant 
changes in some bacterial genera in MS rats, suggesting that some polyphenol-
enriched diets have the potential to modify bacterial composition in the gastrointestinal 
system. Several studies have demonstrated the capacity of polyphenolic intake to 
shape the gut microbiota (Etxeberria et al. 2013, Ozdal et al. 2016). The fact that all 
types of polyphenol intake was found to alter β-diversity compared to MS control, but 
only xanthohumol and quercetin yielded differences in the abundances of specific 
genera may suggest the polyphenols induce a general shift in the microbial 
composition, which may be indicative of a change in functionality in the microbiome. 
Therefore, we performed a functional prediction of the gut metagenome and used this 
to infer the abundance of GBMs, metabolic modules that are involved in the 
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microbiota-gut-brain axis (Valles-Colomer et al. 2019). Indeed, the analysis predicted 
that MS is able to increase the abundance of GBMs associated with the modulation of 
several pathways altered in depression and other neuropsychiatric disorders, including 
metabolism of tryptophan (Curzon et al. 1970, Oxenkrug 2010), inositol (Coupland et 
al. 2005), p-cresol (Persico et al. 2013), quinolinic acid (Steiner et al. 2011), nitric 
oxide (Dhir et al. 2011), and glutamate (Sanacora et al. 2012, Murrough et al. 2017). 
Interestingly, treatment with xanthohumol and phlorotannins reversed these predicted 
MS-induced changes, suggesting that restoration of these GBMs may partially explain 
their positive effects in behaviour. An important limitation due to the nature of 16S 
sequencing is that functional analysis can only be inferential. Future metabolomics-
based studies should address this experimentally. 
In addition, our data revealed that MS rats exhibited decreased production of SCFAs 
compared with the NS-control group. We detected a significant reduction of acetate, 
propionate, isobutyrate, and isovalerate. The production of SCFAs is highly associated 
to certain bacterial populations in the gut, and there is common agreement surrounding 
the impact of SCFAs on human metabolism and health (Morrison et al. 2016). Indeed, 
it is widely accepted that SCFAs play a critical role in gut-microbiota-brain 
communication, and consequences for mental health and behaviour (Stilling et al. 
2016, Dalile et al. 2019). A preclinical study showed that a depression-associated 
microbiota makeup can impact SCFA production (Kelly et al. 2016), and that SCFAs 
can reverse the enduring effects of stress in a mouse model (van de Wouw et al. 2018). 
In our study, we demonstrated that treatment with xanthohumol specifically prevented 
the reduction of propionate in MS rats. Since the xanthohumol diet intervention 
induced acute changes in bacterial composition of the MS gut microbiota, we presume 
that the changes observed in propionate levels could be a product of improved 
microbial metabolism. 
In conclusion, our present work confirmed that the naturally derived polyphenols 
xanthohumol, quercetin and phlorotannins display therapeutic potential in the 
alleviation of depressive- and anxiety-like behaviours in the rat MS model. We further 
found that treatment with xanthohumol prevented exacerbated production of 
corticosterone after acute stress in MS animals, and reversed MS-induced plasma 
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BDNF depletion. In addition, our data revealed that MS-induced behavioural despair 
correlated with significant changes in bacterial composition and diversity, alteration 
of predicted microbiota-gut-brain pathways, and reduced SCFA production. Although 
all polyphenols caused changes in diversity, only xanthohumol induced significant 
changes in several bacterial taxa and prevented the reduction of propionate in MS rats. 
Taken together, our findings present evidence of the therapeutic properties of 
polyphenols and provide a novel insight into the potential mechanisms underlying 
their antidepressant effect. 
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4.1 Abstract 
Nutrition is a crucial component for maintenance of brain function and mental health. 
Accumulating evidence suggests that certain molecular compounds derived from diet 
can exert neuroprotective effects against environmental factors and chronic stress, and 
moreover improve important neuronal processes, such as plasticity and hippocampal 
neurogenesis. Dietary phospholipids are naturally occurring amphipathic molecules 
with promising potential to promote brain health. However, it is unclear whether 
phospholipids are able to modulate neuronal function directly. In this study, we 
investigate the neuroprotective effects against corticosterone (CORT)-induced 
cytotoxicity in primary cultured cortical neurons. In addition, we examine the capacity 
of phospholipids to modulate proliferation and differentiation of hippocampal neural 
progenitor cells (NPCs). 
We show that certain phospholipids can reverse CORT-induced cytotoxicity and 
neuronal depletion in cortical cells. On the other hand, phospholipid treatment was 
unable to prevent the decrease of Bdnf expression produced by CORT. Interestingly, 
only phosphatidylserine was able to increase hippocampal NPCs neurospheres. 
Finally, phosphatidylethanolamine elicited a significant increase in astrocytic 
differentiation in hippocampal NPCs. These results suggest that phospholipids protect 
cortical cells against CORT-induced cytotoxicity, and improve proliferation and 
astrocytic differentiation in hippocampal NPCs. 
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4.2 Introduction 
It has long been known that neuronal function can affect cognitive processes and 
emotions, and impairments in neuronal signalling directly impact on mental health 
(Wohleb 2016, Birkel 2017). The relative abundance of specific nutrients from dietary 
sources can positively modulate neuronal function and can offer protective effects 
against environmental and physiological factors (Gómez-Pinilla 2008). Indeed, dietary 
nutritional components of diet have been demonstrated to be crucial in several brain 
processes including brain development, neuroplasticity and neurogenesis (Georgieff 
2007). In particular, evidence suggest that optimal nutrition is important for the 
maintenance of adult hippocampal neurogenesis (An et al. 2008, Dyall et al. 2010, 
Heberden 2016, Poulose et al. 2017), the process where new neurons are produced 
from neural progenitor cells (NPCs) in the hippocampus (Eriksson et al. 1998). The 
process of neurogenesis is most pronounced during embryonic development, but there 
is evidence that it persists into adulthood with relevant implications for hippocampal-
dependent cognitive function throughout (Kohman et al. 2013). However, it is 
noticeable that although accumulating evidence support the fact that adult human 
hippocampal neurogenesis exists, in the last few years contradicting reports (Boldrini 
et al. 2018, Sorrells et al. 2018) show that the very existence of this neuronal process 
can still be a subject for debate (Lee et al. 2018). 
On the other hand, the emerging and compelling evidence for nutrition as a crucial 
factor in the high prevalence and incidence of mental disorders suggests that changes 
in diet are a viable strategy for improving mental health and treatment of stress-related 
psychiatric disorders including anxiety and depression (Sanchez-Villegas et al. 2013, 
Jacka et al. 2014, Opie et al. 2015, Adan et al. 2019). Stress-related mental disorders 
are associated with alterations in the hypothalamic-pituitary-adrenal (HPA) axis, 
which can be activated in response to stress leading to a release of glucocorticoids into 
the circulation (Sapolsky et al. 2000). Although these steroid hormones are critically 
involved in the homeostatic regulation of metabolism, chronic exposure in the central 
nervous system to glucocorticoids has been associated to deleterious effects on 
neuronal structure and function (Mitra et al. 2008). 
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Although, all nutrients are important for neuronal function, some appear to have a 
prime role in terms of neuronal growth and development as well as neuroprotection 
during vulnerable stages (Calabrese et al. 2008, Keunen et al. 2014). Based on these 
observations, the identification of key nutrients and nutritional components that can 
boost and protect mental health from neuropsychiatric disorders by modulating 
neuronal processes may represent novel therapeutic strategies against stress-related 
physiological and environmental factors such as aging and chronic stress. 
In this regard, dietary-available phospholipids are a specific type of lipids consisting 
of a hydrophilic head formed by a phosphate group and two hydrophobic tails 
(Kullenberg et al. 2012). Naturally occurring phospholipids can be found in plant and 
animal food sources, including eggs, organ and lean meats, fish, shellfish, cereal 
grains, oilseeds and milk (Cohn et al. 2010). Phospholipids are considered to be 
important components of nutrition, since studies have demonstrated that phospholipid-
enriched diets significantly impact behaviour (Kullenberg et al. 2012). Indeed, 
phospholipid supplementation have showed significant improvements in aged patients 
in terms of cognitive performance (Crook et al. 1991), and attenuated the negative 
effects of stress in young adult subjects (Benton et al. 2001). However, is not clear 
whether the positive effects of phospholipids on behaviour are linked with direct 
modulation of neuronal function or indirect systemic responses. 
Currently, there is a lack of studies looking at phospholipid potential on mental health 
and disease, and more research is needed to understand their therapeutic effects. The 
purpose of the present study was to explore through an in vitro approach the 
implications of phospholipids in neuromodulatory processes. We first performed a 
screening of nine phospholipids to assess their neuroprotective capacity against 
CORT-induced cytotoxicity in neurons derived from the brain cortex, a key brain area 
involved in the pathophysiology of stress-related disorders. In addition, we tested the 
role of phospholipids on proliferation and neural differentiation using hippocampal 
NPCs formed neurospheres, considering the implications of this brain area in 
neurodevelopment and neurogenesis. Hippocampal NPCs forming neurospheres are a 
valuable tool for isolating, and understanding the biology of adult CNS stem cells and 
neurogenesis (Reynolds et al. 2005). Considering that PS, the phospholipid tested in 
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this study with positive effects on neuroprotection, proliferation and differentiation, 
crosses the blood-brain barrier (BBB) and it is efficiently absorbed by neurons (Glade 
et al. 2015), it shows potential implications for future pre-clinical and clinical 
interventions. To date the capacity of other phospholipids to cross the BBB has not 
been confirmed yet. However, since the chemical and physical properties of the BBB 
allow the transport of a number of molecules with specific features (Fong 2015), 
including drugs and chemicals with zwitterionic structure, it is plausible that most of 
the phospholipids tested in our work are capable of cross it. Together, findings from 
this study provide new insights into the potential neuromodulatory effects of 
phospholipids and add important direction to future dietary advice on optimal nutrition 
for cognition and mental health. 
  
110 
 
4.3 Methods 
4.3.1 Chemicals and reagents 
Dulbecco’s modified Eagle’s medium (DMEM), penicillin/streptomycin, D-glucose, 
foetal bovine serum (FBS), L-glutamine, Trypsin, DNAase I, corticosterone (CORT), 
poly-L-lisyne, 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide 
(MTT), fibroblast growth factor (FGF), epidermal growth factor (EGF), dimethyl 
sulfoxide,  phosphatidylcholine (PC; from egg yolk), lysophosphatidylcholine (LPC; 
from egg yolk), phosphatidylserine (PS; from bovine brain), 
phosphatidylethanolamine (PE; from egg yolk), phosphatidylinositol (PI; from 
soybean), phosphatidylglycerol (PG; from egg yolk), phosphatidic acid (PA; from egg 
yolk), sphingomyelin (SM; from egg yolk) and cardiolipin (CL; from bovine heart) 
were purchased from Sigma. B-27 supplement was obtained from Thermo Fisher 
Scientific. 
4.3.2 Animals 
All procedures on live animals were performed under licence from the Government of 
Ireland Department of Health (B100/3774) in accordance with National and European 
Union directive 2010/63/EU, with prior ethical approval by University College Cork 
(AEEC #2012/045). Experiments were conducted in accordance with guidelines 
established by University College Cork's Animal Welfare Body. 
4.3.3 Primary culturing of post-natal day 1 rat cortical neurons 
Mixed neuron and astrocyte cultures were prepared as described previously (Pusceddu 
et al. 2016). Briefly, post-natal day (PND) 1 Sprague Dawley male rats were sacrificed 
and cerebral cortices dissected. Cortical tissue was dissociated into a cellular 
suspension using trypsin (0.25%; 37 °C) and physical trituration with a glass Pasteur 
pipette in warmed DMEM-F12 with 10% FBS and 100 µg/mL DNase I. Cell 
suspension was passed through 40 µm strainer and then centrifuged at 1000 rpm for 
10 min at room temperature. Cells were re-suspended in warmed culture media 
(DMEM-F12 supplemented with B-27, 1% FBS, 100 U/mL penicillin, 100 µg/mL 
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streptomycin, L-glutamine 2 mM and D-glucose 55 mM), and then cultured at 37 °C 
with 5% CO2. 
4.3.4 Isolation and culturing of rat hippocampal neural progenitor 
cells 
Hippocampal cultures containing neural stem cells (NSC) and neural progenitor cells 
(NPC) were obtained as described previously (O'Leime et al. 2018). Briefly, 
hippocampal tissue was dissected from embryonic day (E) 18 rats, and then gently 
triturated with a glass Pasteur pipette in warmed proliferative media (DMEM-F12 
supplemented with 10 ng/mL EGF and 10 ng/mL FGF, B-27, 100 U/mL penicillin, 
100 µg/mL streptomycin, 2 mM L-glutamine and 33 mM D-glucose). For 
differentiation studies, untreated NPCs were dissociated to a single cell suspension 
after proliferation for 7 days in vitro (DIV), and seeded at a density of 4×104 cells/well 
in poly-L-lysine-coated 13 mm glass coverslip in 24-well tissue culture plates using 
differentiation media (DMEM-F12 supplemented with B-27, 1% FBS, 100 U/mL 
penicillin, 100 µg/mL streptomycin, 2 mM L-glutamine and 33 mM D-glucose), and 
then cultured at 37 °C with 5% CO2. 
4.3.5 Cell treatment 
Phospholipids (0.05 – 30 µg/mL; depending of each phospholipid solubility) were 
added to cortical cells at day in vitro (DIV) 5 and maintained for 24 hours. Then the 
media was replaced with fresh media containing 200 µM CORT at DIV6 and kept for 
96 hours (Fig. 1A). For NPC at proliferative condition, phospholipids (0.05 – 30 
µg/mL) were added at DIV0 and maintained until DIV7 (Fig. 1B). For differentiation 
studies, untreated NPCs were treated with phospholipids (0.05 – 30 µg/mL) for 5 days 
(Fig. 1C). The doses of phospholipids were chosen based in previous publications, 
which reported functional activity in vitro (Arakawa et al. 1991, Kalvodova et al. 
2005, Treede et al. 2007). 
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Figure 1 Schematic representing the in vitro experiments performed. (A) Neuroprotective experiment. 
Cortical cells were incubated with various concentrations of phospholipids for 24 hours from DIV5 to 
DIV6, then the media was replaced with 200 µM CORT and kept until DIV10. (B) Proliferation 
experiment. NPCs were exposed to phospholipids and allowed to form neurospheres under proliferative 
conditions from DIV0 to DIV7. (C) Differentiation experiment. NPCs-forming neurospheres were 
incubated in proliferative conditions from DIV0 to DIV7 without any stimulus. At DIV7 neurospheres 
were disaggregated and incubated with differentiation media. Phospholipids were added to the media 
from DIV9 to DIV14.   
4.3.6 Cell viability measurement 
Cell viability was determined by the MTT assay which is based on mitochondrial 
dehydrogenase activity of viable cells as previously described (Mosmann 1983). 
Briefly, cortical cells or NPCs were cultured at 4×10P4 P cells per well in 24 well-plates 
in triplicate. After treatment, medium was removed and replaced with fresh culture 
medium containing MTT (500 µg/mL), and then incubated at 37 °C for 3 hours. Then, 
in order to dissolve the formazan produced after MTT reaction 100 µL of dimethyl 
sulfoxide were added to each well. The absorbance values were measured by 
spectrophotometry at 570 nm with a microplate reader (BioTek Synergy HT). The 
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results were expressed as a percentage of vehicle control group in three independent 
experiments 
4.3.7 Immunocytochemistry 
Cellular staining for neuronal (βIII-tubulin) and astrocytic (GFAP) markers, was 
assessed as through immunofluorescence detection as previously described (Pusceddu 
et al. 2016). Briefly, cortical cells and NPCs were fixed with ice-cold methanol for 10 
min and then blocked overnight in 5% horse serum at 4 °C. Then the cells were 
incubated overnight at 4 °C in primary antibody solution (mouse anti-βIII-tubulin 
1:300, Promega; rabbit anti-GFAP 1:300, Dako). The following day, cells are washed 
and incubated with secondary antibody solution (Alexa Fluor 594 donkey anti-mouse 
1:2000, Thermo Fisher; Alexa Fluor 488 donkey anti-rabbit 1:2000, Thermo Fisher) 
for 1 hour at room temperature. Nuclear staining was performed with Hoechst 33258 
(Sigma) for 5 min. Cells then were counted in 5 fields of view for each coverslip and 
analysed using an Olympus BX53 upright fluorescence microscope. The experiment 
was performed in duplicate and repeated in three different experiments. 
4.3.8 Analysis of NPC neurosphere growth 
NPCs were cultured in 6-well plates at 4×105 cells per well under proliferative 
conditions. Selected doses of phospholipids were added at DIV0. Neurospheres were 
viewed under an inverted Olympus IX70 microscope at DIV2, DIV4 and DIV7 using 
bright field imaging. At least five images per treatment condition were captured (five 
different fields of view from one well; 5-8 neurospheres analysed per field of view. 
Neurospheres were randomly chosen each day), and the neurosphere diameter was 
quantified using ImageJ 1.51j8 software. Each experiment was repeated 3 times. At 
DIV0 NPCs received selected doses of phospholipids for 7 days, and micrographs 
were taken at DIV2, DIV4 and DIV7. Since the number of experimental conditions 
was elevated, phospholipids were distributed randomly in two experiments performed 
in different days. In the first experiment, PS, PG, PA, and CL were tested (Fig. 5A); 
while PC, PI, PE, and SM were examined in the second experiment (Fig. 5C). 
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4.3.9 Quantitative RT-PCR 
Total RNA from primary cortical cells was isolated using the High Pure RNA isolation 
kit (Roche). Briefly, cells were seeded at density of 1.5×106 cells per well in 6-well 
plates, followed by pre-treatments with phospholipids and CORT insult. Then, cells 
were homogenised in lysis buffer and transferred into the filter tubes provided in the 
kit. Following procedure was performed according to manufacturer instructions. RNA 
concentration was determined using the ND-1000 spectrophotometer, and reverse 
transcription was assessed using the ExiLERATE LNA™ qPCR, cDNA synthesis kit 
(Exiqon). Subsequently, PCR reaction was performed using the ExiLERATE LNA™ 
qPCR, SYBR® Green master mix kit (Exiqon) in a lightcycler 480 II (Roche). Each 
sample was analysed in triplicate for both target gene and reference gene (β-actin), and 
the relative mRNA expressions were calculated using the 2-ΔΔCt method (Livak et al. 
2001). 
4.3.10 Statistical analysis 
Statistical analysis was performed using the software SPSS 24.0, and the results were 
presented as mean ± SEM. Data from the neuroprotection experiment was analysed 
using T-test to compare ‘Vehicle’ vs ‘CORT’, then the effect of 
‘phospholipids+CORT’ groups were compared to ‘CORT’ using one-way ANOVA 
followed by Dunnett’s test. For proliferation studies, the data were analysed using two-
way ANOVA followed by Tukey (HSD) post-test. For the differentiation experiment 
data, ‘phospholipids’ groups were compared to ‘Vehicle’ using one-way ANOVA 
followed by Dunnett’s test. A p-value of 0.05 was considered statistically significant. 
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4.4 Results 
4.4.1 Phospholipids attenuate CORT-induced cytotoxicity in 
cortical cells 
To test the potential capacity of phospholipids to protect cortical cells from CORT-
elicited neurotoxicity, cortical cells were first incubated for 24 hours with different 
concentrations of each phospholipid to examine potential cytotoxicity (data not 
shown). None of the phospholipids tested in this study reduced cell viability in the 
range of concentration examined. Subsequently, cortical cells were pre-incubated for 
24 hours with phospholipids at different concentrations, and then exposed to CORT 
for 96 hours. A protective effect of phospholipid exposure was observed, specifically 
PS 0.5 – 7.5 µg/mL (main effect F6,14 = 10.863, p < .001), PE 0.75 – 1.50 µg/mL (main 
effect F6,14 = 11.240, p < .001), PG 0.05 – 0.75 µg/mL (main effect F6,14  = 17.787, p 
< .001) and PA 0.5 – 15.0 µg/mL (main effect F6,14 = 19.728, p < .001) were able to 
significantly prevent the cytotoxicity caused by 200 µM CORT exposure (Fig. 2). 
116 
 
 
Figure 2 Phospholipids protect against CORT-induced cytotoxicity in cortical cells. Cortical cells 
were pre-treated with the indicated concentrations of phospholipids for 24 hours and then with 200 µM 
CORT for 96 hours. Cell viability was measured by MTT assay. Results are expressed as the mean ± 
SEM of three independent experiments performed in triplicate (**p < 0.01; ***p < 0.001 versus 
‘vehicle’ groups; ##p < 0.01; ###p < 0.001 versus ‘CORT’ groups). 
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4.4.2 Phospholipids inhibit CORT-induced alterations in neurons 
but not astrocytes 
To further determine the protective effects of PS (4 µg/mL), PE (1.5 µg/mL), PG (0.4 
µg/mL) and PA (1 µg/mL) against CORT-induced cytotoxicity in cortical cells, we 
studied whether the negative impact of CORT on neuronal and astrocytic quantity and 
morphology (Pusceddu et al. 2016) could be ameliorated by pre-treatment with these 
phospholipids. Indeed, 96-hour exposure with CORT induced a significant reduction 
in the number of βIII-tubulin+ cells (neurons), from approximately 27% to 18%; while 
the number of GFAP+ cells (astrocytes) was significantly increased from 34% to 43%. 
Following a 24-hour pre-treatment with PS, PE and PG ameliorated the negative 
effects on neuronal integrity (main effect F4,10 = 4.470, p = .025), as measured by 
number of βIII-tubulin+ cells, after CORT insult (Fig. 3A). In addition, these 
phospholipids significantly abolished the CORT-induced reduction of βIII-tubulin+ 
cells (Fig. 3B). However, no phospholipid treatment was able to reverse the CORT-
induced increase in GFAP+ cells in cortical cells (Fig. 3C), suggesting this a secondary 
event following neuronal injury. 
118 
 
 
Figure 3 Phospholipids attenuated CORT-induced changes in neuron but not in astrocyte 
proportion. (A – C) Cortical cells were pre-treated for 24 hours with phospholipids that showed positive 
effects in cell viability, including PS (4 µg/mL), PE (1.5 µg/mL), PG (0.4 µg/mL) and PA (1 µg/mL), 
and then exposed to 200 µM CORT for 96 hours. Quantitative analysis of neurons and astrocytes was 
assessed by immunostaining of βIII-tubulin+ and GFAP+ cells. Scale bar = 50 µm. (*p < 0.05; **p < 
0.01 versus ‘vehicle’ groups; #p < 0.05 versus ‘CORT’ groups). 
4.4.3 No effect of phospholipids on CORT-induced reduction of 
Bdnf expression in cortical cells 
Since BDNF expression is highly associated with neuronal survival, it is one of the 
mechanisms used by some neuroprotective agents (Zhao et al. 2017). Thus, we 
hypothesised that the phospholipid mediated protective effect against CORT-induced 
neuronal injury would occur through this mechanism. Therefore, we explored the 
effects of PS, PE, PG and PA on CORT-induced decreased of Bdnf mRNA expression 
119 
 
in cortical cells. In addition, we measured the mRNA levels of Creb1, an important 
nuclear factor involved in the expression of BDNF (Lee et al. 2009). Following a 24-
hour treatment with PS, PE, PG and PA did not induce changes in the expression of 
Creb1 (Fig. 4A), and its mRNA levels were unaffected after CORT exposure (Fig. 
4B), suggesting that neither phospholipids or CORT are capable of modulate the 
upstream BDNF signalling pathway in terms of Creb1 expression in cortical cells. 
Although, 24-hour treatment with phospholipids did not produce significant changes 
in Bdnf expression (Fig. 4C), 200 µM CORT insult significantly altered the expression 
of Bdnf by reducing its mRNA levels around a 60%. Accordingly, we already have 
demonstrated the capacity of long CORT exposure to negatively modulate Bdnf 
expression in cortical cells (Pusceddu et al. 2016) (Fig. 4D). However, phospholipid 
treatments were not able to ameliorate the Bdnf mRNA depletion produced by CORT 
insult, suggesting that their neuroprotective capacity might be mediated by a different 
mechanism (Fig. 4D). 
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Figure 4 Neuroprotective effects of phospholipids are not associated to BDNF expression. Total RNA 
was isolated under two different conditions; (A & C) Cortical cells were incubated with phospholipids 
for 24 hours, then BDNF and Creb1 expression was analysed. (B & D) Cortical cells were pre-
incubated with phospholipids and then exposed to 200 µM CORT for 96 hours. The gene expression 
was quantitatively measured using real time RT-PCR. Results are expressed as the mean ± SEM of 
three independent experiments performed in triplicate. (**p < 0.01 versus ‘vehicle’ groups). 
4.4.4 Phosphatidylserine induces proliferation of neural progenitor 
cells 
Next, we investigated whether phospholipids can modulate proliferation in NPCs by 
inducing changes in the size of neurospheres. Analysis of untreated NPC neurosphere 
diameter revealed an increase over 7 days of around 100 – 120%, which it was 
considered to be strictly dependent of culture conditions. On the other hand, treatment 
with PG (0.05 µg/mL), PA (4 µg/mL), CL (1 µg/mL), PC (4 µg/mL), PE (0.75 µg/mL), 
PI (1.5 µg/mL), and SM (30 µg/mL) did not alter the size of NPC neurospheres after 
a 7-day exposure (Fig. 5B and D). Doses of phospholipids were based in the maximum 
concentration that is not cytotoxic for neurosphere cultures after 7 DIV (data not 
shown). Notably, treatment with PS (4 µg/mL) induced a significant increase (p = 
.014) of the neurosphere diameter at DIV7 by a 14% more compared to the control 
group (treatment effect F4,10 = 4.628, p = .023), suggesting a positive proliferative 
effect on NPCs (Fig. 5B). LPC was excluded of this experiment since it induced 
cytotoxic effects on NPC in all doses tested (data not shown). 
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Figure 5 PS induced increase growth size in NPCs. Selected doses of phospholipids were incubated 
with NPCs cultures from DIV0 to DIV7. Two independent experiments were performed due to the high 
number of treatments; (A – B) experiment 1, including PS (4 µg/mL), PG (0.05 µg/mL), PA (4 µg/mL) 
and CL (1 µg/mL); (C – D) experiment 2, including PC (4 µg/mL), PE (0.75 µg/mL), PI (1.5 µg/mL) 
and SM (30 µg/mL). Quantitative analysis of NPC growth size was assessed by measuring neurosphere 
diameter. Scale bar = 100 µm. (*p < 0.05 vs Vehicle group at DIV7). 
 
4.4.5 Phospholipids induce astrocytic differentiation in neural 
progenitor cells 
To explore the role of phospholipids on neural differentiation, we examined the 
number of astrocytes and neurons in NPCs after treatment with PC, PS, PG, PE, PI, 
PA, SM and CL (Fig. 6A). After 5 day-treatment with these phospholipids, no changes 
were detected in the proportion of βIII-tubulin+ cells (Fig. 6B); however, PI tends to 
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increase the overall number of βIII-tubulin+ cells from approximately 7% to 11%, but 
this increase failed to reach statistical significance (p = .292). In contrast, PE (p = 
.035), PS (p = .061) and PG (p = .052) increased the number of GFAP+ cells from 
approximately 29% to 45% respect to the vehicle group (Fig. 6C), suggesting positive 
astrocytic differentiation (main effect F8,18 = 3.967, p = .007). However, only PE 
demonstrated to be able to significantly increase the GFAP+ cell number. 
 
Figure 6 Phospholipids increased astrocyte numbers in differentiated NPCs. (A) NPCs were 
incubated with selected doses of phospholipids in differentiation conditions for 5 days. (B – C) 
Quantitative analysis of neurons and astrocytes was assessed by immunostaining of βIII-tubulin+ and 
GFAP+ cells. Scale bar = 50 µm. (*p < 0.05 versus ‘vehicle’ groups).  
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4.5 Discussion 
Dietary available phospholipids are nutritional lipids with recognised potential to 
protect neuronal functioning linked with cognition and behaviour, from the negative 
effects of aging and stress (Crook et al. 1991, Benton et al. 2001, Kullenberg et al. 
2012, Boyle et al. 2019). In the present study, we demonstrated that natural occurring 
and dietary phospholipids can significantly modify neuromodulatory processes in 
vitro. In particular, we showed that PS, PE, PG and PA protected cortical cells against 
CORT-elicited cytotoxicity and altered neuronal/astrocytic ratio. In addition, we 
demonstrated that PS facilitates neurosphere self-renewal, while PE improved 
astrocytic differentiation in hippocampal NPCs. Thus, our findings suggest a 
promising protective and beneficial effect of phospholipids in neuronal function in 
vitro. 
Elevated concentration of CORT in rodent models have been associated with 
depressive- and anxiety-like behaviours (Rosa et al. 2014, Mendez-David et al. 2017). 
Similarly, accumulating lines of evidence indicate that depressive or chronically 
stressed individuals have an over activated HPA axis (Pariante et al. 2008, Keller et 
al. 2017). Indeed, several in vitro studies showed that chronic exposure to CORT 
exerts toxic effects on neurons (Gao et al. 2015, Pusceddu et al. 2016, Zhao et al. 
2018). Since, phospholipid-enriched diets have demonstrated therapeutic effects 
against human stress-related conditions (Hellhammer et al. 2004, Boyle et al. 2019), 
demonstrating that phospholipids can prevent the neurotoxic effects of glucocorticoids 
in vitro, it could provide novel insights into the mechanism underpinning such effect 
in vivo. Our data show that CORT treatment decreased the cell viability of primary 
cultured cortical cells. Next, we demonstrated that treatment with PS, PE, PG and PA 
significantly reduced this CORT-elicited cytotoxicity. However, we did not find a 
protective effect on CORT-induced cytotoxicity when using the phospholipids PC, 
LPC, PI, SM, and CL. The reason why other phospholipids tested did not exhibit this 
neuroprotective effect could be associated to structural differences between these 
molecules, as similarly occurs in other physiological contexts. For instance, it has been 
demonstrated that anti-inflammatory properties of phospholipids strongly depend of 
their structure (Furnkranz et al. 2004, Lordan et al. 2017). Indeed, although most of 
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the phospholipids tested shared similar chemical structure in the hydrophobic fatty 
acid tail, their hydrophilic phosphate head differs from each other. For example, PC is 
linked with choline, a molecule with demonstrated neuropharmacological potential 
(Kusuda et al. 2019). In contrast, PS has a serine attached to its carbon chain, an amino 
acid with proven capacity to modulate neuronal function (Billard 2008). Thus, the 
neuroprotective capacity of PS, PE, PG and PA might be related to their chemical 
structure in the hydrophilic head. However, future studies are needed to demonstrated 
this structure-dependent function associated to phospholipids. 
In addition, we confirmed the neuroprotective potential of these compounds by 
preventing the reduction of neuronal percentage in cortical cells caused by CORT 
treatment. However, none of these phospholipids were able to prevent the CORT-
induced increase of astrocytes suggesting a phenotype-specific effect favouring 
neuronal viability. Accordingly, astrocytic overgrowth or astrogliosis is described as 
a critical process for neural protection and repair (Zhang et al. 2007), and it has been 
detected in similar studies using CORT high exposure in neural tissue (Bridges et al. 
2008, Pusceddu et al. 2016). Thus, it is likely that the increase in astrocytes is a direct 
consequence to compensate CORT-induced neuronal injury and not an effect product 
of exposure to phospholipids. 
To further investigate the potential mechanism underpinning the neuroprotective 
effect of PS, PE, PG and PA against CORT-elicited cytotoxicity we explored the 
implication of BDNF gene expression. BDNF is a member of the neurotrophin family 
of proteins involved in neuroplasticity and neuronal survival (Brunoni et al. 2008), 
which also has been associated with neuroprotective effects in vitro (Almeida et al. 
2005). In addition, patients suffering from stress-related disorders display decreased 
levels of BDNF, and its expression has strongly been implicated in antidepressant 
activity (Sen et al. 2008, Lee et al. 2010). We demonstrated that CORT induced a 
significant reduction of Bdnf mRNA levels, however none of the phospholipids were 
capable of preventing this negative consequence, suggesting that Bdnf rescue is not 
crucial for phospholipid-mediated neuroprotection. In contrast, we did not find 
differences in Creb1 mRNA levels after neither CORT or phospholipid treatment. As 
CREB1 is a key nuclear factor involved in the expression of BDNF (Murphy et al. 
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2013), this result suggests that CORT-induced reduction expression of Bdnf mRNA is 
not dependent of Creb1 expression.  
Neurogenesis is an important brain process highly associated with mental health and 
cognition (Eisch et al. 2008). In order to investigate the effects of phospholipids on 
neuromodulatory processes associated with neurogenesis and neurodevelopment, we 
used hippocampal NPC cultures to evaluate proliferation and differentiation in vitro. 
Providing new evidence highlighting a role of phospholipids in this neuronal function 
would directly support the nutritional impact of phospholipids on brain health and 
function. In this study, we found increased size of neurosphere diameter after treatment 
with PS. Neurosphere growth is a common measure of cell self-renewal and 
proliferation (Molofsky et al. 2003). Indeed, an increased in the neurosphere size is 
associated with proliferative activity of NPCs (O'Leime et al. 2018). Interestingly, PC, 
LPC, PI, PG, PA, PE, SM, and CL did not produce comparable effects to PS, 
suggesting a specific activity for this compound, which mechanism needs to be further 
investigated. 
In addition, our data revealed that PE, PS and PG have a significant impact on NPC 
astrocytic differentiation. In this regard, increased astrocyte differentiation has been 
associated with maintenance of adult neurons in terms of neurite growth and synaptic 
formation (Yasui et al. 2017). For example, high levels of synaptic glutamate can 
cause over-activation of neurons leading to excitotoxicity. However, astrocytes have 
specific Na+ dependent transporters able to remove rapidly extracellular glutamate 
from the synaptic cleft, improving neuronal survival (Dong et al. 2009). Astrogenesis, 
the process where new astrocytes are produced, is mainly initiated by the activation of 
JAK-STAT, the canonical pathway regulating astrocyte gene expression (Bonni et al. 
1997). Nevertheless, the mechanism of phospholipid-mediated astrocytic 
differentiation in NPCs and the role of JAK-STAT activation herein remains to be 
investigated. 
In conclusion, our present work confirmed that phospholipids modulated important 
neuronal functions linked to neuroprotection and neurodevelopment in vitro. In our 
knowledge, this is the first study screening a wide range of individual phospholipids 
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in neuronal in vitro models. Indeed, we demonstrated that PS, PE, PG and PA 
protected cortical neurons against CORT-induced neurotoxicity. In addition, we found 
that PS produced an increase in NPC neurosphere size, which is associated with active 
neural proliferation. Finally, we detected that astrocytic differentiation on NPCs was 
improved after treatment with PE. Our findings support that fact that a diet rich in 
phospholipids may have potential beneficial effects for brain health (Kullenberg et al. 
2012, Boyle et al. 2019). Although the signalling pathways involved in these 
phospholipid-mediated neuromodulatory effects, and their capacity to cross the blood-
brain-barrier need to be further explored, we provide novel insights into the potential 
role of dietary available phospholipids on mental health. 
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5.1 Abstract 
Chronic stress is considered a critical risk factor associated with the development of 
various concerning neuropsychiatric disorders, including depression and anxiety. For 
this reason, there is growing interest in the search of novel therapeutic strategies to 
prevent and alleviate the neurobehavioural consequences of stress-related mental 
disorders. In particular, nutritional approaches have become an interesting alternative 
due to their non-invasive nature, and few side effects. Phospholipids are a type of 
dietary lipids present in all cellular membranes, which have been demonstrated to 
modulate brain function. However, their therapeutic effects against chronic 
psychosocial stress-induced neurobehavioural changes have not been explored. In this 
study, we investigated the effects of a phospholipid-enriched dietary intervention in a 
mouse model of chronic psychosocial stress, specifically in sociability, anxiety- and 
depressive-like behaviours, as well as the implications of the HPA axis in stress 
regulation. 
After 6 weeks of repeated psychosocial stress (PS), mice developed an increased 
anxiety-like phenotype and higher HPA axis activity, while no changes in social and 
depressive-like behaviours were detected. Although phospholipid treatment did not 
improve dysregulation of the HPA axis, it exerted a potential anxiolytic effect in PS 
animals. These results provide interesting insights into the effects of dietary 
phospholipids on behaviour and their therapeutic potential against chronic stress. 
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5.2 Introduction 
Stress-related neuropsychiatric disorders, including depression, anxiety, anorexia 
nervosa, and post-traumatic stress disorder are considered a challenge to medicine and 
public health worldwide (deVries et al. 2003, Singla et al. 2018). Indeed, several lines 
of evidence suggest that chronic stress events are an important risk factor for 
developing depression in humans (Hammen 2005, de Kloet et al. 2016). Nowadays, 
one of the most common ways to be exposed to chronic stress is in environments of 
social context, which can lead to adverse and uncomfortable events or even negative 
experiences. Thus, these stressors are considered to be part of a specific type of stress, 
termed psychosocial stress (Siegrist 2008, Lu et al. 2016). In rodents, the chronic 
social defeat stress (CSDS) model is a well described translational paradigm to 
understand the neurobehavioral consequences of psychosocial stress in humans 
(Golden et al. 2011). Although different protocols of CSDS in rodents have been 
developed in different laboratories (Sgoifo et al. 2002, Finger et al. 2011, Golden et 
al. 2011, Vasconcelos et al. 2015), similar phenotypic outcomes are obtained after 
these procedures. Indeed, evidence suggests that CSDS can induce a robust 
depressive-like phenotype marked by anhedonia, anxiety and social avoidance 
behaviour in mice (Rygula et al. 2006, Macedo et al. 2018).  
Increasing evidence is demonstrating a direct relationship between diet, stress 
susceptibility and mental health (Adan et al. 2019). Brain health is dependent on the 
availability of appropriate nutrients, including lipids, amino acids, vitamins and 
minerals from the diet, which contribute to brain structure, composition and neuronal 
function (Gómez-Pinilla 2008, Jones 2016, Moore et al. 2018). Thus food quality and 
intake directly impact on brain function, which suggest that health, mood and cognitive 
performance can be modified by diet (Wahl et al. 2016, Meeusen et al. 2018). Indeed, 
poor dietary habits have been shown to be critical in the prevalence of mental disorders 
(Jacka et al. 2014, Lai et al. 2014, Dawson et al. 2016). The search for new strategies 
to improve mental health and treatment of neuropsychiatric disorders has directed its 
attention to the identification of nutritional factors, and their mechanism of action 
(Adan et al. 2019). In this regard, functional foods and dietary components are being 
considered as potential therapeutic supplements for alleviating the behavioural 
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symptoms of affective disorders (Owen et al. 2017), and their capacity to interact with 
other systems involved in the pathophysiology of stress-related mental illnesses, such 
as the hypothalamic-pituitary-adrenal (HPA) axis (Yau et al. 2013), the immune 
system (Klasing 2007), and the microbiota-gut-brain axis (Robertson et al. 2017). 
Specific dietary lipids known as phospholipids, are biomolecules characterised to have 
a hydrophilic head formed by a phosphate group and two hydrophobic tails 
(Kullenberg et al. 2012). In addition, phospholipids are primary components of all 
animal and plant cellular membranes. For this reason, dietary phospholipids can be 
detected at significant concentration in different food sources, including eggs, organ 
and lean meats, fish, shellfish, cereal grains, oilseeds and milk (Cohn et al. 2010). 
Particularly, much interest has emerged for dairy-derived phospholipids as crucial 
nutrients for brain health, since they show a unique composition and a more balanced 
distribution in each phospholipid subclass compared to other food sources (Garcia et 
al. 2012)(Schverer et al. in press). In addition, milk and other dairy products are 
consumed globally and are considered crucial components for human health, since 
these foods contain various nutritional compounds, such as vitamins and lipids (Hill 
et al. 2015). For example, a supplementation with bovine milk-derived phospholipids 
improved cognitive performance in young human adults subjected to acute PS (Boyle 
et al. 2019). However, the implications for a nutritional intervention with dairy-
derived phospholipids on prolonged chronic PS and its neurobehavioral consequences 
have not been investigated previously. 
Taken together, the purpose of the present study was to explore the therapeutic 
potential of a phospholipid nutritional treatment against the detrimental effects on 
behaviour produced by PS using the mice CSDS model. In particular, we studied the 
effects of a phospholipid-based product derived from buttermilk on sociability, 
depressive- and anxiety-like behaviours, and HPA axis response in mice subjected to 
PS.  
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5.3 Methods 
5.3.1 Animals 
All experimental procedures involving animals were approved by the Ethics 
Committee of University College Cork (AEEC #2018/015). Male C57BL/6J mice 
(Envigo, 8 weeks old at the beginning of the study) were used. Animals were kept 
single-house in a temperature and humidity controlled room on a 12-h light, 12-h dark 
cycle (lights on from 7.00–19.00 h). Food and water were available ad libitum. 
5.3.2 Diets 
Phospholipid-enriched buttermilk was provided by Cremo. All diets were prepared by 
ssniff Spezialdiäten (Ferdinand-Gabriel-Weg, Germany). The phospholipid-enriched 
diet contained 360 mg of phospholipids per 100 g of chow. 
5.3.3 Treatments 
On arrival, animals were single housed and put under specific diets. Mice were 
randomly assigned into 4 different groups. [1] non-stressed (NS)-control (n = 10); [2] 
NS-phospholipid (PL) (n = 10); [3] Stressed (PS)-control (n = 10); [4] PS-PL (n = 10). 
The concentration of the phospholipid-enriched food was calculated based in previous 
reports (Kanno et al. 2014, Kivity et al. 2017) in order to obtain an approximated 
consumption of 450 mg/kg/day of  phospholipids. 
5.3.4 Social defeat/overcrowding procedure 
The PS stress was carried out for 6 weeks in total as previously described with some 
modifications (Finger et al. 2011, van de Wouw et al. 2018). Firstly, 45 male CD1 
mice (Envigo, 8-12 weeks old) were tested for aggression for three consecutive days 
using other CD1 intruder mice in their home cage. The 38 CD1 mice with the shortest 
attack latencies were selected for the social defeat procedure, while the others were 
used in the social interaction test. The C57BL/6J mice undergoing the social defeat 
procedure were pseudo-randomly assigned to a different CD1 aggressor mouse. 
During the procedure, test mice were gently placed into the CD1 aggressor home cage, 
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and permitted to interact until the first attack inducing a defeat posture on the test 
mouse (Beitia et al. 2005). Mice were then separated for 2 h by a perforated Plexiglass 
divider allowing for auditory, olfactory and visual, but not physical contact. The 
divider was subsequently removed, after which another social defeat took place, and 
test mice were transferred back to their home cage. For overcrowding sessions, stress 
mice of one diet group (n = 5) were placed all in one half of a standard holding cage 
divided by a Plexiglas divider for 24 or 48 hours. 
5.3.5 Social interaction test 
Social avoidance to the CD1 aggressor mice was performed as previously described 
(Tsankova et al. 2006, Burokas et al. 2017). Briefly, after 1-hour habituation in the 
test room, the social interaction is assessed in two sessions: First, the test mouse is 
placed in the centre of an open arena (42 × 30 × 24 cm; 5 lux) containing an empty 
wired mesh cage (9.5 × 7.5 × 7.0 cm), and allowed to explored for 2.5 min. Then, the 
test mouse is returned to its home cage. Second, 1 min after the first session ended, the 
same test mouse is placed again in the centre of the arena and allowed to explore for 
another 2.5 min, but now with an unfamiliar CD1 mouse into the wired mesh cage. 
Finally, both mice are returned to their home cage, and the open arena and wired mesh 
cage are cleaned with 70% ethanol.  All the sessions were videotaped, and the time 
spent in the interaction zone was analysed later using a tracking system (Ethovision 
XT 13, Noldus). 
5.3.6 Three‐chamber sociability test 
To evaluate social and novelty preference in mice, the three-chamber sociability test 
(3CT) was used. This test was performed as previously described (Burokas et al. 2017, 
van de Wouw et al. 2018). Briefly, the procedure consisted of three sessions of 10 
min, including habituation, social preference, and social recognition. During 
habituation, the mouse is placed in the centre of the apparatus (a three-chambered box 
with small circular openings allowing for access to all chambers; 60 lux), where it is 
allowed to explore the apparatus with two empty wire cup-like cages in the outer 
chambers. Secondly, in the social preference session, one of the cages contains a 
mouse (male conspecific and age-matched), while the other contains an object (rubber 
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duck). Finally, during the last session of social recognition, the first cage contains the 
same mouse used in the social preference session (familiar mouse), whereas the object 
in the second cage is replaced with a novel mouse (male conspecific and age-matched). 
In between each test mice, the apparatus was cleaned while the location of object and 
conspecific mice was randomised. All the sessions were videotaped, and the time spent 
in each chamber was analysed later using a tracking system (Ethovision XT 13, 
Noldus). 
5.3.7 Elevated plus maze 
The elevated plus maze (EPM) is one of the most commonly used rodent tests for 
assessing anxiety and was performed as previously described (Burokas et al. 2017). 
Briefly, the apparatus consisted of two open arms (50 × 5 cm; red light) and two 
enclosed arms (50 × 5 × 15 cm). After 1-hour habituation to the test room, animals 
were placed in the centre of the maze facing an open arm to begin. Behaviour was 
recorded for 5 min. Frequency of open and closed arms entries were scored, as well as 
percentage time spent in each arm using a tracking system (Ethovision XT 13, 
Noldus). 
5.3.8 Open field test 
The open field test (OFT) was used to assess locomotor activity and anxiety-like 
behaviour, which was conducted as previously described (Burokas et al. 2017). 
Briefly, animals were first habituated to the room for 1 hour. Mice were then placed 
in the centre of an open field arena (45 × 45 cm; 60 lux) and allowed to explore it for 
10 min. The arena was cleaned between mice test with 70% ethanol, and finally the 
animals were returned to their home cage. Percentage of time spent in inner zone, and 
frequency of inner zone entries were analysed using a tracking system (Ethovision XT 
13, Noldus). 
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5.3.9 Forced swim test 
The forced swim test (FST) is the most widely used model for predicting 
antidepressant activity in rodents, and increased immobility in this test is generally 
considered to reflect a state of behavioural despair (Porsolt et al. 1978). Briefly, mice 
were individually placed in a glass cylinder (H: 45 cm; D: 20 cm) filled with water to 
a depth of 15 cm at 24 ± 1 °C for a 6 min. The mice were removed from the water, 
dried and placed in their home cage. The water was changed between each trial. The 
behaviour was monitored from above with a video camera and only the last 4 min were 
analysed. 
5.3.10 Plasma corticosterone determination 
Blood sample collection was performed as previously described (van de Wouw et al. 
2018). Briefly, blood samples were collected on FST day via a tail-tip incision at four 
different time points: immediately before (baseline), 15 min, 45 min, and 90 min after 
the test was started. Approximately 40 μl of whole blood was taken per time point 
using an EDTA‐containing capillary, deposited in an Eppendorf and centrifuged for 
15 min at 10000 g at 4°C. Plasma corticosterone levels were measured using the 
Corticosterone EIA kit (Enzo) according to the manufacturer instructions, and 
absorbance signal was detected with a conventional plate reader (Synergy HT, Biotek). 
5.3.11 Statistical analysis 
Statistical analysis was performed using the software SPSS 24.0, and the results were 
presented as mean ± SEM. Overall effect of stress condition and diet were assessed 
using two-way analysis of variance (ANOVA), while multiple comparisons were 
performed with the Tukey HSD post hoc test. A p-value of 0.05 was considered 
statistically significant. 
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5.4 Results 
5.4.1 Phospholipid-enriched diet increases body weight in NS mice 
To investigate the therapeutic effect of a nutritional intervention with phospholipids 
against chronic PS, NS and PS animals received diets from 8-weeks old until week 16 
(Fig. 1A). Analysis of body weight (Fig. 1B and C) revealed a significant overall effect 
of chronic stress (F1,33 = 23.760; p < .001) and diet (F1,33 = 52.424; p < .001) in total 
weight gain. In particular, the phospholipid-enriched diet produced a significant 
increase in weight gain in NS mice and PS mice (F3,33 = 26.489; p = .001 and p < .001 
respectively) when they were compared to control-diet group. No significant 
differences were detected in weekly food intake and phospholipid intake between 
groups (Fig. 1D and E).  
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Figure 1 Phospholipid intake monitoring and effect on body weight. (A) Timeline representing the 
experimental procedure and dietary intervention. (B – C) Animals were weighed in a weekly basis using 
a regular scale (± 0.01 g). Weight gain was calculated as the difference between final and initial weight. 
(D – E) Chow was weighted weekly, and phospholipid consumption was estimated considering total 
phospholipid concentration in food (360 mg/100 g chow). Results are expressed as the mean ± SEM 
(**p < 0.01; ***p < 0.001).  
5.4.2 Phospholipid-enriched diet did not alleviate psychosocial 
stress-induced anxiety-like behaviours  
To explore the anxiolytic capacity of a phospholipid-enriched diet, mice were 
subjected to a battery of behavioural tests to assess anxiety-like behaviours (Fig. 2). 
In the EPM test, an overall significant anxiogenic effect of chronic stress in terms of 
time spent in open arms (F1,35 = 11.988; p = .001), and entries in open arms (F1,34 = 
36.567; p = .000) (Fig. 2A and B) was detected. Interestingly, the phospholipid-
enriched diet showed a subtle improvement in anxiety-like behaviour in the PS group 
in terms of time spent and entries in the centre compared to the PS-control diet. 
However, although this effect was found to be not statistically significant (F3,35 = 
5.172; p = .317), the stressed animals treated with phospholipids are no longer 
different that the NS control in terms of time (F3,35 = 5.172; p = .397) (Fig. 2A and B). 
In the OFT, PS displayed an anxiogenic effect on time spent in centre (F1,35 = 3.300; 
p = .078) and entries in the centre of the arena (F1,35 = 8.651; p = .006) (Fig. 2C and 
D).  
137 
 
 
Figure 2 Psychosocial stress-induced anxiety like behaviour was not reversed by phospholipid 
treatment. (A – B) PS mice exhibited increased anxiety-like behaviour in the EPM as reflected by the 
reduced time spent and entries in the open arms. (C – D) Similarly, animals subjected to PS displayed 
increased anxiety-like behaviour in the OFT. Results are expressed as the mean ± SEM (*p < 0.0; ***p 
< 0.001). 
5.4.3 Phospholipid-enriched diet had no effect on social behaviour 
To study the effects of chronic PS on social behaviour, animals were evaluated in the 
SIT and 3CT (Fig. 3A and D). PS mice group performed similarly to the NS control 
group in terms of interaction ratio and time of social avoidance during the SIT (Fig. 
3B and C), as well as no difference was found in social preference and novelty as 
revealed in the 3CT (3E and F). In addition, the phospholipid-enriched diet did not 
impact on social behaviour in either PS and NS groups. 
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Figure 3 No effects of psychosocial stress nor phospholipid supplementation on social behaviour. 
(A) Schematic representing SIT setup; IZ = Interaction zone; C = Corner. (B – C) PS did not induce 
social avoidance in mice during the SIT. (D) Schematic representing 3CT setup. (E – F) Social 
preference and social novelty were not altered by PS or phospholipid supplementation in mice after the 
3CT. Results are expressed as the mean ± SEM. 
5.4.4 Chronic psychosocial stress induced high corticosterone 
production but did not affect depressive-like behaviours 
To further examine the depressive-like phenotype in mice subjected to CSDS and the 
effects of a phospholipid-enriched diet, we measured the immobility time in the FST. 
Although there was a certain trend toward significance in terms of a PS overall effect 
in a two-way-ANOVA analysis (F1,33 = 3.288; p = .079), was not detected a clear 
difference between the NS-control and PS-control groups (F3,33 = 1.476; p = .237) 
(Fig. 4A). In addition, to determine the role of the HPA axis in the mouse PS 
phenotype, the concentration of corticosterone in plasma was measured at different 
time points after an acute stress. Baseline levels of plasma corticosterone were found 
to be significantly higher in PS animals compared to NS under the control diet (F3,25 
= 5.167; p = .019) (Fig. 4B). Moreover, an acute stress produced an exacerbated 
production of corticosterone in PS animals at 15 and 45 min after (F3,25 = 14.478; p < 
.001; F3,23 = 5.639; p = .005) (Fig. 4C). Similarly, the AUC of the corticosterone 
response over 90 min after acute stress was significantly increased in the PS-control 
group compared to the NS-control group (F3,20 = 4.347; p = .032) (Fig. 4D). 
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Figure 4 Chronically stressed mice displayed abnormal elevation of plasma corticosterone levels after 
acute stress. (A) No behavioural changes were detected in the FST between NS and PS animals. The 
FST was used as acute stressor to measure the corticosterone response, which consisted in 6 min 
swimming in 24 ± 1 °C water. (B) Baseline levels of corticosterone of PS mice are significantly higher 
compared to NS animals. (C) Corticosterone levels in plasma rise after acute stress. PS-control animals 
displayed higher peaks of corticosterone concentration at 15 and 45 min compared to NS-control 
group. (D) Corticosterone release over 90 min after acute stress is significantly higher in PS groups. 
Plasma corticosterone was determined using ELISA. Results are expressed as the mean ± SEM (*p < 
.05; **p < .01; ***p < .001, ‘NS-control’ vs ‘PS-control’)  
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5.5 Discussion 
Since there is increasing interest in nutritional strategies to ameliorate the effects of 
chronic stress (Lakhan et al. 2008, Marzola et al. 2013, Rechenberg et al. 2013), we 
investigated the therapeutic potential of a phospholipid-enriched dietary intervention 
against the negative neurobehavioral effects produced in a mouse model of PS. In 
particular, we evaluated behaviours associated with anxiety, depression, and 
sociability, as well as the effects on the HPA axis. 
The mouse chronic social defeat stress is an interesting model to investigate the 
neurobehavioral implications of psychosocial stress (Rygula et al. 2005, Golden et al. 
2011, Gururajan et al. 2019). Indeed, PS in mice is known to induce significant 
changes in behaviour associated with depression and anxiety (Venzala et al. 2012, 
Burokas et al. 2017). Accordingly, we found that PS mice presented anxiety-like 
behaviours in the EPM and the OFT. Although not significant, the phospholipid-
enriched diet ameliorated these PS-induced anxiety-like behaviours. Similarly,  a 
previous study that used a phospholipid supplementation for 8 weeks failed to restore 
normal anxiety behaviour in a mouse model of omega 3 deficiency (Carrie et al. 2000). 
Interestingly, the duration of the phospholipid supplementation was the same as in our 
study, it is tempting to speculate that increased periods of phospholipid treatment 
would produce significant effects on anxiety-like behaviour. 
Next, we examined the consequences of PS on social behaviour using the SIT and the 
3CT. We did not detect either social avoidance in the SIT or altered social preference 
in the 3CT in mice subjected to PS. The SIT is widely used to validate a stressed 
phenotype in rodents subjected to repeated social defeat, where it is expected to find 
aversive social behaviour in the test mouse (Golden et al. 2011). However, the fact 
that we found significant increased anxiety- behaviours in other tests and an over-
regulated stress neuroendocrine response, confirms a clear stressed phenotype in the 
PS group compared to NS mice. In this regard, the effect of the phospholipid-enriched 
diet in both SIT and 3CT was not significant, suggesting that phospholipid 
supplementation do not impact social behaviour. Further investigation is required to 
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study the effect of phospholipid dietary interventions in conditions where social 
behaviour would be altered. 
In contrast, the FST revealed a non-significant increase in immobility behaviour in 
animals subjected to PS, suggesting that the stress paradigm did not result in an 
increase in depression-related behaviour. Previous studies have reported significant 
increase of immobility time in the FST after repeated CSDS (Finger et al. 2011, 
Brachman et al. 2016, Burokas et al. 2017). However, in accordance with a previous 
report (Slattery et al. 2012), this is not the first time where the CSDS procedure fails 
to induce a depressive-like phenotype in the FST. In this regard, the phospholipid 
supplementation did not exert antidepressant-like effect in the FST in either NS or PS 
animals. Perhaps, inducing a strong depressive-like phenotype in a different mouse 
model would help to understand the preventive capacity of phospholipids against a 
stress-related mental phenotype. 
The CSDS induced a profound anxiety-like phenotype, and increased activity of the 
HPA axis, as reported previously (Reader et al. 2015, Burokas et al. 2017). Although 
the phospholipid treatment showed subtle improvements against PS-elicited anxiety-
like behaviour (no statistically significant), it was not able to prevent the exacerbated 
stress physiological response. Indeed, dysfunctional HPA axis response has been 
implicated in the pathophysiology of anxiety disorders (Faravelli et al. 2012), and 
pharmacological treatments that have alleviated anxiety-like behaviours, are 
accompanied by reduction of abnormal HPA axis activation (Sartori et al. 2012, Wang 
et al. 2018).  
Some aspects of behaviour were not examined in PS mice, where the impact of 
phospholipids would be interesting to investigate. For instance, it is well known that 
chronic stress is able to induce cognitive impairment, including disruption of attention, 
memory and executive functions (Iosifescu 2012, Fjell et al. 2014). Indeed, mice have 
shown altered working memory after prolonged CSDS (Bergamini et al. 2016, 
Burokas et al. 2017). On the other hand, clinical and pre-clinical evidence suggest a 
potential therapeutic effect of dietary phospholipids against chronic stress-induced 
cognitive impairment (Kanno et al. 2014, Boyle et al. 2019, O'Mahony et al. 2019). 
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For this reason, further investigation into the protective role of dietary phospholipids 
against PS-induced cognitive impairment is required. 
In conclusion, our present work demonstrates that a phospholipid-enriched dietary 
intervention shows potential in the alleviation of the anxiety-like phenotype produced 
in a mouse model of chronic PS. In addition, these data demonstrate that PS and 
phospholipid supplementation do not impact social and depressive-like behaviours in 
the mouse. Therefore, whether phospholipids have the potential to alleviate social and 
cognitive deficits remains unclear. Future studies focusing on animal models with 
impaired social and cognitive behaviour might be useful to improve our knowledge 
about phospholipid nutritional impact on mouse behaviour. Nevertheless, future 
studies are required to investigate alternative phospholipid dose and treatment duration 
in order to enhance its therapeutic effect against chronic PS. 
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Chapter 6  
General  
Discussion  
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6.1 Overview and summary 
Work presented in this thesis has demonstrated that nutritional interventions using 
dietary-derived polyphenols and phospholipids have therapeutic potential in treating 
stress-related neuropsychiatric disorders. Firstly, it was shown that the polyphenolic 
compounds quercetin and xanthohumol protected cortical neurons against 
corticosterone (CORT)-elicited cytotoxicity in vitro. Moreover, treatment with both 
polyphenols abolished the BDNF reduction produced by CORT, and restored altered 
neuronal/astrocytic ratio. In addition, the molecular mechanism involved in their 
neuroprotective effect was explored. We detected an activation of the Nrf2 pathway 
after xanthohumol treatment, while quercetin was observed modulating glucocorticoid 
receptor sensitivity by up-regulating FKBP5. 
Secondly, the rat maternal separation model was utilised as a paradigm for early-life 
stress to study the therapeutic potential of polyphenol-enriched diets. maternal 
separation is known to induce a robust depressive phenotype, including behavioural 
despair, dysregulation of the HPA axis, an imbalance of monoaminergic 
neurotransmission, and an alteration of gut microbiota composition. Indeed, 
nutritional intervention with quercetin, xanthohumol or phlorotannins prevented 
maternal separation-induced depressive- and anxiety-like behaviours. Treatment with 
xanthohumol decreased the exacerbated release of CORT in maternally separated 
animals, and induced significant changes in gut microbiota composition and diversity.  
In contrast, we observed a deficiency of monoamine neurotransmitters in the 
brainstem of maternally separated animals; however, polyphenolic treatments were 
unable to prevent this deficiency, suggesting that restoration of the neurochemical 
balance in brainstem is not required for polyphenol-mediated alleviation of 
depressive- and anxiety-like behaviours in the maternal separation model. 
Thirdly, we also investigated the neuromodulatory impact of dietary phospholipids on 
cellular models of cytotoxicity and neurodevelopment. Using the same approach 
utilised previously, the neuroprotective capacity of phospholipids was tested against 
CORT-induced cytotoxicity in cortical neurons. Indeed, we found that certain 
phospholipids (PS, PE, PG and PA; see Chapter 4) prevented the cytotoxic effects of 
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CORT as measured by an MTT assay, and ameliorated the CORT-induced neuronal 
reduction as determined with immunocytochemistry. However, these phospholipids 
did not affect the CORT-induced reduction of BDNF mRNA levels. In addition, it was 
demonstrated that PS positively regulated the proliferation in hippocampal NPCs by 
increasing the size of neurospheres (free-floating clusters of NPCs). On the other hand, 
it was observed that only PE induced significant astrocytic differentiation in NPCs. 
Finally, the behavioural effects of a phospholipid-enriched food were investigated in 
a mouse model of psychosocial stress. After repeated bouts of social defeat, mice 
developed an anxiety- and depressive-like phenotype. To examine the potential 
therapeutic properties of phospholipids, behaviours associated with sociability, 
anxiety and depression were analysed. Phospholipid supplementation was 
demonstrated to have anxiolytic potential against chronic stress as assessed in 
behavioural tests linked to anxiety-like phenotype. However, this treatment did not 
attenuate the chronic stress-induced depressive-like behaviour observed in mice, and 
it could not restore normal HPA axis activation after an acute stress. 
The studies outlined in this thesis advance our understanding of the role of nutrition, 
and more precisely, the impact of dietary polyphenols and phospholipids as future 
therapeutic strategies against stress-related neuropsychiatric disorders. 
6.2 Polyphenols and phospholipids as modulators of 
neuronal function in vitro: A cellular convergence for 
nutritional anti-stress interventions? 
In chapters 2 and 4, we investigated the neuroprotective capacity of polyphenols and 
phospholipids against CORT-induced neurotoxicity in cells derived from brain cortex. 
CORT is the main stress hormone in rodents, and increasing levels of CORT have 
been associated with depressive- and anxiety-like behaviours in these animals (Rosa 
et al. 2014, Mendez-David et al. 2017). For this reason, long-term exposure of CORT 
to neurons represents an interesting in vitro approach to examine the cellular and 
molecular implications of chronic stress in neuronal biology (Gao et al. 2015, Zhao et 
al. 2018). Indeed, we found that CORT produced significant neurotoxicity in cortical 
cells. Using this approach, we demonstrated for the first time that treatment with 
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polyphenolic compounds, xanthohumol and quercetin (chapter 2), and phospholipids, 
in particular PS, PE, PG and PA (chapter 4), were able to prevent CORT-induced 
neurotoxicity in primary cortical cells.  
Notably, although we found that both treatments were capable of protecting cortical 
cells against CORT insult, their mechanisms of neuroprotection did not converge. 
Indeed, our data indicate that while polyphenols reversed the CORT-induced reduction 
in BDNF levels, phospholipids did not require restoration of BDNF to protect cortical 
cells. Other studies have suggested neuronal pro-survival mechanisms independent of 
BDNF (Fujita et al. 2002, Choudhury et al. 2016). This divergence could also be 
associated with the fact that polyphenols attenuate CORT-induced astrogliosis, or 
abnormal increase of astrocytes, in cortical cultures, and phospholipids only prevented 
CORT-induced reduction of neurons but not attenuate astrocytic increase. Although, 
in this thesis the signalling pathways linked to polyphenol-mediated neuroprotection 
were investigated in chapter 2, future work is needed to elucidate the mechanisms 
involved in the neuroprotective mechanism of phospholipids. 
Nevertheless, the clinical implications of this anti-stress convergence of polyphenols 
and phospholipids are highly promising, since both types of compounds display 
different mechanism which can be suitable for the treatment of different phenotypes 
of stress-related neuropsychiatric disorders. Indeed, mental disorders associated with 
chronic stress, including depression and anxiety, represent a clinical challenge due to 
the complexity of their aetiology (Biaggi et al. 2016, Menard et al. 2016, Read et al. 
2017). Moreover, considering that both polyphenols and phospholipids have 
biochemical features that allow them to cross the blood-brain-barrier (Fong 2015, 
Glade et al. 2015, Figueira et al. 2017), their neuroprotective capacity in vitro 
represent an attractive and plausible strategy to design nutritional therapies to treat 
stress-related disorders. Thus, in chapter 3 and 5 we aimed to investigate the 
therapeutic potential of polyphenols and phospholipids in animal models of stress. 
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6.3 Polyphenols as nutritional strategies for stress-related 
disorders: Promises and challenges  
It is well known that dietary habits have a profound impact on mental health, and for 
this reason there is increasing interest in discovering novel nutritional approaches for 
the prevention and treatment of stress-related neuropsychiatric disorders (Jacka et al. 
2014, Adan et al. 2019). Moreover, there is evidence that early-life stress events are 
an important risk factor for the development of depression and anxiety (Lupien et al. 
2009, O'Mahony et al. 2011). Therefore, in chapter 3 we decided to investigate the 
therapeutic potential of naturally-derived polyphenols used against the detrimental 
effects of a rat maternal separation model of early life stress.  
This model is an excellent way to study the negative effects of early-life stress, since 
it has been demonstrated to induce a robust depressive phenotype in adult animals, 
including changes in gut microbiota composition, dysregulated the HPA axis, and 
alteration of neurotransmitter levels in the brain (Daniels et al. 2004, O'Mahony et al. 
2009, Liao et al. 2019). In this study, we confirmed that maternally separated rats 
displayed a depressive- and anxiety-like phenotype, which is in line with previous 
studies (Prut et al. 2003, Aisa et al. 2007, Desbonnet et al. 2010). 
In chapter 2 we detected a promising anti-stress capability of polyphenols in vitro. 
However, the exploration of the multisystemic implications of dietary interventions 
with polyphenolic-enriched foods is necessary to support their therapeutic potential. 
Therefore, to test the antidepressant and anxiolytic effects of polyphenols, we 
performed a dietary intervention with 3 different compounds, including xanthohumol, 
quercetin and phlorotannins. Interestingly, quercetin and phlorotannins attenuated 
depressive-like behaviours as shown in the FST, suggesting that these polyphenols 
have potential antidepressant properties. Similarly, intervention with all polyphenolic 
compounds produced potential anxiolytic effects in maternally separated animals.  
In addition, our data confirm that the exacerbated production of CORT in plasma 
present in maternally separated rats is significantly reversed by treatment with 
xanthohumol, suggesting a re-normalisation of the HPA axis. These results would 
correlate with the apparent rescue of early life stress-induced BDNF reduction in 
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plasma –as long as this consequence would be found statistically significant– 
suggesting that the improvement of the stress-related phenotype caused by 
polyphenols may be mediated by BDNF restoration. However, future studies should 
address the role of BDNF in the beneficial effects of polyphenols, by determining the 
levels of this neurotrophic factor not only in plasma but also in brain regions at 
transcriptomic and proteomic level. In this way, the findings of this preclinical 
investigation would match with the in vitro results presented in chapter 2, giving novel 
insights into the potential mechanism involved in polyphenol-mediated 
neuroprotection in cortical cells against stress. 
On the other hand, more questions about the mechanisms involved in the protective 
capacity of polyphenols in vivo remain unanswered. For instance, we demonstrated in 
chapter 2 that polyphenol-driven restoration of BDNF in cortical neurons exposed to 
CORT may be mediated by activation of the Nrf2 pathway (key nuclear factor 
involved in antioxidant and cytoprotective cellular response) and modulation of the 
glucocorticoid receptor sensitivity (Kansanen et al. 2013, Mendez-David et al. 2015). 
We did not examine the therapeutic implications of activation of these signalling 
pathways and BDNF restoration produced polyphenols in chapter 3, therefore whether 
polyphenols used similar mechanisms observed in vitro remains unclear. 
In this regard, the role of the Nrf2 signalling in mood disorders has been strongly 
considered as target for the treatment of depression (Hashimoto 2018). Similarly, 
FKBP5 appears to modulate connectivity deficits in stress related disorders, 
representing another potential target for the development of therapeutic approaches 
(O'Leary et al. 2013, de Castro-Catala et al. 2017). Future studies should evaluate the 
implications of these signalling pathways in the antidepressant and anxiolytic effects 
of polyphenols in animal models of early life stress. Transcriptomic and proteomic 
analysis of Nrf2 and FKBP5 expression in relevant brain areas sensitive to stress, such 
as prefrontal cortex and hippocampus (Kim et al. 2015, Czeh et al. 2018), may help to 
elucidate and understand the mechanisms underlying polyphenol-mediated 
improvements of depressive-like behaviour caused after early life stress exposure. 
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Taken together, in chapter 3 we demonstrated that certain polyphenols were able to 
alleviate depressive- and anxiety-like behaviours. These data correlate with the 
findings observed in chapter 2, where xanthohumol protected cortical neurons from 
CORT-induced neurotoxicity and BDNF downregulation, tempting speculation that 
similar anti-stress mechanism are being activated during xanthohumol treatment in 
vitro and in vivo. However, in order to support therapeutic alternatives based in dietary 
interventions with polyphenols, further investigation must address the potential 
pharmacological mechanisms of polyphenols in the brain, and their interactions with 
other physiological systems such as immunity, metabolism and the microbiota-gut-
brain axis.   
6.4 Phospholipids in models of stress: Highlights and 
hurdles 
Previously, we showed in chapter 4 that phospholipid treatment in vitro improved 
important neuronal function associated with neurodevelopment, including 
proliferation and differentiation of neural progenitor cells, as well as neuroprotection 
under stress conditions. Indeed, increased hippocampal neural progenitor cell 
proliferation was highly associated with neurogenesis (Pino et al. 2017), the process 
where new-born neurons are produced (Cameron et al. 2015). Although there is still 
controversy and debate around the concept of adult hippocampal neurogenesis (Lee et 
al. 2018), a relationship between anti-depression and neurogenesis has been observed. 
Indeed, hippocampal neurogenesis appears to be reduced in stress-related conditions, 
and some antidepressant treatments are able to improve neurogenesis in pre-clinical 
models  (Mahar et al. 2014, Krzak et al. 2017, Sun et al. 2017, Micheli et al. 2018). 
Therefore, given the promising effects of phospholipids against stress observed in 
vitro, in chapter 5 we hypothesised that a diet enriched in phospholipids may 
ameliorate the detrimental effects on behaviour in a mouse model of psychosocial 
stress. However, we did not detect significant improvements in the anxiety-like 
phenotype of psychosocially stressed animals after supplementation with 
phospholipids, which is contrary to what we observed in chapters 2 and 3. The reason 
may be linked to cofounding factors involving metabolic changes. Indeed, in chapter 
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5 we found that a phospholipid-enriched diet significantly increased the body weight 
of mice. Accumulating evidence suggests that high fat diet-induced obesity facilitates 
stress-related behaviours in rats (de Noronha et al. 2017). Moreover, clinical studies 
have associated obesity and anxiety symptoms with unregulated HPA axis (Rajan et 
al. 2017, Amiri et al. 2019). Therefore, the therapeutic potential of dietary 
phospholipids in stress-related disorders could be abolished by this increased body 
weight and obesity phenotype caused by phospholipid intake. 
Despite the promising effects of phospholipids observed in vitro, these dietary 
compounds seem to interact with metabolic pathways producing significant an 
increase in body weight and potential aggravation of the stress-related phenotype in a 
mouse model of psychosocial stress. Future work is needed to harness the potential of 
phospholipids in vivo without negatively impacting host metabolism. Perhaps, 
phospholipid supplementation could be tested in stress-related disorders that are 
accompanied by symptoms of cachexia or sarcopenia, syndromes associated with 
weight loss due to inappropriate nutrition (Evans et al. 2008). Thus, animal models of 
cachexia and sarcopenia (Ishida et al. 2017) tested in a chronic stress paradigm could 
help to elucidate the potential therapeutic role of dietary phospholipids in both mental 
health and metabolism. 
6.5 The microbiota-gut-brain axis as target for nutritional 
treatments against stress-related disorders 
Given the increasing evidence suggesting a bi-directional communication between the 
CNS and the gut microbiota (Cryan et al. 2019), the relationship with stress (and 
stress-related mental disorders) has gained a lot of attention. Indeed, novel insights 
into the regulation of the stress response by the microbiome (Foster et al. 2017) 
highlight its potential implication for the development of new strategies to treat 
neuropsychiatric disorders associated with chronic stress. For these reasons, and 
considering the therapeutic potential of polyphenolic dietary interventions observed in 
chapter 3, we hypothesised whether polyphenol-mediated improvement of depressive- 
and anxiety-like behaviours were associated with changes in the gut microbiota.  
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In our work outlined in chapter 3 we confirmed that our model of early-life stress was 
able to significantly impact composition and diversity of the gut microbiota, which is 
in line with previous reports (O'Mahony et al. 2009, Moussaoui et al. 2017). 
Specifically, although we did not detect significant changes at the α-diversity level 
comparing the maternal separation and non-separation control groups, we found that 
phlorotannin treatment induced a decrease in the Simpson index of diversity. In 
contrast, analysis of β-diversity revealed that maternal separation control group is 
significantly different from the non-separation control group, suggesting that early-
life stress alone is sufficient to induce long-lasting changes in the gut microbiota. 
Moreover, all groups of maternally separated animals treated with polyphenols differ 
from the maternal separation control group. We followed this up by assessing 
differential abundance of bacterial genera between treatment groups. Notably, only 
xanthohumol and quercetin treatments produced significant changes in some bacterial 
genera in maternally separated rats, suggesting that some polyphenol-enriched diets 
have the potential to modify bacterial composition in the gastrointestinal system. 
Several studies have demonstrated the capacity of polyphenolic intake to shape the gut 
microbiota (Etxeberria et al. 2015, Ozdal et al. 2016). The fact that all types of 
polyphenol intake were found to alter β-diversity compared to the maternal separation 
control, but only xanthohumol and quercetin yielded differences in the abundances of 
specific genera, which may suggest that polyphenols induce a general shift in the 
microbial composition, that may be indicative of a change in functionality in the 
microbiome. 
Therefore, we performed a functional prediction of the gut metagenome and used this 
to infer the abundance of gut-brain modules (GBMs), metabolic modules that are 
involved in the microbiota-gut-brain axis (Valles-Colomer et al. 2019). Indeed, the 
analysis predicted that maternal separation is able to increase the abundance of GBMs 
associated with the modulation of several pathways altered in depression and other 
neuropsychiatric disorders, including metabolism of tryptophan (Curzon et al. 1970, 
Oxenkrug 2010), inositol (Coupland et al. 2005), p-cresol (Persico et al. 2013), 
quinolinic acid (Steiner et al. 2011), nitric oxide (Dhir et al. 2011), and glutamate 
(Sanacora et al. 2012, Murrough et al. 2017). Interestingly, treatment with 
xanthohumol and phlorotannins reversed these predicted maternal separation-induced 
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changes, suggesting that restoration of these GBMs may partially explain their positive 
effects in behaviour. An important limitation due to the nature of 16S sequencing is 
that functional analysis can only be inferential. Future metabolomics-based studies 
should address this experimentally. 
In addition, our data revealed that maternally separated rats exhibited decreased 
production of gut microbial metabolites compared with the non-separation group. In 
particular, we detected a significant reduction of acetate, propionate, isobutyrate, and 
isovalerate in rats subjected to maternal separation. The production of SCFAs is highly 
associated with certain bacterial populations in the gut, and there is common 
agreement surrounding the impact of SCFAs on human metabolism and health 
(Morrison et al. 2016). Indeed, it is widely accepted that SCFAs play a critical role in 
gut-microbiota-brain communication, and consequences for mental health and 
behaviour (Stilling et al. 2016, Dalile et al. 2019). In chapter 3, we demonstrated that 
treatment with xanthohumol specifically prevented the reduction of propionate in 
maternally separated rats. Since the xanthohumol diet intervention induced acute 
changes in bacterial composition of the gut microbiota of maternally separated rats, 
we hypothesise that the changes observed in propionate levels could be a product of 
improved gut microbial metabolism. 
Taken together, the work outlined in this chapter confirms that dietary interventions 
based in polyphenols have the capacity to modulate the gut microbiota in terms of 
composition and diversity, which demonstrates their potential to target the microbiota-
gut-brain axis. Indeed, we detected potential Gut-brain pathways altered in maternally 
separated animals that were restored by treatment with xanthohumol and quercetin as 
inferred in the functional prediction analysis. Moreover, we detected that maternal 
separation-induced deficiency of SCFA production was reversed by xanthohumol, 
suggesting a potential mechanism underlying polyphenol-mediated modulation of the 
microbiota-gut-brain axis. 
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6.5.1 Do we require the microbiome to exert effects of nutritional 
interventions? 
The therapeutic potential of dietary polyphenols against stress-related disorders 
observed in chapter 3 was discussed in section 6.3. Considering the findings from a 
cellular model of stress in chapter 2, we speculated that the mechanisms underlying 
mental health benefits of polyphenols might be mediated locally in the brain 
considering their capacity to cross the blood-brain-barrier and activate anti-stress 
intracellular pathways. Further, in chapter 3 we explored the implications of the 
microbiota-gut-brain axis in polyphenol-mediated improvement of depressive-like 
phenotype in rats subjected to early life stress. Indeed, we demonstrated that 
polyphenol supplementation induced profound changes in gut microbiota composition 
and diversity. Moreover, polyphenols reversed the abundance of bacteria associated 
with metabolic pathways related to gut-brain communication (see section 6.5). 
Therefore, these findings raise an interesting question about the mechanisms involved 
in polyphenol mental health benefits; do we require the microbiome to exert beneficial 
effects of nutritional intervention with polyphenols? 
To answer this, future investigations should use models of depleted microbiota such 
as germ-free and antibiotic treated animals. For instance, germ-free animal models 
represent an interesting approach to assess the influence of the gut microbiota on brain 
and behaviour (Luczynski et al. 2016, Hoban et al. 2018). Also models of antibiotic-
induced microbiota depletion in animals allow one to study the implications of a 
depleted microbiota on brain and behaviour across different stages of life (Desbonnet 
et al. 2015). Thus, looking at the behavioural responses of animals with depleted 
microbiota under conditions of chronic stress and dietary supplementation with 
polyphenols may help to elucidate the role of the microbiome in this effect. 
6.6 Future directions into polyphenols and phospholipids 
dietary interventions 
In view of the evidence highlighted by this thesis, naturally-derived polyphenols have 
shown protective effects against stress in cellular and animal models. Thereby, this 
finding raises the possibility that polyphenol supplementation may represent a 
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potential strategy to reduce the risk of development of psychopathologies linked to 
stress-related mental disorders. However, further studies are required to elucidate the 
mechanisms underlying polyphenol-mediated improvements in behavior and 
physiology in models of early-life stress. On the other hand, the work outlined in 
chapter 4 and 5 show that the neuromodulatory potential exerted by phospholipids in 
vitro did not translate to an animal model, with the inefficacy to reverse the anxiety-
like phenotype and dysregulated HPA axis produced in a mouse model of chronic 
psychosocial stress. Thus, future pre-clinical investigations should address alternative 
phospholipid dose and treatment duration in order to enhance its therapeutic effect 
against chronic psychosocial stress. 
Additional research is required to understand the potential mechanisms involved in the 
antidepressant and anxiolytic actions of polyphenols; our results obtained from in vitro 
assays in chapter 2 highlight a possible interaction with the Nrf2 and the FKBP5/GR 
signalling pathways, which may be considered as an explanation for our behavioural 
findings. Moreover, we have demonstrated that treatment with xanthohumol is capable 
of preventing CORT-induced downregulation of Bdnf expression in cortical cells 
(Chapter 2). Intriguingly, we observed a similar effect in our in vivo study, where 
dietary intervention with xanthohumol seems to rescue BDNF levels in plasma of 
animals subjected to early-life stress (Chapter 3). BDNF has strongly been implicated 
in antidepressant activity, and plasma BDNF has been shown to reflect aspects of that 
centrally and to be a biomarker of antidepressant effect (Sen et al. 2008, Lee et al. 
2010). Although the possible pathways involved in BDNF rescue must be further 
investigated, it is tempting to speculate that the positive effects of xanthohumol on 
behaviour could be partly mediated by normalising BDNF expression. In addition, we 
have observed profound changes in gut microbiota composition and diversity in rats 
treated with xanthohumol and phlorotannins, which correlate with predicted 
restoration of metabolic pathways associated with gut-microbiota communication 
(Chapter 3). Further studies are needed to experimentally evaluate the role of the 
microbiota-gut-brain axis in the therapeutic effect of dietary polyphenols against 
early-life stress induced changes in behaviour. 
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We also found that phospholipid supplementation was not capable of preventing the 
anxiety-like phenotype produced in a mouse chronic psychosocial stress paradigm 
(Chapter 5). Many questions are thus raised: were the source, dose and duration of the 
treatment appropriate for this dietary intervention? In addition, the novel 
neuromodulatory effects exerted by phospholipids in neuronal in vitro models in terms 
of NPC proliferation and differentiation (Chapter 4), suggest that the implications of 
phospholipid nutritional impact on behavior may be crucial in early-life stages, where 
neurodevelopmental processes are still critical. Future investigation should address the 
impact of phospholipid supplementation in early-life, such as maternal and post-
weaning dietary interventions, and their protective role against stress in different life 
stages.  
Some aspects of behaviour were not examined in mice subjected to chronic 
psychosocial stress, where the impact of dietary phospholipids would be interesting to 
investigate. For instance, it is well known that chronic stress is able to induce cognitive 
impairment, including disruption of attention, memory and executive functions 
(Iosifescu 2012, Fjell et al. 2014). In this regard, clinical and pre-clinical evidence 
suggest a potential therapeutic effect of dietary phospholipids against chronic stress-
induced cognitive impairment (Kanno et al. 2014, Boyle et al. 2019, O'Mahony et al. 
2019). However, the therapeutic potential of dietary phospholipids, and more 
specifically those derived from dairy products, has not been investigated in animal 
models of psychosocial stress. Thus, further investigation into the protective role of 
dietary phospholipids against psychosocial stress-induced cognitive deficits is needed. 
Finally, considering the role of dietary polyphenols in attenuating depressive- and 
anxiety-like phenotype in rats, the implications for interventions using these natural 
compounds for the treatment of stress-related disorders in humans, especially for those 
associated with early-life trauma, have evident therapeutic potential. Previously, we 
highlighted the need to find novel approaches for the prevention and attenuation of 
symptoms linked with stress-related neuropsychiatric disorders such as depression, 
since available strategies are not effective in all cases, and usually are accompanied 
by negative side effect. Therefore, clinical trials should investigate the effects of 
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polyphenol-enriched diets as alternative strategies for the treatment of patients 
diagnosed with depression and anxiety. 
6.7 Conclusions 
In this thesis, we have conducted research which has advanced our understanding 
about the neurobiological effects of naturally-derived polyphenols and phospholipids 
in cellular and animal models of stress. Indeed, this piece of work involves important 
implications for polyphenols and phospholipids as therapeutic strategies able to treat 
and reduce the risk of development of stress-related neuropsychiatric disorders. To our 
knowledge, this work shows for the first time the beneficial effects of polyphenols 
against the behavioural and physiological changes produced in a rat model of early-
life stress. Further, this thesis emphasises the in vitro implications of polyphenols in 
neuronal mechanisms associated with stress response, survival and plasticity, which 
could have potential role in polyphenol-mediated improvements in mental health. 
Moreover, we showed novel insights into the interaction between polyphenols and the 
gut microbiota, highlighting important implications for the microbiota-gut-brain axis 
as therapeutic target against stress-related disorders. Nevertheless, in order to build on 
this work, further investigation is needed to address this experimentally.  
On the other hand, although not significant, we demonstrated that treatment with a 
phospholipid-enriched diet provisionally shows subtle improvements in the anxiety-
like phenotype produced in a mouse psychosocial stress paradigm. However, the 
modulatory effects of phospholipids in neurodevelopmental processes detected in 
vitro, undoubtedly open up for further investigation focused on the nutritional impact 
of phospholipids at different life stages where brain development could be affected. 
Indeed, alternative timelines and behavioural outcomes should be considered in future 
studies for a complete elucidation of the neurobehavioural effects of phospholipids in 
animal models of stress.  
Taken together, our findings demonstrate that naturally-derived polyphenols may 
represent a potential strategy for the prevention and treatment of stress-related mental 
disorders. In contrast, more research is required for a better understanding of the 
therapeutic potential of phospholipid supplementations in stress-related mental 
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disorders. Thus, this thesis represents a detailed and well-characterised portfolio of 
pre-clinical studies focused on the neurobiological effects of polyphenols and 
phospholipids in cellular and animal models of stress, representing an appropriate 
source of knowledge crucial for human clinical studies investigating novel approaches 
against stress-related neuropsychiatric disorders.  
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Chapter 2: Supplementary Information 
 
Table S1. List and detail of antibodies for RPPA used by MD Anderson Center 
Antibody Name Origin* Gene Name Validation Status* Slide Id 
14-3-3-beta R YWHAB V GBL1144582 
14-3-3-zeta R YWHAZ V GBL1144583 
4E-BP1 R EIF4EBP1 V GBL1144348 
4E-BP1_pS65 R EIF4EBP1 V GBL1144349 
53BP1 R TP53BP1 V GBL1144437 
A-Raf R ARAF V GBL1144487 
ACC1 R ACACA/ ACACB C GBL1144351 
ACC_pS79 R ACACA/ACACB V GBL1144350 
Akt R AKT1/2/3 V GBL1144660 
Akt_pS473 R AKT1/2/3 V GBL1144374 
Akt_pT308 R AKT1/2/3 V GBL1144474 
AMPK-a2_pS345 R PRKAA2 V GBL1144504 
AMPKa R PRKAA1/2 C GBL1144352 
AMPKa_pT172 R PRKAA1/2 C GBL1144353 
AR R AR V GBL1144565 
ARID1A R ARID1A C GBL1144515 
Atg3 R ATG3 V GBL1144523 
Atg7 R ATG7 V GBL1144524 
ATM R ATM V GBL1144506 
ATM_pS1981 R ATM V GBL1144507 
ATR_pS428 R ATR C GBL1144546 
Aurora-B R AURKB V GBL1144512 
Axl R AXL V GBL1144497 
b-Actin R ACTB C GBL1144480 
b-Catenin R CTNNB1 V GBL1144357 
b-Catenin_pT41_S45 R CTNNB1 V GBL1144481 
B-Raf R BRAF C GBL1144559 
B-Raf_pS445 R BRAF V GBL1144361 
B7-H4 R VTCN1 C GBL1144541 
Bad_pS112 R BAD V GBL1144354 
Bak R BAK1 C GBL1144355 
Bax R BAX V GBL1144356 
Bcl-xL R BCL2L1 V GBL1144358 
Beclin R BECN1 C GBL1144591 
Bid R BID C GBL1144359 
Bim R BCL2L11 V GBL1144360 
BRD4 R BRD4 V GBL1144519 
c-Abl R ABL1 V GBL1144518 
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c-IAP2 R BIRC3 C GBL1144525 
c-Jun_pS73 R JUN V GBL1144367 
c-Kit R KIT V GBL1144670 
c-Met_pY1234_Y1235 R MET V GBL1144416 
c-Myc R MYC C GBL1144585 
C-Raf R RAF1 C GBL1144485 
C-Raf_pS338 R RAF1 V GBL1144369 
Caspase-3 R CASP3 C GBL1144362 
Caspase-7-cleaved- R CASP7 C GBL1144363 
Caveolin-1 R CAV1 V GBL1144364 
CD134 R TNFRSF4 V GBL1144561 
CD20 R MS4A1 C GBL1144341 
CD4 R CD4 V GBL1144563 
cdc25C R CDC25C V GBL1144555 
cdc2_pY15 R CDK1 C GBL1144545 
Cdc6 R CDC6 V GBL1144654 
CDK1_pT14 R CDK1/2/3 C GBL1144534 
CDT1 R CDT1 V GBL1144655 
Chk1_pS296 R CHEK1 V GBL1144503 
Chk2_pT68 R CHEK2 C GBL1144366 
Claudin-7 R CLDN7 V GBL1144566 
COG3 R COG3 V GBL1144533 
Collagen-VI R COL6A1 V GBL1144577 
Connexin-43 R GJA1 C GBL1144520 
Cox-IV R COX4I1 V GBL1144343 
Cox2 R PTGS2 C GBL1144488 
Creb R CREB1 C GBL1144370 
Cyclin-B1 R CCNB1 V GBL1144371 
Cyclin-D1 R CCND1 C GBL1144578 
D-a-Tubulin R TUBA4A/TUBA3C V GBL1144510 
DJ1 R PARK7 V GBL1144430 
DM-Histone-H3 R HIST1H3A V GBL1144568 
DUSP4 R DUSP4 V GBL1144513 
E-Cadherin R CDH1 V GBL1144673 
eEF2 R EEF2 C GBL1144447 
eEF2K R EEF2K V GBL1144448 
EGFR R EGFR V GBL1144674 
EGFR_pY1173 R EGFR V GBL1144372 
eIF4E R EIF4E V GBL1144415 
eIF4E_pS209 R EIF4E V GBL1144554 
eIF4G R EIF4G1 C GBL1144663 
Elk1_pS383 R ELK1 C GBL1144373 
ER R ESR1 V GBL1144579 
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ER-a_pS118 R ESR1 V GBL1144375 
ERCC5 R ERCC5 C GBL1144505 
Ets-1 R ETS1 V GBL1144586 
FAK R PTK2 C GBL1144376 
FAK_pY397 R PTK2 V GBL1144491 
FASN R FASN V GBL1144475 
Fibronectin R FN1 V GBL1144377 
FOXM1 R FOXM1 V GBL1144344 
FOXO3 R FOXO3 V GBL1144567 
FoxO3a_pS318_S321 R FOXO3 C GBL1144378 
G6PD R G6PD V GBL1144544 
Gab2 R GAB2 V GBL1144435 
GATA6 R GATA6 V GBL1144666 
GCLM R GCLM C GBL1144542 
GCN5L2 R KAT2A V GBL1144495 
Glutamate-D1-2 R GLUD1 V GBL1144575 
Glutaminase R GLS C GBL1144517 
Granzyme-B R GZMB V GBL1144549 
GSK-3a-b_pS21_S9 R GSK3A/GSK3B V GBL1144379 
Gys R GYS1 V GBL1144444 
Gys_pS641 R GYS1 V GBL1144445 
HER2_pY1248 R ERBB2 C GBL1144452 
HER3 R ERBB3 V GBL1144584 
HER3_pY1289 R ERBB3 C GBL1144417 
Heregulin R NRG1 V GBL1144429 
HES1 R HES1 V GBL1144521 
Hexokinase-II R HK2 V GBL1144570 
Histone-H3 R HIST3H3 V GBL1144494 
HSP27_pS82 R HSBP1 V GBL1144380 
HSP70 R HSPA1A C GBL1144381 
IGF1R_pY1135_Y1136 R IGF1R/INSR V GBL1144489 
IGFBP2 R IGFBP2 V GBL1144382 
IGFRb R IGF1R C GBL1144383 
INPP4b R INPP4B V GBL1144451 
IR-b R INSR C GBL1144522 
IRF-1 R IRF1 C GBL1144587 
IRS1 R IRS1 V GBL1144423 
Jagged1 R JAG1 V GBL1144514 
Jak2 R JAK2 V GBL1144479 
JNK2 R MAPK9 C GBL1144384 
JNK_pT183_Y185 R MAPK8 V GBL1144428 
LC3A-B R MAP1LC3A/B C GBL1144526 
Lck R LCK V GBL1144385 
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LDHA R LDHA C GBL1144436 
LRP6_pS1490 R LRP6 V GBL1144508 
MAPK_pT202_Y204 R MAPK1/MAPK3 V GBL1144386 
Mcl-1 R MCL1 V GBL1144490 
MCT4 R SLC16A3 V GBL1144532 
MDM2_pS166 R MDM2 V GBL1144478 
MEK1 R MAP2K1 V GBL1144387 
MEK1_p_S217-S221 R MAP2K1/MAP2K1 V GBL1144453 
MERIT40_pS29 R BABAM1 V GBL1144556 
Merlin R NF2 C GBL1144446 
MIF R MIF C GBL1144588 
MMP2 R MMP2 V GBL1144388 
Mnk1 R MKNK1 V GBL1144438 
MSH6 R MSH6 C GBL1144449 
MSI2 R MSI2 C GBL1144539 
mTOR R MTOR V GBL1144389 
mTOR_pS2448 R MTOR C GBL1144390 
MYH11 R MYH11 C GBL1144576 
Myosin-IIa_pS1943 R MYH9 V GBL1144477 
Myt1 R PKMYT1 C GBL1144548 
N-Cadherin R CDH2 V GBL1144672 
NAPSIN-A R NAPSA C GBL1144498 
NDRG1_pT346 R NDRG1 V GBL1144679 
NF-kB-p65_pS536 R RELA C GBL1144392 
Notch1 R NOTCH1 V GBL1144450 
Notch3 R NOTCH3 C GBL1144580 
Oct-4 R POU5F1 C GBL1144537 
P-Cadherin R CDH3 C GBL1144399 
p16INK4a R CDKN2A V GBL1144492 
p21 R CDKN1A C GBL1144573 
p27-Kip1 R CDKN1B V GBL1144431 
p27_pT198 R CDKN1B V GBL1144427 
p38-MAPK R MAPK14/11/12 V GBL1144393 
p38_pT180_Y182 R MAPK11/12/13/14 V GBL1144394 
p44-42-MAPK R MAPK1/MAPK3 V GBL1144662 
p53 R TP53 C GBL1144395 
p70-S6K1 R RPS6KB1 V GBL1144396 
p70-S6K_pT389 R RPS6KB1 V GBL1144397 
p90RSK_pT573 R RPS6K C GBL1144482 
PAICS R PAICS C GBL1144500 
PAK1 R PAK1 V GBL1144550 
PAK4 R PAK4 V GBL1144511 
PAR R PAR C GBL1144509 
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PARP R PARP1 V GBL1144564 
Paxillin R PXN C GBL1144398 
PD-L1 R CD274 C GBL1144540 
Pdcd4 R PDCD4 C GBL1144425 
PDGFR-b R PDGFRB V GBL1144346 
PDHK1 R PDHK1 C GBL1144527 
PDK1 R PDPK1 V GBL1144400 
PDK1_pS241 R PDPK1 V GBL1144401 
PEA-15 R PEA15 V GBL1144439 
PEA-15_pS116 R PEA15 V GBL1144440 
PI3K-p110-a R PIK3CA C GBL1144424 
PI3K-p85 R PIK3R1 V GBL1144402 
PKA-a R PRKAR1A V GBL1144536 
PKC-b-II_pS660 R PRKCA/B/D/E/H/Q V GBL1144470 
PKC-delta_pS664 R PRKCD V GBL1144434 
PKCa R PRKCA V GBL1144476 
PKM2 R PKM C GBL1144441 
PLC-gamma2_pY759 R PLCG2 C GBL1144442 
PLK1 R PLK1 C GBL1144419 
PMS2 R PMS2 V GBL1144493 
PR R PGR V GBL1144665 
PRAS40_pT246 R AKT1S1 V GBL1144418 
PREX1 R PREX1 V GBL1144486 
PTEN R PTEN V GBL1144404 
Rab11 R RAB11A/B C GBL1144342 
Rab25 R RAB25 V GBL1144473 
Rad50 R RAD50 V GBL1144516 
Rad51 R RAD51 C GBL1144590 
Raptor R RPTOR V GBL1144467 
RBM15 R RBM15 V GBL1144471 
Rb_pS807_S811 R RB1 V GBL1144403 
Rictor R RICTOR C GBL1144468 
Rictor_pT1135 R RICTOR V GBL1144469 
RIP R RIP C GBL1144528 
RPA32_pS4_S8 R RPA2 C GBL1144589 
RSK R RPS6KA1/2/3 C GBL1144420 
S6_pS235_S236 R RPS6 V GBL1144405 
S6_pS240_S244 R RPS6 V GBL1144406 
SDHA R SDHA V GBL1144502 
Shc_pY317 R SHC1 V GBL1144443 
SHP-2_pY542 R PTPN11 C GBL1144483 
SHP2 R PTPN11 V GBL1144652 
SLC1A5 R SLC1A5 C GBL1144499 
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Slfn11 G SLFN11 C GBL1144340 
Smad1 R SMAD1 V GBL1144433 
Smad3 R SMAD3 V GBL1144422 
SOD2 R SOD2 V GBL1144569 
Sox2 R SOX2 V GBL1144538 
Src_pY416 R SRC V GBL1144407 
Src_pY527 R SRC V GBL1144408 
Stat3 R STAT3 C GBL1144484 
Stat3_pY705 R STAT3 V GBL1144562 
Stat5a R STAT5A V GBL1144409 
Stathmin-1 R STMN1 V GBL1144414 
STING R TMEM173 V GBL1144560 
TAZ R WWTR1 V GBL1144553 
TFAM R TFAM V GBL1144501 
TFRC R TFRC V GBL1144472 
TIGAR R TIGAR V GBL1144661 
TRIM25 R TRIM25 C GBL1144543 
TSC1 R TSC1 C GBL1144664 
TTF1 R NKX2-1 V GBL1144659 
Tuberin R TSC2 V GBL1144410 
Tuberin_pT1462 R TSC2 V GBL1144411 
TUFM R TUFM V GBL1144552 
Tyro3 R TYRO3 V GBL1144454 
U-Histone-H2B R HIST1H2BB C GBL1144535 
UBAC1 R UBAC1 V GBL1144496 
ULK1_pS757 R ULK1 C GBL1144529 
VASP R VASP V GBL1144412 
VEGFR-2 R KDR V GBL1144413 
Wee1 R WEE1 C GBL1144547 
Wee1_pS642 R WEE1 C GBL1144558 
WIPI1 R WIPI1 C GBL1144530 
WIPI2 R WIPI2 C GBL1144531 
XBP-1 G XBP1 C GBL1144339 
XPF R ERCC4 C GBL1144557 
XRCC1 R XRCC1 C GBL1144432 
YAP R YAP1 C GBL1144581 
YAP_pS127 R YAP1 V GBL1144421 
YB1_pS102 R YBX1 V GBL1144426 
ZAP-70 R ZAP70 C GBL1144551 
*V = Validated antibody; C = Validation in progress; R = Rabbit antibody; G = Goat 
antibody 
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